| 1 | Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials. (Mainou M, Alsadhan M, Tsapa K, Visram A, Mian H, Popat R, Mai EK, Chakraborty R, Al Hadidi S, Mohan M, Szabo A, Van Oekelen O, Scheffer Cliff ER, Mohyuddin GR) J Natl Cancer Inst 2026 Mar 01;118(3):448-458 |
| 1 | The Michigan Appropriateness Guide for Intravenous Catheters in Adult Patients With Cancer (MAGIC-ONC): Results From a Multispecialty Panel Using the RAND/UCLA Appropriateness Method. (Major A, Paje DG, Taxbro K, McQuilten Z, Kin AD, Alexandrou E, Hsaiky L, Hill J, Moss JG, Kamboj M, White SB, Horowitz JK, McLaughlin E, Flanders SA, Bernstein SJ, Chopra V) Ann Intern Med 2025 Dec;178(12_Supplement):S143-S177 1 Citation |
| 1 | Molecular insights into the anticancer properties of dieckol: a comprehensive review. (Pandi A, Sen N, Kalappan VM, Chandrashekar N, Perumal MK) Naunyn Schmiedebergs Arch Pharmacol 2026 Feb;399(3):3303-3319 1 Citation |
| 1 | HJ-4, a novel piperine derivative, inhibits tumor growth and angiogenesis via p53 activation and oncogenic pathway inhibition in colorectal cancer models. (Zhang L, Liu S, Wang D, Zhang X, Hu Z, Zou X, Li X, Wang X, Xu D, Liu W, Liu B) Sci Rep 2025 Sep 29;15(1):33541 |
| 4 | Characterization of anticancer therapy-induced microvascular dysfunction in patients with breast cancer supports targeted intervention. (Terwoord JD, Norwood Toro LE, Hader SN, Hammond ST, Hockenberry JC, Linn J, Vazirabad IY, Kong AL, Kriegel AJ, Liu Z, Kivelä RM, Murtagh G, Gutterman DD, Beyer AM) JCI Insight 2025 Nov 24;10(22) 2 Citations |
| 2 | Drug Delivery in Retinoblastoma. (Trinh S, Joshi A, Chaurasia SS, Ramasubramanian A) Int Ophthalmol Clin 2025 Oct 01;65(4):51-59 1 Citation |
| 1 | Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study. (Shah NN, Zinzani PL, Wang M, Nasta SD, Lech-Maranda E, Ogawa Y, Fakhri B, Kuss B, Miyashita K, Patel K, Coombs CC, Ma S, Patel MR, Barve MA, Tessoulin B, Stathis A, Ennishi D, Hashimoto D, Kojima K, Zelenetz AD, Cohen JB, Vose JM, Maddocks KJ, Munir T, Sun F, Bian Y, Balbas M, Tsai DE, Abada P, Cheah CY) Blood Adv 2025 Dec 09;9(23):5954-5964 2 Citations |
| 1 | Ag(e)nostic precision oncology therapy approvals across the years. (Kudek MR, Adashek JJ, Kurzrock R) Trends Cancer 2025 Aug;11(8):726-735 5 Citations |
| 1 | Highly Adaptable Dendrimer Gel Nanoparticles with Dual Targeting of uPAR and Ribonucleotide Reductase R2 for Better Retention and Improved Therapeutic Outcomes in Triple-Negative Breast Cancer. (Chuang HY, Huang D, Qi L, Singh V, Chernatynskaya A, Huang YW, Yang H) ACS Appl Mater Interfaces 2025 Jun 11;17(23):33439-33450 3 Citations |
| 1 | Nephrotoxicity Surveillance for Childhood and Young Adult Survivors of Cancer: Recommendations From the International Late Effects of Childhood Cancer Guideline Harmonization Group. (Kooijmans ECM, Mulder RL, Marks SD, Pavasovic V, Motwani SS, Walwyn T, Larkins NG, Kruseova J, Constine LS, Wallace WH, Green DM, Bökenkamp A, van der Pal HJH, van den Heuvel-Eibrink MM, Hjorth L, Andrés-Jensen L, Bardi E, van Dalen EC, Demoor-Goldschmidt C, Becktell K, Grönroos M, Kieran K, Mironova D, Terenziani M, Veening MA, Zieg J, Onder S, Onder AM, Routh JC, Thompson J, Hudson MM, Kremer LCM, Skinner R, Ehrhardt MJ) J Clin Oncol 2025 Jul 20;43(21):2433-2448 5 Citations |
| 3 | Understanding the Mechanisms of Chemotherapy-Related Cardiotoxicity Employing hiPSC-Derived Cardiomyocyte Models for Drug Screening and the Identification of Genetic and Epigenetic Variants. (Solomon AD, Dabral S, Brajesh RG, Day BW, Juric M, Zielonka J, Bosnjak ZJ, Pant T) Int J Mol Sci 2025 Apr 23;26(9) 5 Citations |
| 1 | Tumour-agnostic kinase inhibitors. (Adashek JJ, Nikanjam M, Kurzrock R) Nat Rev Drug Discov 2025 Jul;24(7):504-520 7 Citations |
| 1 | Modulation of blood-tumor barrier transcriptional programs improves intratumoral drug delivery and potentiates chemotherapy in GBM. (Jimenez-Macias JL, Vaughn-Beaucaire P, Bharati A, Xu Z, Forrest M, Hong J, Sun M, Schmidt A, Clark J, Hawkins W, Mercado N, Real J, Huntington K, Zdioruk M, Nowicki MO, Cho CF, Wu B, Li W, Logan T, Manz KE, Pennell KD, Fedeles BI, Bertone P, Punsoni M, Brodsky AS, Lawler SE) Sci Adv 2025 Feb 28;11(9):eadr1481 8 Citations |
| 1 | A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies. (Kwiatek M, Murthy GSG, Hoffmann M, Tessoulin B, Danilov A, Alencar AJ, Shah NN, Ghesquieres H, Le Gouill S, Jurczak W, Han H, Yuen E, Patel V, Guo-Avrutin Y, Pauff JM, Roeker LE) Clin Lymphoma Myeloma Leuk 2025 Jul;25(7):512-519 3 Citations |
| 1 | A novel piperine derivative HJJ_3_5 inhibits colorectal cancer progression by modulating EMT signaling pathways. (Cheng W, Liu S, He J, Li H, Liu X, Hu Z, Wang X, Wu Z, Xu G, Liu W, Liu B) Biochem Biophys Res Commun 2025 Feb 16;749:151323 5 Citations |
| 2 | The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma. (Ahmed G, Hamadani M, Al-Juhaishi T) Expert Opin Biol Ther 2025;25(2):161-173 2 Citations |
| 1 | A Photoinducible DNA Cross-Linking Agent with Potent Cytotoxicity and Selectivity Toward Triple-Negative Breast Cancer Cell Line. (Zhang Q, Ali T, Ponnamperumage TNF, Lin Z, Setu NI, Awoyera WO, Oddiri RT, Rasmussen AD, Felli MC, Frick DN, Peng X) Chem Res Toxicol 2025 Jan 20;38(1):216-228 1 Citation |
| 1 | At the right time: Moving precision therapy to newly diagnosed cancer. (Wahida A, George B, Kurzrock R) Med 2024 Dec 13;5(12):1463-1465 2 Citations |
| 1 | Smart Polymer-Based Delivery Systems for Curcumin in Colon Cancer Therapy: A Review. (Kamath AJ, Donadkar AD, Nair B, Kumar AR, Sabitha M, Sethi G, Chauhan AS, Nath LR) Phytother Res 2025 Feb;39(2):698-713 5 Citations |
| 1 | Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial. (Atallah EL, Mauro MJ, Sasaki K, Levy MY, Koller P, Yang D, Laine D, Sabo J, Gu E, Cortes JE) Future Oncol 2024;20(38):3065-3075 10 Citations |
| 3 | The role of short-chain fatty acids in cancer prevention and cancer treatment. (Kalyanaraman B, Cheng G, Hardy M) Arch Biochem Biophys 2024 Nov;761:110172 20 Citations |
| 1 | Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. (Shah NN, Wang M, Roeker LE, Patel K, Woyach JA, Wierda WG, Ujjani CS, Eyre TA, Zinzani PL, Alencar AJ, Ghia P, Lamanna N, Hoffmann MS, Patel MR, Flinn I, Gerson JN, Ma S, Coombs CC, Cheah CY, Lech-Maranda E, Fakhri B, Kim WS, Barve MA, Cohen JB, Jurczak W, Munir T, Thompson MC, Tsai DE, Bao K, Cangemi NA, Kherani JF, Walgren RA, Han H, Ruppert AS, Brown JR) Haematologica 2025 Jan 01;110(1):92-102 17 Citations |
| 1 | Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature. (Iriarte C, Yeh JE, Alloo A, Boull C, Carlberg VM, Coughlin CC, Lara-Corrales I, Levy R, Nguyen CV, Oza VS, Patel AB, Rotemberg V, Shah SD, Zheng L, Miller CH, Hlobik M, Daigneault J, Choi JN, Huang JT, Vivar KL) Support Care Cancer 2024 Aug 23;32(9):610 6 Citations |
| 1 | Expanded profiling of WD repeat domain 5 inhibitors reveals actionable strategies for the treatment of hematologic malignancies. (Meyer CT, Smith BN, Wang J, Teuscher KB, Grieb BC, Howard GC, Silver AJ, Lorey SL, Stott GM, Moore WJ, Lee T, Savona MR, Weissmiller AM, Liu Q, Quaranta V, Fesik SW, Tansey WP) Proc Natl Acad Sci U S A 2024 Aug 27;121(35):e2408889121 6 Citations |
| 1 | Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies. (Roeker LE, Coombs CC, Shah NN, Jurczak W, Woyach JA, Cheah CY, Patel K, Maddocks K, Wang Y, Zinzani PL, Munir T, Koh Y, Thompson MC, Muehlenbein CE, Wang C, Sizelove R, Abhyankar S, Hasanabba S, Tsai DE, Eyre TA, Wang M) Acta Haematol 2025;148(2):180-197 2 Citations |
| 1 | Reverse repurposing: Potential utility of cancer drugs in nonmalignant illnesses. (Nikanjam M, Wells K, Kato S, Adashek JJ, Block S, Kurzrock R) Med 2024 Jul 12;5(7):689-717 6 Citations |
| 1 | Pharmacological induction of chromatin remodeling drives chemosensitization in triple-negative breast cancer. (Bagheri M, Mohamed GA, Mohamed Saleem MA, Ognjenovic NB, Lu H, Kolling FW, Wilkins OM, Das S, LaCroix IS, Nagaraj SH, Muller KE, Gerber SA, Miller TW, Pattabiraman DR) Cell Rep Med 2024 Apr 16;5(4):101504 14 Citations |
| 1 | Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations. (Park JJ, Chu A, Li J, Ali A, McKay RR, Hwang C, Labriola MK, Jang A, Kilari D, Mo G, Ravindranathan D, Graham LS, Sokolova A, Tripathi A, Pilling A, Jindal T, Ravindra A, Cackowski FC, Sweeney PL, Thapa B, Amery TS, Heath EI, Garje R, Zakharia Y, Koshkin VS, Bilen MA, Schweizer MT, Barata PC, Dorff TB, Cieslik M, Alva AS, Armstrong AJ) JCO Precis Oncol 2024 Apr;8:e2300567 18 Citations |
| 2 | Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. (Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Al-Hadidi S, Cooper D, Lentzsch S, van Rhee F, D'Souza A, Szabo A, Schinke C, Chakraborty R) Blood Cancer J 2024 Mar 05;14(1):35 74 Citations |
| 1 | Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. (Chakraborty R, Bhutani D, Maurer MS, Mohan M, Lentzsch S, D'Souza A) Blood Cancer J 2023 Nov 27;13(1):172 26 Citations |
| 1 | Novel therapies for pediatric acute lymphoblastic leukemia. (Graff Z, Burke MJ, Gossai N) Curr Opin Pediatr 2024 Feb 01;36(1):64-70 8 Citations |
| 1 | Revolutionizing cancer drug development: Harnessing the potential of basket trials. (Subbiah V, Burris HA 3rd, Kurzrock R) Cancer 2024 Jan;130(2):186-200 22 Citations |
| 1 | Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20+ B Cell Lymphoma. (Munoz J, Flinn IW, Cohen JB, Sachs J, Exter B, Ranger A, Harris P, Payumo F, Nath R, Hamadani M, Westin JR, Bachanova V) Transplant Cell Ther 2024 Feb;30(2):241.e1-241.e8 4 Citations |
| 1 | At the right dose: personalised (N-of-1) dosing for precision oncology. (Nikanjam M, Kato S, Sicklick JK, Kurzrock R) Eur J Cancer 2023 Nov;194:113359 11 Citations |
| 1 | Development and validation of an LC-MS/MS method for the determination of ARN14988, an acid ceramidase inhibitor, and its application to a pharmacokinetic study in a mouse model. (Rajaratnam V, Islam MM, Kub EF, Rajaratnam S, Kim KB, Rahman MT, Rashid F, Benko AM, Cook JM, Arnold LA, Mirza SP) Biomed Chromatogr 2024 Jan;38(1):e5754 1 Citation |
| 3 | OXPHOS-targeting drugs in oncology: new perspectives. (Kalyanaraman B, Cheng G, Hardy M, You M) Expert Opin Ther Targets 2023;27(10):939-952 49 Citations |
| 1 | Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. (Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, Munir T, Lech-Maranda E, Lamanna N, Tam CS, Shah NN, Coombs CC, Ujjani CS, Fakhri B, Cheah CY, Patel MR, Alencar AJ, Cohen JB, Gerson JN, Flinn IW, Ma S, Jagadeesh D, Rhodes JM, Hernandez-Ilizaliturri F, Zinzani PL, Seymour JF, Balbas M, Nair B, Abada P, Wang C, Ruppert AS, Wang D, Tsai DE, Wierda WG, Jurczak W) N Engl J Med 2023 Jul 06;389(1):33-44 23 Citations |
| 1 | Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia. (Guru Murthy GS, Atallah E) Hematol Oncol Stem Cell Ther 2023 May 23;16(4):346-350 1 Citation |
| 2 | Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells. (Fraunhoffer NA, Moreno Vega AI, Abuelafia AM, Morvan M, Lebarbier E, Mary-Huard T, Zimmermann MT, Lomberk G, Urrutia R, Dusetti N, Blum Y, Nicolle R, Iovanna J) EBioMedicine 2023 Jun;92:104602 3 Citations |
| 1 | DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma. (Arend R, Dholakia J, Castro C, Matulonis U, Hamilton E, Jackson CG, LyBarger K, Goodman HM, Duska LR, Mahdi H, ElNaggar AC, Kagey MH, Liu A, Piper D, Barroilhet LM, Bradley W, Sachdev J, Sirard CA, O'Malley DM, Birrer M) Gynecol Oncol 2023 May;172:82-91 19 Citations |
| 1 | Chemotherapy-induced peripheral neuropathy in the detroit research on cancer survivors (ROCS) cohort. (Sreeram K, Seaton R, Greenwald MK, Kamgar M, Assad H, Baird T, Schwartz AG, Ruterbusch J, Simon MS) Cancer Causes Control 2023 May;34(5):459-468 6 Citations |
| 1 | Peripheral transient receptor potential vanilloid type 4 hypersensitivity contributes to chronic sickle cell disease pain. (Ehlers VL, Sadler KE, Stucky CL) Pain 2023 Aug 01;164(8):1874-1886 9 Citations |
| 1 | Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors. (Gounder M, Ratan R, Alcindor T, Schöffski P, van der Graaf WT, Wilky BA, Riedel RF, Lim A, Smith LM, Moody S, Attia S, Chawla S, D'Amato G, Federman N, Merriam P, Van Tine BA, Vincenzi B, Benson C, Bui NQ, Chugh R, Tinoco G, Charlson J, Dileo P, Hartner L, Lapeire L, Mazzeo F, Palmerini E, Reichardt P, Stacchiotti S, Bailey HH, Burgess MA, Cote GM, Davis LE, Deshpande H, Gelderblom H, Grignani G, Loggers E, Philip T, Pressey JG, Kummar S, Kasper B) N Engl J Med 2023 Mar 09;388(10):898-912 8 Citations |
| 1 | Development of recalcitrant cutaneous eruptions in patients with relapsed/refractory Hodgkin's lymphoma undergoing treatment with camidanlumab tesirine. (Himed S, Chung C, Dulmage B, Jaglowski S, Bond D, Maddocks K, Kaffenberger BH) J Eur Acad Dermatol Venereol 2023 Jul;37(7):e890-e893 1 Citation |
| 1 | Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors. (Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D) J Cancer Res Clin Oncol 2023 Aug;149(9):6247-6262 19 Citations |
| 1 | The role of cancer cell bioenergetics in dormancy and drug resistance. (Tau S, Miller TW) Cancer Metastasis Rev 2023 Mar;42(1):87-98 15 Citations |
| 1 | BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma. (Eyre TA, Shah NN, Dreyling M, Jurczak W, Wang Y, Cheah CY, Song Y, Gandhi M, Chay C, Sharman J, Andorsky DJ, Messersmith HM, Ruppert AS, Muthig VA, Ito R, Wang ML) Future Oncol 2022 Nov;18(36):3961-3969 22 Citations |
| 1 | Exposure-response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma. (Toukam M, Boni JP, Hamadani M, Caimi PF, Cruz HG, Wuerthner J) Cancer Chemother Pharmacol 2023 Jan;91(1):1-12 5 Citations |
| 1 | Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. (Toukam M, Wuerthner J, Havenith K, Hamadani M, Caimi PF, Kopotsha T, Cruz HG, Boni JP) Cancer Chemother Pharmacol 2023 Jan;91(1):13-24 6 Citations |
| 1 | Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials. (Roth ME, Parsons SK, Ganz PA, Wagner LI, Hinds PS, Alexander S, Bingen K, Bober SL, Brackett J, Cella D, Henry NL, Indelicato DJ, Johnson RH, Miller TP, Rosenberg SM, Schmitz KH, Thanarajasingam G, Reeve BB, Salsman JM) J Natl Cancer Inst 2023 Jan 10;115(1):21-28 35 Citations |
| 1 | Crucial conceptual concepts in the evaluation and management of advanced basal cell carcinoma. (Cohen PR, Kurzrock R) J Am Acad Dermatol 2023 Jan;88(1):e61-e62 2 Citations |
| 1 | Accelerated approvals hit the target in precision oncology. (Subbiah V, Wirth LJ, Kurzrock R, Pazdur R, Beaver JA, Singh H, Mehta GU) Nat Med 2022 Oct;28(10):1976-1979 34 Citations |
| 1 | Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses. (Mehra N, Fizazi K, de Bono JS, Barthélémy P, Dorff T, Stirling A, Machiels JP, Bimbatti D, Kilari D, Dumez H, Buttigliero C, van Oort IM, Castro E, Chen HC, Di Santo N, DeAnnuntis L, Healy CG, Scagliotti GV) Oncologist 2022 Oct 01;27(10):e783-e795 17 Citations |
| 1 | A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. (D'Souza A, Shah N, Rodriguez C, Voorhees PM, Weisel K, Bueno OF, Pothacamury RK, Freise KJ, Yue S, Ross JA, Polepally AR, Talati C, Lee S, Jin Z, Buelow B, Vij R, Kumar S) J Clin Oncol 2022 Nov 01;40(31):3576-3586 113 Citations |
| 1 | Combining ablative radiotherapy and anti CD47 monoclonal antibody improves infiltration of immune cells in tumor microenvironments. (Rostami E, Bakhshandeh M, Ghaffari-Nazari H, Alinezhad M, Alimohammadi M, Alimohammadi R, Mahmoodi Chalbatani G, Hejazi E, Webster TJ, Tavakkol-Afshari J, Jalali SA) PLoS One 2022;17(8):e0273547 6 Citations |
| 2 | Marine Natural Products in Clinical Use. (Haque N, Parveen S, Tang T, Wei J, Huang Z) Mar Drugs 2022 Aug 18;20(8) 123 Citations |
| 2 | Emerging mitochondrial signaling mechanisms in cardio-oncology: beyond oxidative stress. (Bikomeye JC, Terwoord JD, Santos JH, Beyer AM) Am J Physiol Heart Circ Physiol 2022 Oct 01;323(4):H702-H720 27 Citations |
| 1 | Management of Myeloproliferative Neoplasms in the Molecular Era: From Research to Practice. (Pettit K, Rezazadeh A, Atallah EL, Radich J) Am Soc Clin Oncol Educ Book 2022 Apr;42:1-19 |
| 1 | Baicalein: A review on its anti-cancer effects and mechanisms in lung carcinoma. (Chandrashekar N, Pandi A) J Food Biochem 2022 Sep;46(9):e14230 52 Citations |
| 3 | Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferation. (Cheng G, Hardy M, You M, Kalyanaraman B) Sci Rep 2022 Mar 24;12(1):5143 15 Citations |
| 1 | New and emerging pharmacotherapies for the management of multiple myeloma. (Moore DC, Oxencis CJ, Shank BR) Am J Health Syst Pharm 2022 Jul 08;79(14):1137-1145 6 Citations |
| 1 | Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. (Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B, ARASENS Trial Investigators) N Engl J Med 2022 Mar 24;386(12):1132-1142 802 Citations |
| 1 | Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences. (Burke MJ, Zalewska-Szewczyk B) Future Oncol 2022 Mar;18(10):1285-1299 50 Citations |
| 2 | Endothelial dysfunction as a complication of anti-cancer therapy. (Terwoord JD, Beyer AM, Gutterman DD) Pharmacol Ther 2022 Sep;237:108116 70 Citations |
| 1 | The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy. (Caimi PF, Ardeshna KM, Reid E, Ai W, Lunning M, Zain J, Solh M, Kahl BS, Hamadani M) Clin Lymphoma Myeloma Leuk 2022 May;22(5):e335-e339 32 Citations |
| 1 | A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse. (Lin X, Xu Z, Carey L, Romero J, Makriyannis A, Hillard CJ, Ruggiero E, Dockum M, Houk G, Mackie K, Albrecht PJ, Rice FL, Hohmann AG) Pain 2022 May 01;163(5):834-851 27 Citations |
| 1 | Did brentuximab vedotin's rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results? (Hamadani M) Haematologica 2022 Jul 01;107(7):1500-1502 |
| 1 | Treatment-Free Remission: the New Goal in CML Therapy. (Atallah E, Sweet K) Curr Hematol Malig Rep 2021 Oct;16(5):433-439 32 Citations |
| 1 | Avapritinib in the Treatment of Systemic Mastocytosis: an Update. (Below S, Michaelis LC) Curr Hematol Malig Rep 2021 Oct;16(5):464-472 10 Citations |
| 1 | Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study. (Wenzel L, Huang HQ, Cella D, McKinney CO, Zevon MA, LaChance JA, Walker JL, Salani R, Modesitt SC, Morris RT, Bradley WH, Boente MP, von Gruenigen VE) Gynecol Oncol 2021 Nov;163(2):392-397 |
| 1 | Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. (Schulte R, Hinson A, Huynh V, Breese EH, Pierro J, Rotz S, Mixon BA, McNeer JL, Burke MJ, Orgel E) Cancer Med 2021 Nov;10(21):7551-7560 18 Citations |
| 1 | Regulation of miR-126 and miR-122 Expression and Response of Imatinib Treatment on Its Expression in Chronic Myeloid Leukemia Patients. (Ali Beg MM, Guru SA, Abdullah SM, Ahmad I, Rizvi A, Akhter J, Goyal Y, Verma AK) Oncol Res Treat 2021;44(10):530-537 7 Citations |
| 1 | Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. (Sokolova AO, Marshall CH, Lozano R, Gulati R, Ledet EM, De Sarkar N, Grivas P, Higano CS, Montgomery B, Nelson PS, Olmos D, Sokolov V, Schweizer MT, Yezefski TA, Yu EY, Paller CJ, Sartor O, Castro E, Antonarakis ES, Cheng HH) Prostate 2021 Dec;81(16):1382-1389 14 Citations |
| 1 | Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer. (Tsimberidou AM, Shaw JV, Juric D, Verschraegen C, Weise AM, Sarantopoulos J, Lopes G, Nemunaitis J, Mita M, Park H, Ellers-Lenz B, Tian H, Xiong W, Kaleta R, Kurzrock R) J Hematol Oncol 2021 Aug 18;14(1):127 23 Citations |
| 1 | Cardiotoxicity screening of long-term, breast cancer survivors-The CAROLE (Cardiac-Related Oncologic Late Effects) Study. (Puckett LL, Saba SG, Henry S, Rosen S, Rooney E, Filosa SL, Gilbo P, Pappas K, Laxer A, Eacobacci K, Kapyur AN, Robeny J, Musial S, Chaudhry A, Chaudhry R, Lesser ML, Riegel A, Ramoutarpersaud S, Rahmani N, Shah A, Papas V, Dawodu T, Charlton J, Knisely JPS, Lee L) Cancer Med 2021 Aug;10(15):5051-5061 21 Citations |
| 1 | Prediction of Anticancer Peptides with High Efficacy and Low Toxicity by Hybrid Model Based on 3D Structure of Peptides. (Zhao Y, Wang S, Fei W, Feng Y, Shen L, Yang X, Wang M, Wu M) Int J Mol Sci 2021 May 26;22(11) 15 Citations |
| 1 | Interactions between cardiology and oncology drugs in precision cardio-oncology. (Kamaraju S, Mohan M, Zaharova S, Wallace B, McGraw J, Lokken J, Tierney J, Weil E, Fatunde O, Brown SA) Clin Sci (Lond) 2021 Jun 11;135(11):1333-1351 19 Citations |
| 2 | Minimally Invasive Stabilization with or without Ablation for Metastatic Periacetabular Tumors. (English DI, Lea WB, King DM, Tutton SM, Neilson JC) J Bone Joint Surg Am 2021 Jul 07;103(13):1184-1192 28 Citations |
| 1 | Protein expression and purification of G-protein coupled receptor kinase 6 (GRK6), toward structure-based drug design and discovery for multiple myeloma. (Olson TL, Zhang S, Labban D, Kaschner E, Aceves M, Iyer S, Meza-Aguilar JD, Zook JD, Chun E, Craciunescu FM, Liu W, Shi CX, Stewart AK, Hansen DT, Meurice N, Fromme P) Protein Expr Purif 2021 Sep;185:105890 5 Citations |
| 1 | Antitumor effects of iPSC-based cancer vaccine in pancreatic cancer. (Ouyang X, Liu Y, Zhou Y, Guo J, Wei TT, Liu C, Lee B, Chen B, Zhang A, Casey KM, Wang L, Kooreman NG, Habtezion A, Engleman EG, Wu JC) Stem Cell Reports 2021 Jun 08;16(6):1468-1477 41 Citations |
| 1 | Preclinical Models of Cancer Therapy-Associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association. (Asnani A, Moslehi JJ, Adhikari BB, Baik AH, Beyer AM, de Boer RA, Ghigo A, Grumbach IM, Jain S, Zhu H, American Heart Association Council on Basic Cardiovascular Sciences; Cardio-Oncology Science Subcommittee of Council on Genomic and Precision Medicine and Council on Clinical Cardiology; Council on Peripheral Vascular Disease; and Council on Arteriosclerosis, Thrombosis and Vascular Biology) Circ Res 2021 Jun 25;129(1):e21-e34 70 Citations |
| 1 | Identification of a new TRAF6 inhibitor for the treatment of hepatocellular carcinoma. (Li N, Luo L, Wei J, Liu Y, Haque N, Huang H, Qi Y, Huang Z) Int J Biol Macromol 2021 Jul 01;182:910-920 11 Citations |
| 1 | Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors. (Kato S, Porter R, Okamura R, Lee S, Zelichov O, Tarcic G, Vidne M, Kurzrock R) Eur J Cancer 2021 May;149:184-192 4 Citations |
| 1 | Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. (Kaoutari AE, Fraunhoffer NA, Hoare O, Teyssedou C, Soubeyran P, Gayet O, Roques J, Lomberk G, Urrutia R, Dusetti N, Iovanna J) EBioMedicine 2021 Apr;66:103332 38 Citations |
| 1 | Pediatric classical Hodgkin lymphoma. (Lo AC, Dieckmann K, Pelz T, Gallop-Evans E, Engenhart-Cabillic R, Vordermark D, Kelly KM, Schwartz CL, Constine LS, Roberts K, Hodgson D) Pediatr Blood Cancer 2021 May;68 Suppl 2:e28562 30 Citations |
| 4 | Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. (Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, Saber W, Weisdorf D) Leukemia 2021 Jul;35(7):2076-2085 35 Citations |
| 3 | Leveraging Antiprogestins in the Treatment of Metastatic Breast Cancer. (Kamaraju S, Fowler AM, Weil E, Wisinski KB, Truong TH, Lehr M, Chaudhary LN, Cheng YC, Chitambar CR, Rui H, Yee D, Lange C) Endocrinology 2021 Aug 01;162(8) 10 Citations |
| 1 | Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer. (Aissa AF, Islam ABMMK, Ariss MM, Go CC, Rader AE, Conrardy RD, Gajda AM, Rubio-Perez C, Valyi-Nagy K, Pasquinelli M, Feldman LE, Green SJ, Lopez-Bigas N, Frolov MV, Benevolenskaya EV) Nat Commun 2021 Mar 12;12(1):1628 196 Citations |
| 1 | Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. (Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BGM, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, João C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja JG, Leal da Costa F, Maiolino A, Waage A, Vesole DH, Ocio EM, Quach H, Driessen C, Bladé J, Leleu X, Riva E, Bergsagel PL, Hou J, Chng WJ, Mellqvist UH, Dytfeld D, Harousseau JL, Goldschmidt H, Laubach J, Munshi NC, Gay F, Beksac M, Costa LJ, Kaiser M, Hari P, Boccadoro M, Usmani SZ, Zweegman S, Holstein S, Sezer O, Harrison S, Nahi H, Cook G, Mateos MV, Rajkumar SV, Dimopoulos MA, Richardson PG) Lancet Oncol 2021 Mar;22(3):e105-e118 248 Citations |
| 1 | Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma. (Dou R, Qian J, Wu W, Zhang Y, Yuan Y, Guo M, Wei R, Yang S, Jurczyszyn A, Janz S, Beksac M, Gu C, Yang Y) Cell Death Dis 2021 Feb 24;12(2):206 22 Citations |
| 1 | Immune function in childhood cancer survivors: a Children's Oncology Group review. (Guilcher GMT, Rivard L, Huang JT, Wright NAM, Anderson L, Eissa H, Pelletier W, Ramachandran S, Schechter T, Shah AJ, Wong K, Chow EJ) Lancet Child Adolesc Health 2021 Apr;5(4):284-294 49 Citations |
| 2 | Xanthomatous Dermal Changes in a Patient With Locally Advanced Basal Cell Carcinoma Treated Using Vismodegib. (Smith SDB, Clarke CN, Clark MA, Harker-Murray AK, Sokumbi O) Am J Dermatopathol 2021 Aug 01;43(8):585-587 1 Citation |
| 1 | Black Raspberries Suppress Colorectal Cancer by Enhancing Smad4 Expression in Colonic Epithelium and Natural Killer Cells. (Huang YW, Lin CW, Pan P, Shan T, Echeveste CE, Mo YY, Wang HT, Aldakkak M, Tsai S, Oshima K, Yearsley M, Xiao J, Cao H, Sun C, Du M, Bai W, Yu J, Wang LS) Front Immunol 2020;11:570683 20 Citations |
| 1 | Cutaneous reactions to pediatric cancer treatment part II: Targeted therapy. (Carlberg VM, Davies OMT, Brandling-Bennett HA, Leary SES, Huang JT, Coughlin CC, Gupta D) Pediatr Dermatol 2021 Jan;38(1):18-30 14 Citations |
| 1 | International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. (van Rhee F, Oksenhendler E, Srkalovic G, Voorhees P, Lim M, Dispenzieri A, Ide M, Parente S, Schey S, Streetly M, Wong R, Wu D, Maillard I, Brandstadter J, Munshi N, Bowne W, Elenitoba-Johnson KS, Fössa A, Lechowicz MJ, Chandrakasan S, Pierson SK, Greenway A, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Chadburn A, Fajgenbaum DC) Blood Adv 2020 Dec 08;4(23):6039-6050 184 Citations |
| 1 | A stem cell reporter based platform to identify and target drug resistant stem cells in myeloid leukemia. (Spinler K, Bajaj J, Ito T, Zimdahl B, Hamilton M, Ahmadi A, Koechlein CS, Lytle N, Kwon HY, Anower-E-Khuda F, Sun H, Blevins A, Weeks J, Kritzik M, Karlseder J, Ginsberg MH, Park PW, Esko JD, Reya T) Nat Commun 2020 Nov 26;11(1):5998 13 Citations |
| 1 | Cutaneous reactions to pediatric cancer treatment: Part I. Conventional chemotherapy. (Sous D, Armstrong AE, Huang JT, Shah S, Carlberg VM, Coughlin CC) Pediatr Dermatol 2021 Jan;38(1):8-17 6 Citations |
| 3 | Potent inhibition of tumour cell proliferation and immunoregulatory function by mitochondria-targeted atovaquone. (Cheng G, Hardy M, Topchyan P, Zander R, Volberding P, Cui W, Kalyanaraman B) Sci Rep 2020 Oct 21;10(1):17872 43 Citations |
| 1 | Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. (Caplin ME, Pavel M, Phan AT, Ćwikła JB, Sedláčková E, Thanh XT, Wolin EM, Ruszniewski P, CLARINET Investigators) Endocrine 2021 Feb;71(2):502-513 75 Citations |
| 1 | Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. (Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, Kuo DJ, Eskander RN, Goodman A, Galanina N, Fanta PT, Schwab RB, Shatsky R, Plaxe SC, Sharabi A, Stites E, Adashek JJ, Okamura R, Lee S, Lippman SM, Sicklick JK, Kurzrock R) Nat Commun 2020 Oct 02;11(1):4965 236 Citations |
| 1 | The ASTRO clinical practice guidelines in cervical cancer: Optimizing radiation therapy for improved outcomes. (Chino J, Annunziata CM, Beriwal S, Bradfield L, Erickson BA, Fields EC, Fitch J, Harkenrider MM, Holschneider CH, Kamrava M, Leung E, Lin LL, Mayadev JS, Morcos M, Nwachukwu C, Petereit D, Viswanathan AN) Gynecol Oncol 2020 Dec;159(3):607-610 35 Citations |
| 2 | Do Bisphosphonates Alleviate Pain in Children? A Systematic Review. (Celin MR, Simon JC, Krzak JJ, Fial AV, Kruger KM, Smith PA, Harris GF) Curr Osteoporos Rep 2020 Oct;18(5):486-504 19 Citations |
| 3 | The 3D genomic landscape of differential response to EGFR/HER2 inhibition in endocrine-resistant breast cancer cells. (Yang Y, Choppavarapu L, Fang K, Naeini AS, Nosirov B, Li J, Yang K, He Z, Zhou Y, Schiff R, Li R, Hu Y, Wang J, Jin VX) Biochim Biophys Acta Gene Regul Mech 2020 Nov;1863(11):194631 13 Citations |
| 1 | miRNAs Modulate the Dichotomy of Cisplatin Resistance or Sensitivity in Breast Cancer: An Update of Therapeutic Implications. (Safi A, Bastami M, Delghir S, Ilkhani K, Seif F, Alivand MR) Anticancer Agents Med Chem 2021;21(9):1069-1081 9 Citations |
| 1 | Chondroblastoma Expresses RANKL by RNA In Situ Hybridization and May Respond to Denosumab Therapy. (Suster DI, Kurzawa P, Neyaz A, Jarzembowski JA, Lozano-Calderon S, Raskin K, Schwab J, Choy E, Chebib I, Deshpande V) Am J Surg Pathol 2020 Dec;44(12):1581-1590 14 Citations |
| 1 | Cytokines, JAK-STAT Signaling and Radiation-Induced DNA Repair in Solid Tumors: Novel Opportunities for Radiation Therapy. (Hall WA, Sabharwal L, Udhane V, Maranto C, Nevalainen MT) Int J Biochem Cell Biol 2020 Oct;127:105827 8 Citations |
| 1 | Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. (Okamura R, Kurzrock R, Mallory RJ, Fanta PT, Burgoyne AM, Clary BM, Kato S, Sicklick JK) Int J Cancer 2021 Feb 01;148(3):702-712 65 Citations |
| 1 | Evaluation of Imatinib Concentrations in Samples Submitted for BCR-ABL1 or Imatinib Testing-Evidence to Support Therapeutic Drug Monitoring for Dose Optimization? (Smy L, Sadler AJ, McMillin GA) Ther Drug Monit 2020 Aug;42(4):559-564 9 Citations |
| 1 | Cell Lineage-Based Stratification for Glioblastoma. (Wang Z, Sun D, Chen YJ, Xie X, Shi Y, Tabar V, Brennan CW, Bale TA, Jayewickreme CD, Laks DR, Alcantara Llaguno S, Parada LF) Cancer Cell 2020 Sep 14;38(3):366-379.e8 84 Citations |
| 1 | Early stage triple negative breast cancer: Management and future directions. (Chaudhary LN) Semin Oncol 2020 Aug;47(4):201-208 42 Citations |
| 2 | From Theory to Practice: Implementation of Strategies to Reduce Acute Care Visits in Patients With Cancer. (Daly B, Michaelis LC, Sprandio JD, Kapke JT, Narra RK, Malosh E, Zervoudakis A, Holland J, Zablocki M) Am Soc Clin Oncol Educ Book 2020 May;40:85-94 |
| 2 | BCR-ABL tyrosine kinase inhibitors promote pathological changes in dilator phenotype in the human microvasculature. (Durand MJ, Hader SN, Derayunan A, Zinkevich N, McIntosh JJ, Beyer AM) Microcirculation 2020 Oct;27(7):e12625 9 Citations |
| 1 | Gefitinib Inhibits Invasion and Metastasis of Osteosarcoma via Inhibition of Macrophage Receptor Interacting Serine-Threonine Kinase 2. (Maloney C, Kallis MP, Edelman M, Tzanavaris C, Lesser M, Soffer SZ, Symons M, Steinberg BM) Mol Cancer Ther 2020 Jun;19(6):1340-1350 26 Citations |
| 1 | Flavonoid-Based Cancer Therapy: An Updated Review. (Hosseinzadeh E, Hassanzadeh A, Marofi F, Alivand MR, Solali S) Anticancer Agents Med Chem 2020;20(12):1398-1414 44 Citations |
| 1 | Identifying Cancer Patients at Risk for Heart Failure Using Machine Learning Methods. (Yang X, Gong Y, Waheed N, March K, Bian J, Hogan WR, Wu Y) AMIA Annu Symp Proc 2019;2019:933-941 18 Citations |
| 1 | Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability. (Wu PK, Hong SK, Starenki D, Oshima K, Shao H, Gestwicki JE, Tsai S, Park JI) Oncogene 2020 May;39(21):4257-4270 38 Citations |
| 1 | KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. (Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM) N Engl J Med 2020 Apr 02;382(14):1331-1342 1579 Citations |
| 1 | Boholamide A, an APD-Class, Hypoxia-Selective Cyclodepsipeptide. (Torres JP, Lin Z, Fenton DS, Leavitt LU, Niu C, Lam PY, Robes JM, Peterson RT, Concepcion GP, Haygood MG, Olivera BM, Schmidt EW) J Nat Prod 2020 Apr 24;83(4):1249-1257 15 Citations |
| 1 | Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. (van Rhee F, Casper C, Voorhees PM, Fayad LE, Gibson D, Kanhai K, Kurzrock R) Lancet Haematol 2020 Mar;7(3):e209-e217 55 Citations |
| 1 | New drug approvals in oncology. (Kurzrock R, Kantarjian HM, Kesselheim AS, Sigal EV) Nat Rev Clin Oncol 2020 Mar;17(3):140-146 45 Citations |
| 1 | Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. (Jardim DL, De Melo Gagliato D, Nikanjam M, Barkauskas DA, Kurzrock R) Oncoimmunology 2020;9(1):1710052 28 Citations |
| 1 | Experience with ponatinib in paediatric patients with leukaemia. (Rossoff J, Huynh V, Rau RE, Macy ME, Sulis ML, Schultz KR, Burke MJ, Athale U, O'Brien MM, Gregory JJ Jr, van der Sluis IM, Keller FG, Zwaan CM, Suttorp M, Hijiya N) Br J Haematol 2020 Apr;189(2):363-368 30 Citations |
| 1 | Antiproliferative activity of diarylnaphthylpyrrolidine derivative via dual target inhibition. (Verma AK, Fatima K, Dudi RK, Tabassum M, Iqbal H, Kumar Y, Luqman S, Mondhe DM, Chanda D, Khan F, Shanker K, Negi AS) Eur J Med Chem 2020 Feb 15;188:111986 10 Citations |
| 1 | Statistical determination of synergy based on Bliss definition of drugs independence. (Demidenko E, Miller TW) PLoS One 2019;14(11):e0224137 121 Citations |
| 1 | A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. (Kahl BS, Hamadani M, Radford J, Carlo-Stella C, Caimi P, Reid E, Feingold JM, Ardeshna KM, Solh M, Heffner LT, Ungar D, He S, Boni J, Havenith K, O'Connor OA) Clin Cancer Res 2019 Dec 01;25(23):6986-6994 95 Citations |
| 1 | Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy. (Shee K, Wells JD, Jiang A, Miller TW) PLoS One 2019;14(11):e0224267 39 Citations |
| 1 | Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma. (August KJ, Farooki S, Fulbright JM, August A, Portnoy JM, Pommert L, Burke MJ, Guest EM) Pediatr Blood Cancer 2020 Jan;67(1):e28021 23 Citations |
| 1 | A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition. (Shee K, Wells JD, Ung M, Hampsch RA, Traphagen NA, Yang W, Liu SC, Zeldenrust MA, Wang L, Kalari KR, Yu J, Boughey JC, Demidenko E, Kettenbach AN, Cheng C, Goetz MP, Miller TW) Clin Cancer Res 2020 Jan 01;26(1):159-170 1 Citation |
| 1 | Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. (González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ, PRIMA/ENGOT-OV26/GOG-3012 Investigators) N Engl J Med 2019 Dec 19;381(25):2391-2402 1888 Citations |
| 1 | Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. (Falchook G, Rosen S, LoRusso P, Watts J, Gupta S, Coombs CC, Talpaz M, Kurzrock R, Mita M, Cassaday R, Harb W, Peguero J, Smith DC, Piha-Paul SA, Szmulewitz R, Noel MS, Yeleswaram S, Liu P, Switzky J, Zhou G, Zheng F, Mehta A) Clin Cancer Res 2020 Mar 15;26(6):1247-1257 70 Citations |
| 2 | Goals of Treatment Sequencing for Localized Pancreatic Cancer. (Evans DB, Kamgar M, Tsai S) Ann Surg Oncol 2019 Nov;26(12):3815-3819 8 Citations |
| 1 | Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. (Nikanjam M, Arguello D, Gatalica Z, Swensen J, Barkauskas DA, Kurzrock R) Int J Cancer 2020 Jun 01;146(11):3087-3097 23 Citations |
| 1 | microRNA-21 Expression as Prognostic and Therapeutic Response Marker in Chronic Myeloid Leukaemia Patients. (Mirza MAB, Guru SA, Abdullah SM, Rizvi A, Saxena A) Asian Pac J Cancer Prev 2019 Aug 01;20(8):2379-2383 12 Citations |
| 6 | Use of Neoadjuvant Chemotherapy in the Treatment of Locally Advanced Rectal Cancer. (Hu KY, Simpson MT, Blank JJ, Szabo A, Eastwood D, Ludwig KA, Peterson CY, Ridolfi TJ) J Surg Res 2019 Nov;243:447-452 11 Citations |
| 1 | Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals. (Kurzrock R, Gurski LA, Carlson RW, Ettinger DS, Horwitz SM, Kumar SK, Million L, von Mehren M, Benson AB 3rd) Ann Oncol 2019 Oct 01;30(10):1647-1652 16 Citations |
| 1 | Covered and uncovered biliary metal stents provide similar relief of biliary obstruction during neoadjuvant therapy in pancreatic cancer: a randomized trial. (Seo DW, Sherman S, Dua KS, Slivka A, Roy A, Costamagna G, Deviere J, Peetermans J, Rousseau M, Nakai Y, Isayama H, Kozarek R, Biliary SEMS During Neoadjuvant Therapy Study Group) Gastrointest Endosc 2019 Oct;90(4):602-612.e4 96 Citations |
| 1 | HPA aptamer functionalized paclitaxel-loaded PLGA nanoparticles for enhanced anticancer therapy through targeted effects and microenvironment modulation. (Duan T, Xu Z, Sun F, Wang Y, Zhang J, Luo C, Wang M) Biomed Pharmacother 2019 Sep;117:109121 62 Citations |
| 1 | Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia. (Keating AK, Gossai N, Phillips CL, Maloney K, Campbell K, Doan A, Bhojwani D, Burke MJ, Verneris MR) Blood Adv 2019 Jul 09;3(13):1926-1929 59 Citations |
| 1 | CID-6033590 inhibits p38MAPK pathway and induces S-phase cell cycle arrest and apoptosis in DU145 and PC-3 cells. (Sharma GP, Gurung SK, Inam A, Nigam L, Bist A, Mohapatra D, Senapati S, Subbarao N, Azam A, Mondal N) Toxicol In Vitro 2019 Oct;60:420-436 14 Citations |
| 1 | 3-Arylindanones and related compounds as antiproliferative agents against colorectal cancer. (Srivastava A, Ravi K, Fatima K, Maheshwari M, Ashraf R, Hasanain M, Yadav P, Iqbal H, Kumar Y, Luqman S, Chanda D, Khan F, Shanker K, Sarkar J, Negi AS) Chem Biol Drug Des 2019 Sep;94(3):1694-1705 4 Citations |
| 1 | Testicular tissue cryopreservation: 8 years of experience from a coordinated network of academic centers. (Valli-Pulaski H, Peters KA, Gassei K, Steimer SR, Sukhwani M, Hermann BP, Dwomor L, David S, Fayomi AP, Munyoki SK, Chu T, Chaudhry R, Cannon GM, Fox PJ, Jaffe TM, Sanfilippo JS, Menke MN, Lunenfeld E, Abofoul-Azab M, Sender LS, Messina J, Klimpel LM, Gosiengfiao Y, Rowell EE, Hsieh MH, Granberg CF, Reddy PP, Sandlow JI, Huleihel M, Orwig KE) Hum Reprod 2019 Jun 04;34(6):966-977 134 Citations |
| 1 | Risk Factors and Outcomes of Nonmelanoma Skin Cancer in Children and Young Adults. (Huang JT, Coughlin CC, Hawryluk EB, Hook K, Humphrey SR, Kruse L, Lawley L, Al-Sayegh H, London WB, Marghoob A, Phung TL, Pope E, Gerami P, Schmidt B, Robinson S, Bartenstein D, Bahrani E, Brahmbhatt M, Chen L, Haddock E, Mansour D, Nguyen J, Raisanen T, Tran G, Travis K, Wolner Z, Eichenfield LF) J Pediatr 2019 Aug;211:152-158 30 Citations |
| 1 | A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. (Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP) Blood Adv 2019 May 28;3(10):1568-1573 25 Citations |
| 4 | Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. (Cheng G, Zhang Q, Pan J, Lee Y, Ouari O, Hardy M, Zielonka M, Myers CR, Zielonka J, Weh K, Chang AC, Chen G, Kresty L, Kalyanaraman B, You M) Nat Commun 2019 May 17;10(1):2205 220 Citations |
| 1 | Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. (Ustun C, Le-Rademacher J, Wang HL, Othus M, Sun Z, Major B, Zhang MJ, Storrick E, Lafky JM, Chow S, Mrózek K, Attar EC, Nand S, Bloomfield CD, Cripe LD, Tallman MS, Appelbaum F, Larson RA, Marcucci G, Roboz GJ, Uy GL, Stone RM, Jatoi A, Shea TC, de Lima M, Foran JM, Sandmaier BM, Litzow MR, Erba HP, Hurria A, Weisdorf DJ, Artz AS) Leukemia 2019 Nov;33(11):2599-2609 95 Citations |
| 3 | STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models. (Jing W, McAllister D, Vonderhaar EP, Palen K, Riese MJ, Gershan J, Johnson BD, Dwinell MB) J Immunother Cancer 2019 Apr 29;7(1):115 168 Citations |
| 1 | The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models. (Zhou R, Wang S, Wen H, Wang M, Wu M) Exp Cell Res 2019 Jul 15;380(2):141-148 20 Citations |
| 1 | Differentiated Thyroid Cancer in the Pediatric/Adolescent Population: Evolution of Treatment. (Remiker AS, Chuang J, Corathers S, Rutter MM, Rutter MJ, Myer CM 4th, Gelfand MJ, Trout AT, Geller JI) J Pediatr Hematol Oncol 2019 Oct;41(7):532-536 11 Citations |
| 2 | FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical? (Levis MJ, Chen YB, Hamadani M, Horowitz MM, Jones RJ, Blood and Marrow Transplant Clinical Trials Network) J Clin Oncol 2019 Jul 01;37(19):1604-1607 28 Citations |
| 1 | Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. (Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR) Clin Cancer Res 2019 Jul 15;25(14):4264-4270 81 Citations |
| 1 | Synergistic antitumor effect of anti-PD-L1 combined with oxaliplatin on a mouse tumor model. (Golchin S, Alimohammadi R, Rostami Nejad M, Jalali SA) J Cell Physiol 2019 Nov;234(11):19866-19874 33 Citations |
| 2 | Stem cell damage after chemotherapy- can we do better? (Tang J, Zhu N, Rao S, Carlson KS) Best Pract Res Clin Haematol 2019 Mar;32(1):31-39 7 Citations |
| 1 | Anti-CD24 Antibody-Nitric Oxide Conjugate Selectively and Potently Suppresses Hepatic Carcinoma. (Sun F, Wang Y, Luo X, Ma Z, Xu Y, Zhang X, Lv T, Zhang Y, Wang M, Huang Z, Zhang J) Cancer Res 2019 Jul 01;79(13):3395-3405 58 Citations |
| 1 | Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. (Garcia-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, Patnaik M, Odenike O, Sayar H, Tummala M, Patel P, Maness-Harris L, Stuart R, Traer E, Karamlou K, Yacoub A, Ghalie R, Giorgino R, Atallah E) Blood Adv 2019 Feb 26;3(4):508-518 77 Citations |
| 1 | Predict drug sensitivity of cancer cells with pathway activity inference. (Wang X, Sun Z, Zimmermann MT, Bugrim A, Kocher JP) BMC Med Genomics 2019 Jan 31;12(Suppl 1):15 39 Citations |
| 1 | Downregulation of HDAC2 and HDAC3 via oleuropein as a potent prevention and therapeutic agent in MCF-7 breast cancer cells. (Bayat S, Mansoori Derakhshan S, Mansoori Derakhshan N, Shekari Khaniani M, Alivand MR) J Cell Biochem 2019 Jun;120(6):9172-9180 41 Citations |
| 1 | Case 1: Syncope in a 16-year-old Girl. (Sadanand A, Ladell M, Fischer K) Pediatr Rev 2019 Jan;40(1):37-39 |
| 1 | Reconstitution and Characterization of BCL-2 Family Proteins in Lipid Bilayer Nanodiscs. (Yao Y, Marassi FM) Methods Mol Biol 2019;1877:233-246 9 Citations |
| 1 | Molecular Mechanism of Inhibition of Acid Ceramidase by Carmofur. (Dementiev A, Joachimiak A, Nguyen H, Gorelik A, Illes K, Shabani S, Gelsomino M, Ahn EE, Nagar B, Doan N) J Med Chem 2019 Jan 24;62(2):987-992 64 Citations |
| 1 | Cytotoxic therapy in acute myeloid leukemia: not quite dead yet. (Michaelis LC) Hematology Am Soc Hematol Educ Program 2018 Nov 30;2018(1):51-62 8 Citations |
| 1 | Metastatic Calcinosis Cutis Associated With a Selective FGFR Inhibitor. (Carr DR, Pootrakul L, Chen HZ, Chung CG) JAMA Dermatol 2019 Jan 01;155(1):122-123 16 Citations |
| 1 | Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. (Gu C, Jing X, Holman C, Sompallae R, Zhan F, Tricot G, Yang Y, Janz S) BMC Cancer 2018 Nov 21;18(1):1152 27 Citations |
| 2 | Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. (Brunstein CG, Pasquini MC, Kim S, Fei M, Adekola K, Ahmed I, Aljurf M, Agrawal V, Auletta JJ, Battiwalla M, Bejanyan N, Bubalo J, Cerny J, Chee L, Ciurea SO, Freytes C, Gadalla SM, Gale RP, Ganguly S, Hashmi SK, Hematti P, Hildebrandt G, Holmberg LA, Lahoud OB, Landau H, Lazarus HM, de Lima M, Mathews V, Maziarz R, Nishihori T, Norkin M, Olsson R, Reshef R, Rotz S, Savani B, Schouten HC, Seo S, Wirk BM, Yared J, Mineishi S, Rogosheske J, Perales MA) Biol Blood Marrow Transplant 2019 Mar;25(3):480-487 13 Citations |
| 2 | Incorporating newer agents in the treatment of acute myeloid leukemia. (Raj RV, Abedin SM, Atallah E) Leuk Res 2018 Nov;74:113-120 9 Citations |
| 1 | Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. (Pavel ME, Phan AT, Wolin EM, Mirakhur B, Liyanage N, Pitman Lowenthal S, Fisher GA Jr, Vinik AI, CLARINET Study Investigators) Oncologist 2019 Apr;24(4):463-474 15 Citations |
| 1 | Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. (Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P) N Engl J Med 2018 Dec 27;379(26):2495-2505 2395 Citations |
| 1 | Perioperative chemotherapy is not associated with improved survival in high-grade truncal sarcoma. (Yu PY, Beal EW, Hughes TM, Suarez-Kelly LP, Shelby RD, Ethun CG, Tran TB, Poultsides G, Charlson J, Gamblin TC, Tseng J, Roggin KK, Chouliaras K, Votanopoulos K, Krasnick BA, Fields RC, Pollock RE, Grignol V, Cardona K, Howard JH) J Surg Res 2018 Nov;231:248-256 3 Citations |
| 4 | Low-Temperature EPR Spectroscopy as a Probe-Free Technique for Monitoring Oxidants Formed in Tumor Cells and Tissues: Implications in Drug Resistance and OXPHOS-Targeted Therapies. (Kalyanaraman B, Cheng G, Zielonka J, Bennett B) Cell Biochem Biophys 2019 Mar;77(1):89-98 15 Citations |
| 1 | Primary peritoneal hepatoid adenocarcinoma: a diagnostic and therapeutic conundrum in patients with gastrointestinal bleeding. (Inayat F, Zafar F, Lodhi HT, Ullah W) BMJ Case Rep 2018 Sep 18;2018 1 Citation |
| 1 | International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. (van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC) Blood 2018 Nov 15;132(20):2115-2124 349 Citations |
| 1 | Lactic Acidosis in a Critically Ill Patient: Not Always Sepsis. (Schuh AM, Leger KJ, Summers C, Uspal NG) Pediatr Emerg Care 2018 Sep;34(9):e165-e167 12 Citations |
| 1 | Synthesis and evaluation of 4-cycloheptylphenols as selective Estrogen receptor-β agonists (SERBAs). (Sampathi Perera KLI, Hanson AM, Lindeman S, Imhoff A, Lu X, Sem DS, Donaldson WA) Eur J Med Chem 2018 Sep 05;157:791-804 5 Citations |
| 2 | Daratumumab in Primary Effusion Lymphoma. (Shah NN, Singavi AK, Harrington A) N Engl J Med 2018 Aug 16;379(7):689-690 35 Citations |
| 1 | Transformation of a non-secretory neuroendocrine tumor to insulinoma after treatment with Sunitinib: A case report and review of the literature. (Clover T, Abdelkader A, Guru Murthy GS) J Oncol Pharm Pract 2019 Sep;25(6):1516-1519 5 Citations |
| 1 | Rare breast metastasis from adenoid cystic carcinoma of the submandibular gland. (Krucoff KB, Shammas RL, Stoecker M, Tolnitch LA) BMJ Case Rep 2018 Aug 01;2018 3 Citations |
| 5 | Incidence and survival of therapy related myeloid neoplasm in United States. (Guru Murthy GS, Hamadani M, Dhakal B, Hari P, Atallah E) Leuk Res 2018 Aug;71:95-99 35 Citations |
| 2 | Stromal PTEN determines mammary epithelial response to radiotherapy. (Sizemore GM, Balakrishnan S, Thies KA, Hammer AM, Sizemore ST, Trimboli AJ, Cuitiño MC, Steck SA, Tozbikian G, Kladney RD, Shinde N, Das M, Park D, Majumder S, Krishnan S, Yu L, Fernandez SA, Chakravarti A, Shields PG, White JR, Yee LD, Rosol TJ, Ludwig T, Park M, Leone G, Ostrowski MC) Nat Commun 2018 Jul 17;9(1):2783 23 Citations |
| 2 | Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. (Allen CE, Marsh R, Dawson P, Bollard CM, Shenoy S, Roehrs P, Hanna R, Burroughs L, Kean L, Talano JA, Schultz KR, Pai SY, Baker KS, Andolina JR, Stenger EO, Connelly J, Ramirez A, Bryant C, Eapen M, Pulsipher MA) Blood 2018 Sep 27;132(13):1438-1451 95 Citations |
| 1 | Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. (Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C) Haematologica 2018 Sep;103(9):1511-1517 153 Citations |
| 1 | The impact of pharmacokinetic gene profiles across human cancers. (Zimmermann MT, Therneau TM, Kocher JA) BMC Cancer 2018 May 21;18(1):577 3 Citations |
| 1 | Cancer research in the United States: A critical review of current status and proposal for alternative models. (Kantarjian HM, Prat F, Steensma DP, Kurzrock R, Stewart DJ, Sekeres MA, Leveque J) Cancer 2018 Jul 15;124(14):2881-2889 19 Citations |
| 1 | Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia. (Michaelis LC, Klepin HD, Walter RB) Expert Opin Pharmacother 2018 Jun;19(8):865-882 21 Citations |
| 1 | Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes. (Hall WA, Pugh SL, Wefel JS, Armstrong TS, Gilbert MR, Brachman DG, Werner-Wasik M, Wendland MM, Brown PD, Chao ST, Roof KS, Robins HI, Mehta MP, Curran WJ Jr, Movsas B) Neurosurgery 2019 Jan 01;84(1):66-76 11 Citations |
| 4 | Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. (Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE) BMC Cancer 2018 Apr 02;18(1):359 17 Citations |
| 1 | The importance of greater speed in drug development for advanced malignancies. (Stewart DJ, Stewart AA, Wheatley-Price P, Batist G, Kantarjian HM, Schiller J, Clemons M, Bradford JP, Gillespie L, Kurzrock R) Cancer Med 2018 May;7(5):1824-1836 37 Citations |
| 4 | Gallium Maltolate Disrupts Tumor Iron Metabolism and Retards the Growth of Glioblastoma by Inhibiting Mitochondrial Function and Ribonucleotide Reductase. (Chitambar CR, Al-Gizawiy MM, Alhajala HS, Pechman KR, Wereley JP, Wujek R, Clark PA, Kuo JS, Antholine WE, Schmainda KM) Mol Cancer Ther 2018 Jun;17(6):1240-1250 51 Citations |
| 1 | Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detection-The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress. (Quryshi N, Norwood Toro LE, Ait-Aissa K, Kong A, Beyer AM) Int J Mol Sci 2018 Mar 10;19(3) 24 Citations |
| 1 | Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics. (Ikeda S, Lim JS, Kurzrock R) Mol Cancer Ther 2018 May;17(5):1114-1122 56 Citations |
| 1 | Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy. (Floros KV, Lochmann TL, Hu B, Monterrubio C, Hughes MT, Wells JD, Morales CB, Ghotra MS, Costa C, Souers AJ, Boikos SA, Leverson JD, Tan M, Serra V, Koblinski JE, Arribas J, Prat A, Paré L, Miller TW, Dozmorov MG, Harada H, Windle BE, Scaltriti M, Faber AC) Proc Natl Acad Sci U S A 2018 Mar 13;115(11):E2594-E2603 30 Citations |
| 1 | Gallium Complexes as Anticancer Drugs. (Chitambar CR) Met Ions Life Sci 2018 Feb 05;18 25 Citations |
| 1 | Dasatinib dose management for the treatment of chronic myeloid leukemia. (Talpaz M, Saglio G, Atallah E, Rousselot P) Cancer 2018 Apr 15;124(8):1660-1672 22 Citations |
| 1 | A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia. (Curtis SA, Curtis BR, Lee AI, Hendrickson JE, Lacy J, Podoltsev NA) Hematology 2018 Aug;23(7):429-432 5 Citations |
| 1 | Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma. (Huynh M, Pak C, Markovina S, Callander NS, Chng KS, Wuerzberger-Davis SM, Bakshi DD, Kink JA, Hematti P, Hope C, Asimakopoulos F, Rui L, Miyamoto S) J Biol Chem 2018 Feb 16;293(7):2452-2465 37 Citations |
| 1 | Considerations for sentinel lymph node biopsy in breast cancer patients with biopsy proven axillary disease prior to neoadjuvant treatment. (Qu LT, Peters S, Cobb AN, Godellas CV, Perez CB, Vaince FT) Am J Surg 2018 Mar;215(3):530-533 6 Citations |
| 1 | Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. (Huang Y, Hu W, Huang J, Shen F, Sun Y, Ivan C, Pradeep S, Dood R, Haemmerle M, Jiang D, Mangala LS, Noh K, Hansen JM, Dalton HJ, Previs RA, Nagaraja AS, McGuire M, Jennings NB, Broaddus R, Coleman RL, Sood AK) Mol Cancer Ther 2018 Feb;17(2):464-473 7 Citations |
| 1 | Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors. (Jardim DL, de Melo Gagliato D, Giles FJ, Kurzrock R) Clin Cancer Res 2018 Apr 15;24(8):1785-1794 46 Citations |
| 1 | Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL). (Zhang JY, Briski R, Devata S, Kaminski MS, Phillips TJ, Mayer TL, Bailey NG, Wilcox RA) Am J Hematol 2018 Mar;93(3):394-400 28 Citations |
| 1 | Resolvins suppress tumor growth and enhance cancer therapy. (Sulciner ML, Serhan CN, Gilligan MM, Mudge DK, Chang J, Gartung A, Lehner KA, Bielenberg DR, Schmidt B, Dalli J, Greene ER, Gus-Brautbar Y, Piwowarski J, Mammoto T, Zurakowski D, Perretti M, Sukhatme VP, Kaipainen A, Kieran MW, Huang S, Panigrahy D) J Exp Med 2018 Jan 02;215(1):115-140 228 Citations |
| 1 | Narrower insight to SIRT1 role in cancer: A potential therapeutic target to control epithelial-mesenchymal transition in cancer cells. (Choupani J, Mansoori Derakhshan S, Bayat S, Alivand MR, Shekari Khaniani M) J Cell Physiol 2018 Jun;233(6):4443-4457 36 Citations |
| 1 | Relapsed acute lymphoblastic leukemia: Is it crucial to achieve molecular remission prior to transplant? (Eapen M) Best Pract Res Clin Haematol 2017 Dec;30(4):317-319 3 Citations |
| 1 | Molecular Tumor Boards: Realizing Precision Oncology Therapy. (Patel M, Kato SM, Kurzrock R) Clin Pharmacol Ther 2018 Feb;103(2):206-209 25 Citations |
| 1 | Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy? (Chaudhary LN, Wilkinson KH, Kong A) Surg Oncol Clin N Am 2018 Jan;27(1):141-153 138 Citations |
| 1 | Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. (Burke MJ, Devidas M, Maloney K, Angiolillo A, Schore R, Dunsmore K, Larsen E, Mattano LA Jr, Salzer W, Winter SS, Carroll W, Winick NJ, Loh ML, Raetz E, Hunger SP, Bleyer A) Leuk Lymphoma 2018 Jul;59(7):1624-1633 41 Citations |
| 1 | Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. (Schöffski P, Gordon M, Smith DC, Kurzrock R, Daud A, Vogelzang NJ, Lee Y, Scheffold C, Shapiro GI) Eur J Cancer 2017 Nov;86:296-304 68 Citations |
| 1 | PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India. (Guru SA, Mir R, Bhat M, Najar I, Zuberi M, Sumi M, Masroor M, Gupta N, Saxena A) Tumour Biol 2017 Oct;39(10):1010428317713857 3 Citations |
| 5 | A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds. (Kalyanaraman B, Cheng G, Hardy M, Ouari O, Lopez M, Joseph J, Zielonka J, Dwinell MB) Redox Biol 2018 Apr;14:316-327 213 Citations |
| 1 | Patient- and Cell Type-Specific Heterogeneity of Metformin Response. (Asiedu MK, Barron M, Aubry MC, Wigle DA) Basic Clin Pharmacol Toxicol 2018 Feb;122(2):214-222 14 Citations |
| 1 | Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. (Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK) Clin Cancer Res 2017 Nov 15;23(22):7034-7046 87 Citations |
| 6 | Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? (Barnes CA, Krepline AN, Aldakkak M, Clarke CN, Christians KK, Khan AH, Hunt BC, Ritch PS, George B, Hall WA, Erickson BA, Evans DB, Tsai S) J Gastrointest Surg 2017 Nov;21(11):1793-1803 29 Citations |
| 1 | First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. (Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Peeters M, Findlay M, Weaver A, Mills J, Wilson C, Adams R, Francis A, Moschandreas J, Virdee PS, Dutton P, Love S, Gebski V, Gray A, FOXFIRE trial investigators, SIRFLOX trial investigators, FOXFIRE-Global trial investigators, van Hazel G, Sharma RA) Lancet Oncol 2017 Sep;18(9):1159-1171 334 Citations |
| 1 | A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma. (Vergote IB, Smith DC, Berger R, Kurzrock R, Vogelzang NJ, Sella A, Wheler J, Lee Y, Foster PG, Weitzman R, Buckanovich RJ) Eur J Cancer 2017 Sep;83:229-236 31 Citations |
| 5 | Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. (Zielonka J, Joseph J, Sikora A, Hardy M, Ouari O, Vasquez-Vivar J, Cheng G, Lopez M, Kalyanaraman B) Chem Rev 2017 Aug 09;117(15):10043-10120 1445 Citations |
| 1 | Emerging treatment options for patients with gastroenteropancreatic neuroendocrine tumors. (Phan AT) Clin Adv Hematol Oncol 2017 Apr;15 Suppl 4(4):10-14 1 Citation |
| 1 | Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: insights from the 2017 ASCO Gastrointestinal Cancers Symposium. (Iyer R, Phan AT, Boudreaux JP) Clin Adv Hematol Oncol 2017 Apr;15 Suppl 4(4):1-24 4 Citations |
| 1 | Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-Small Cell Lung Cancer: NRG Oncology RTOG 0839. (Edelman MJ, Hu C, Le QT, Donington JS, D'Souza WD, Dicker AP, Loo BW, Gore EM, Videtic GMM, Evans NR, Leach JW, Diehn M, Feigenberg SJ, Chen Y, Paulus R, Bradley JD) J Thorac Oncol 2017 Sep;12(9):1413-1420 19 Citations |
| 1 | Elotuzumab as a novel anti-myeloma immunotherapy. (Radhakrishnan SV, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D) Hum Vaccin Immunother 2017 Aug 03;13(8):1751-1757 6 Citations |
| 1 | Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. (Khoury HJ, Williams LA, Atallah E, Hehlmann R) Am Soc Clin Oncol Educ Book 2017;37:468-479 12 Citations |
| 3 | Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation. (Bitan M, Ahn KW, Millard HR, Pulsipher MA, Abdel-Azim H, Auletta JJ, Brown V, Chan KW, Diaz MA, Dietz A, Vincent MG, Guilcher G, Hale GA, Hayashi RJ, Keating A, Mehta P, Myers K, Page K, Prestidge T, Shah NN, Smith AR, Woolfrey A, Thiel E, Davies SM, Eapen M) Biol Blood Marrow Transplant 2017 Sep;23(9):1523-1530 15 Citations |
| 2 | PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. (Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM) Blood 2017 Jul 13;130(2):221-228 219 Citations |
| 3 | Combined AURKA and H3K9 Methyltransferase Targeting Inhibits Cell Growth By Inducing Mitotic Catastrophe. (Mathison A, Salmonson A, Missfeldt M, Bintz J, Williams M, Kossak S, Nair A, de Assuncao TM, Christensen T, Buttar N, Iovanna J, Huebert R, Lomberk G) Mol Cancer Res 2017 Aug;15(8):984-997 18 Citations |
| 5 | Modified Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling, Antiproliferative Effects and Future EPR Studies. (Kalyanaraman B, Cheng G, Hardy M, Ouari O, Sikora A, Zielonka J, Dwinell MB) Cell Biochem Biophys 2017 Dec;75(3-4):311-317 23 Citations |
| 1 | Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients. (Nikanjam M, Liu S, Yang J, Kurzrock R) Oncologist 2017 May;22(5):576-584 41 Citations |
| 1 | Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer. (Rabinowicz N, Mangala LS, Brown KR, Checa-Rodriguez C, Castiel A, Moskovich O, Zarfati G, Trakhtenbrot L, Levy-Barda A, Jiang D, Rodriguez-Aguayo C, Pradeep S, van Praag Y, Lopez-Berestein G, David A, Novikov I, Huertas P, Rottapel R, Sood AK, Izraeli S) Oncotarget 2017 Apr 18;8(16):27380-27392 10 Citations |
| 1 | Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer. (Hampsch RA, Shee K, Bates D, Lewis LD, Désiré L, Leblond B, Demidenko E, Stefan K, Huang YH, Miller TW) Oncotarget 2017 Mar 28;8(13):21806-21817 33 Citations |
| 1 | Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset. (Padi SKR, Luevano LA, An N, Pandey R, Singh N, Song JH, Aster JC, Yu XZ, Mehrotra S, Kraft AS) Oncotarget 2017 May 02;8(18):30199-30216 37 Citations |
| 1 | Hydrogen peroxide activated quinone methide precursors with enhanced DNA cross-linking capability and cytotoxicity towards cancer cells. (Wang Y, Fan H, Balakrishnan K, Lin Z, Cao S, Chen W, Fan Y, Guthrie QA, Sun H, Teske KA, Gandhi V, Arnold LA, Peng X) Eur J Med Chem 2017 Jun 16;133:197-207 30 Citations |
| 1 | Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. (Moy JD, Moskovitz JM, Ferris RL) Eur J Cancer 2017 May;76:152-166 90 Citations |
| 1 | Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. (Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CAF, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM) Cancer 2017 Jul 01;123(13):2489-2496 17 Citations |
| 1 | AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells. (Webster PJ, Littlejohns AT, Gaunt HJ, Prasad KR, Beech DJ, Burke DA) Cell Cycle 2017;16(22):2176-2182 25 Citations |
| 1 | A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma. (Cohen JB, Maddocks KJ, Huang Y, Christian BA, Jaglowski SM, Flowers CR, Blum KA) Leuk Lymphoma 2017 Sep;58(9):1-2 3 Citations |
| 2 | Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts. (Bian B, Bigonnet M, Gayet O, Loncle C, Maignan A, Gilabert M, Moutardier V, Garcia S, Turrini O, Delpero JR, Giovannini M, Grandval P, Gasmi M, Ouaissi M, Secq V, Poizat F, Nicolle R, Blum Y, Marisa L, Rubis M, Raoul JL, Bradner JE, Qi J, Lomberk G, Urrutia R, Saul A, Dusetti N, Iovanna J) EMBO Mol Med 2017 Apr;9(4):482-497 61 Citations |
| 1 | JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease. (Patel M, Ikeda S, Pilat SR, Kurzrock R) JAMA Dermatol 2017 May 01;153(5):449-452 11 Citations |
| 1 | Tumor-Penetrating Nanoparticles for Enhanced Anticancer Activity of Combined Photodynamic and Hypoxia-Activated Therapy. (Wang Y, Xie Y, Li J, Peng ZH, Sheinin Y, Zhou J, Oupický D) ACS Nano 2017 Feb 28;11(2):2227-2238 448 Citations |
| 1 | Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer. (Husain H, Scur M, Murtuza A, Bui N, Woodward B, Kurzrock R) Mol Cancer Ther 2017 Feb;16(2):265-272 38 Citations |
| 1 | Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death. (Qin J, Kunda N, Qiao G, Calata JF, Pardiwala K, Prabhakar BS, Maker AV) Cell Death Dis 2017 Feb 02;8(2):e2584 76 Citations |
| 1 | Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. (Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI) Br J Cancer 2017 Feb 14;116(4):432-440 67 Citations |
| 1 | A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation. (Haverkos BM, Huang Y, Elder P, O'Donnell L, Scholl D, Whittaker B, Vasu S, Penza S, Andritsos LA, Devine SM, Jaglowski SM) Bone Marrow Transplant 2017 Apr;52(4):561-566 9 Citations |
| 1 | Palliative interventions for hepatocellular carcinoma patients: analysis of the National Cancer Database. (Hammad AY, Robbins JR, Turaga KK, Christians KK, Gamblin TC, Johnston FM) Ann Palliat Med 2017 Jan;6(1):26-35 22 Citations |
| 1 | Electrochemotherapy - yet another innovative application. (Olasz EB, Kis E) Br J Dermatol 2016 Dec;175(6):1148-1149 1 Citation |
| 1 | Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review. (Jardim DL, Groves ES, Breitfeld PP, Kurzrock R) Cancer Treat Rev 2017 Jan;52:12-21 86 Citations |
| 1 | Wwox-Brca1 interaction: role in DNA repair pathway choice. (Schrock MS, Batar B, Lee J, Druck T, Ferguson B, Cho JH, Akakpo K, Hagrass H, Heerema NA, Xia F, Parvin JD, Aldaz CM, Huebner K) Oncogene 2017 Apr 20;36(16):2215-2227 44 Citations |
| 1 | Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences. (Ryan P, Phan AT, Adelman DT, Iwasaki M) Clin J Oncol Nurs 2016 Dec 01;20(6):E139-E146 8 Citations |
| 1 | The therapeutic potential of iron-targeting gallium compounds in human disease: From basic research to clinical application. (Chitambar CR) Pharmacol Res 2017 Jan;115:56-64 116 Citations |
| 1 | Immune--Mediated Colitis with Novel Immunotherapy : PD-1 Inhibitor Associated Gastrointestinal Toxicity. (Gondal B, Patel P, Gallan A, Hart J, Bissonnette M) Acta Gastroenterol Belg 2016;79(2):379-381 3 Citations |
| 1 | Targeted therapies: What have we learned from SHIVA? (Le Tourneau C, Kurzrock R) Nat Rev Clin Oncol 2016 Dec;13(12):719-720 24 Citations |
| 1 | PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. (Goodman A, Patel SP, Kurzrock R) Nat Rev Clin Oncol 2017 Apr;14(4):203-220 409 Citations |
| 1 | The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors. (Phan AT, Dave B) Cancer Med 2016 Oct;5(10):2953-2964 14 Citations |
| 1 | Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. (Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AK) JCI Insight 2016 Oct 20;1(17):e87754 13 Citations |
| 1 | The Impact of Advancing Age on Recurrence and Survival Following Major Hepatectomy for Colorectal Liver Metastases. (Bell R, Pandanaboyana S, Nisar S, Upasani V, Toogood G, Lodge JP, Prasad KR) J Gastrointest Surg 2017 Feb;21(2):266-274 9 Citations |
| 4 | Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated? (Krepline AN, Christians KK, George B, Ritch PS, Erickson BA, Tolat P, Evans DB, Tsai S) J Surg Oncol 2016 Oct;114(5):581-586 30 Citations |
| 1 | Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. (Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN) Biol Blood Marrow Transplant 2016 Dec;22(12):2117-2125 92 Citations |
| 1 | Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. (Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM) Int J Cancer 2017 Jan 01;140(1):208-215 12 Citations |
| 1 | Targeting CD38 in Refractory Extranodal Natural Killer Cell-T-Cell Lymphoma. (Hari P, Raj RV, Olteanu H) N Engl J Med 2016 Oct 13;375(15):1501-1502 94 Citations |
| 1 | Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129. (Xiao C, Zhang Q, Nguyen-Tân PF, List M, Weber RS, Ang KK, Rosenthal D, Filion EJ, Kim H, Silverman C, Raben A, Galloway T, Fortin A, Gore E, Winquist E, Jones CU, Robinson W, Raben D, Le QT, Bruner D) Int J Radiat Oncol Biol Phys 2017 Mar 15;97(4):667-677 35 Citations |
| 2 | Exploiting agonist biased signaling of chemokines to target cancer. (Roy I, Getschman AE, Volkman BF, Dwinell MB) Mol Carcinog 2017 Mar;56(3):804-813 18 Citations |
| 1 | Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. (Huang Y, Lichtenberger LM, Taylor M, Bottsford-Miller JN, Haemmerle M, Wagner MJ, Lyons Y, Pradeep S, Hu W, Previs RA, Hansen JM, Fang D, Dorniak PL, Filant J, Dial EJ, Shen F, Hatakeyama H, Sood AK) Mol Cancer Ther 2016 Dec;15(12):2894-2904 45 Citations |
| 1 | Metastatic progression is associated with dynamic changes in the local microenvironment. (Aiello NM, Bajor DL, Norgard RJ, Sahmoud A, Bhagwat N, Pham MN, Cornish TC, Iacobuzio-Donahue CA, Vonderheide RH, Stanger BZ) Nat Commun 2016 Sep 15;7:12819 112 Citations |
| 1 | Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors. (Wolin EM, Manon A, Chassaing C, Lewis A, Bertocchi L, Richard J, Phan AT) J Gastrointest Cancer 2016 Dec;47(4):366-374 30 Citations |
| 1 | Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia. (Burke MJ, Rheingold SR) Leuk Lymphoma 2017 Mar;58(3):540-551 42 Citations |
| 1 | An 84-Year-Old Woman With an Indolent B-Cell Lymphoma. (Goodman AM, Choi M, Wang L, Kurzrock R) Oncology (Williston Park) 2016 Aug 15;30(8):705-8, 710, 712 |
| 3 | Disseminated Mycotic Aneurysms following Intravesical Bacillus Calmette-Guérin Therapy for Bladder Cancer: Case Discussion and Systematic Treatment Algorithm. (Lee CJ, Davila D, Dua A, Keyashian B, Dux J, Seabrook GR, Brown K, Malinowski M, Hieb RA, Lewis B) Ann Vasc Surg 2017 Feb;39:284.e5-284.e10 8 Citations |
| 5 | Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma. (Nguyen HS, Milbach N, Hurrell SL, Cochran E, Connelly J, Bovi JA, Schultz CJ, Mueller WM, Rand SD, Schmainda KM, LaViolette PS) AJNR Am J Neuroradiol 2016 Dec;37(12):2201-2208 71 Citations |
| 1 | TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. (Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong D, Kurzrock R) Mol Cancer Ther 2016 Oct;15(10):2475-2485 99 Citations |
| 1 | An appraisal of drug development timelines in the Era of precision oncology. (Jardim DL, Schwaederle M, Hong DS, Kurzrock R) Oncotarget 2016 Aug 16;7(33):53037-53046 32 Citations |
| 1 | Friend or foe? Telomerase as a pharmacological target in cancer and cardiovascular disease. (Ait-Aissa K, Ebben JD, Kadlec AO, Beyer AM) Pharmacol Res 2016 Sep;111:422-433 31 Citations |
| 1 | Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013. (Nikanjam M, Liu S, Kurzrock R) Int J Cancer 2016 Nov 01;139(9):2135-41 30 Citations |
| 1 | Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib. (Lam LH, Capparelli EV, Kurzrock R) Cancer Chemother Pharmacol 2016 Aug;78(2):427-32 25 Citations |
| 1 | Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. (Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, Monahan PO, Feldman DR, Hamilton R, Vaughn DJ, Beard CJ, Budnick A, Johnson EM, Ardeshir-Rouhani-Fard S, Einhorn LH, Lipshultz SE, Dolan ME, Travis LB) J Clin Oncol 2016 Aug 10;34(23):2712-20 239 Citations |
| 2 | The promise of epigenomic therapeutics in pancreatic cancer. (Lomberk GA, Iovanna J, Urrutia R) Epigenomics 2016 Jun;8(6):831-42 48 Citations |
| 1 | First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development. (Jonas O, Calligaris D, Methuku KR, Poe MM, Francois JP, Tranghese F, Changelian A, Sieghart W, Ernst M, Krummel DA, Cook JM, Pomeroy SL, Cima M, Agar NY, Langer R, Sengupta S) J Biomed Nanotechnol 2016 Jun;12(6):1297-302 42 Citations |
| 1 | A humanized anti-DLL4 antibody promotes dysfunctional angiogenesis and inhibits breast tumor growth. (Jia X, Wang W, Xu Z, Wang S, Wang T, Wang M, Wu M) Sci Rep 2016 Jun 15;6:27985 26 Citations |
| 1 | A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1. (Rodriguez V, Kairalla J, Salzer WL, Raetz EA, Loh ML, Carroll AJ, Heerema NA, Wood BL, Borowitz MJ, Burke MJ, Asselin BL, Devidas M, Winick NJ, Carroll WL, Hunger SP, Dreyer ZE) J Pediatr Hematol Oncol 2016 Aug;38(6):409-17 13 Citations |
| 1 | Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. (Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, Mendelsohn J, Kurzrock R) JAMA Oncol 2016 Nov 01;2(11):1452-1459 305 Citations |
| 3 | Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer. (Asare EA, Evans DB, Erickson BA, Aburajab M, Tolat P, Tsai S) J Surg Oncol 2016 Sep;114(3):291-5 18 Citations |
| 1 | Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation. (Qin YZ, Wang Y, Zhu HH, Gale RP, Zhang MJ, Jiang Q, Jiang H, Xu LP, Chen H, Zhang XH, Liu YR, Lai YY, Jiang B, Liu KY, Huang XJ) Chin J Cancer 2016 May 19;35:46 16 Citations |
| 1 | Gallium and its competing roles with iron in biological systems. (Chitambar CR) Biochim Biophys Acta 2016 Aug;1863(8):2044-53 235 Citations |
| 1 | Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. (O'Donnell PH, Alanee S, Stratton KL, Garcia-Grossman IR, Cao H, Ostrovnaya I, Plimack ER, Manschreck C, Ganshert C, Smith ND, Steinberg GD, Vijai J, Offit K, Stadler WM, Bajorin DF) Clin Genitourin Cancer 2016 Dec;14(6):511-517 5 Citations |
| 1 | Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer. (Chamberlin MD, Bernhardt EB, Miller TW) J Cell Biochem 2016 Nov;117(11):2454-63 13 Citations |
| 1 | Is long-term survival possible after margin-positive resection of retroperitoneal sarcoma (RPS)? (Klooster B, Rajeev R, Chrabaszcz S, Charlson J, Miura J, Bedi M, Gamblin TC, Johnston F, Turaga KK) J Surg Oncol 2016 Jun;113(7):823-7 16 Citations |
| 1 | Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia. (Maddocks K, Jones JA) Semin Oncol 2016 Apr;43(2):251-9 28 Citations |
| 1 | Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. (Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R) Mol Cancer Ther 2016 Apr;15(4):533-47 75 Citations |
| 1 | Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. (Rytelewski M, Maleki Vareki S, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JD) Oncotarget 2016 Apr 12;7(15):20825-39 8 Citations |
| 1 | The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer. (Parsons HA, Baracos VE, Hong DS, Abbruzzese J, Bruera E, Kurzrock R) Oncotarget 2016 Apr 12;7(15):20293-304 29 Citations |
| 1 | Exploration of Imaging Biomarkers for Predicting Survival of Patients With Advanced Non-Small Cell Lung Cancer Treated With Antiangiogenic Chemotherapy. (Hayano K, Kulkarni NM, Duda DG, Heist RS, Sahani DV) AJR Am J Roentgenol 2016 May;206(5):987-93 33 Citations |
| 1 | Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents. (Devata S, Wilcox RA) Am J Clin Dermatol 2016 Jun;17(3):225-37 30 Citations |
| 1 | Signaling Pathways and Emerging Therapies in Multiple Myeloma. (Ramakrishnan V, D'Souza A) Curr Hematol Malig Rep 2016 Apr;11(2):156-64 18 Citations |
| 1 | Response. (Jardim DL, Schwaederle M, Lee JJ, Wei C, Mendelsohn J, Schilsky RL, Kurzrock R) J Natl Cancer Inst 2016 Mar;108(3):djw001 1 Citation |
| 1 | VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer. (Xie W, Liu F, Wang Y, Ren X, Wang T, Chen Z, Tang M, Sun F, Li Z, Wang M, Zhang J) Oncotarget 2016 Mar 29;7(13):16445-61 20 Citations |
| 2 | Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia. (Flynn KE, Atallah E) Curr Hematol Malig Rep 2016 Apr;11(2):80-5 47 Citations |
| 1 | Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K. (Yueh AE, Payne SN, Leystra AA, Van De Hey DR, Foley TM, Pasch CA, Clipson L, Matkowskyj KA, Deming DA) PLoS One 2016;11(2):e0148730 16 Citations |
| 1 | A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma. (Wang T, Sun F, Xie W, Tang M, He H, Jia X, Tian X, Wang M, Zhang J) Cancer Lett 2016 Mar 28;372(2):166-78 48 Citations |
| 1 | A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. (Kantarjian HM, Lioure B, Kim SK, Atallah E, Leguay T, Kelly K, Marolleau JP, Escoffre-Barbe M, Thomas XG, Cortes J, Jabbour E, O'Brien S, Bories P, Oprea C, Hatteville L, Dombret H) Clin Lymphoma Myeloma Leuk 2016 Mar;16(3):139-45 64 Citations |
| 1 | Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs. (Fox JM, Moynihan JR, Mott BT, Mazzone JR, Anders NM, Brown PA, Rudek MA, Liu JO, Arav-Boger R, Posner GH, Civin CI, Chen X) Oncotarget 2016 Feb 09;7(6):7268-79 26 Citations |
| 1 | Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. (Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF) Hepatology 2016 Jul;64(1):106-16 656 Citations |
| 1 | Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. (Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Gomez-Panzani E, Ruszniewski P, CLARINET Investigators) Endocr Relat Cancer 2016 Mar;23(3):191-9 226 Citations |
| 1 | Improving the Safety of Oral Chemotherapy at an Academic Medical Center. (Shah NN, Casella E, Capozzi D, McGettigan S, Gangadhar TC, Schuchter L, Myers JS) J Oncol Pract 2016 Jan;12(1):e71-6 23 Citations |
| 1 | Click chemistry, 3D-printing, and omics: the future of drug development. (Kurzrock R, Stewart DJ) Oncotarget 2016 Jan 19;7(3):2155-8 21 Citations |
| 1 | Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples. (Lu BY, Thanawala SU, Zochowski KC, Burke MJ, Carroll WL, Bhatla T) Leuk Lymphoma 2016 Aug;57(8):1938-41 27 Citations |
| 1 | Long-term follow-up of children with chronic myeloid leukemia after hematopoietic stem cell transplantation and tyrosine kinase inhibitor therapy. (Broglie L, Hijiya N, Helenowski IB, Dilley K, Schneiderman J, Tse W, Duerst R, Kletzel M, Morgan E, Chaudhury S) Leuk Lymphoma 2016;57(4):949-52 5 Citations |
| 1 | Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors. (Falchook GS, Zhou X, Venkatakrishnan K, Kurzrock R, Mahalingam D, Goldman JW, Jung J, Ullmann CD, Milch C, Rosen LS, Sarantopoulos J) Drugs R D 2016 Mar;16(1):45-52 9 Citations |
| 1 | Precision medicine: lessons learned from the SHIVA trial. (Tsimberidou AM, Kurzrock R) Lancet Oncol 2015 Dec;16(16):e579-80 52 Citations |
| 1 | Age-based disparities in treatment and outcomes of retroperitoneal rhabdomyosarcoma. (Kashtan MA, Jayakrishnan TT, Rajeev R, Charlson JC, Johnston F, Clark Gamblin T, Turaga KK) Int J Clin Oncol 2016 Jun;21(3):602-8 4 Citations |
| 2 | Emerging immunotherapy in pediatric lymphoma. (Erker C, Harker-Murray P, Burke MJ) Future Oncol 2016 Jan;12(2):257-70 5 Citations |
| 1 | Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management. (Liu S, Kurzrock R) Semin Oncol 2015 Dec;42(6):863-75 36 Citations |
| 1 | Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress. (Falchook GS, Bastida CC, Kurzrock R) Semin Oncol 2015 Dec;42(6):832-48 100 Citations |
| 1 | First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. (Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R) Clin Cancer Res 2016 Apr 15;22(8):1932-9 90 Citations |
| 1 | Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. (Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE, Cohen EE) Ann Oncol 2016 Feb;27(2):318-23 85 Citations |
| 1 | AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. (Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR) Sci Transl Med 2015 Nov 18;7(314):314ra185 414 Citations |
| 4 | Antitumor Activity of 3-Indolylmethanamines 31B and PS121912. (Guthrie ML, Sidhu PS, Hill EK, Horan TC, Nandhikonda P, Teske KA, Yuan NY, Sidorko M, Rodali R, Cook JM, Han L, Silvaggi NR, Bikle DD, Moore RG, Singh RK, Arnold LA) Anticancer Res 2015 Nov;35(11):6001-7 8 Citations |
| 1 | The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases. (Stewart DJ, Batist G, Kantarjian HM, Bradford JP, Schiller JH, Kurzrock R) Clin Cancer Res 2015 Oct 15;21(20):4561-8 30 Citations |
| 1 | Symptoms and Symptom Clusters Identified by Adolescents and Young Adults With Cancer Using a Symptom Heuristics App. (Ameringer S, Erickson JM, Macpherson CF, Stegenga K, Linder LA) Res Nurs Health 2015 Dec;38(6):436-48 45 Citations |
| 2 | Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Colorectal Liver Metastases: A Meta-Analysis. (Zacharias AJ, Jayakrishnan TT, Rajeev R, Rilling WS, Thomas JP, George B, Johnston FM, Gamblin TC, Turaga KK) PLoS One 2015;10(10):e0139940 47 Citations |
| 1 | New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. (Phan AT, Kunz PL, Reidy-Lagunes DL) Clin Adv Hematol Oncol 2015 May;13(5 Suppl 5):1-18; quiz 1 p following 18 8 Citations |
| 1 | Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction? (Franqui-Machin R, Wendlandt EB, Janz S, Zhan F, Tricot G) Oncotarget 2015 Dec 01;6(38):40496-506 46 Citations |
| 1 | Infliximab Therapy for Corticosteroid-Resistant Ipilimumab-Induced Colitis. (Beniwal-Patel P, Matkowskyj K, Caldera F) J Gastrointestin Liver Dis 2015 Sep;24(3):274 8 Citations |
| 1 | Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion. (de Baere T, Arai Y, Lencioni R, Geschwind JF, Rilling W, Salem R, Matsui O, Soulen MC) Cardiovasc Intervent Radiol 2016 Mar;39(3):334-43 242 Citations |
| 1 | Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. (Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R) J Natl Cancer Inst 2015 Nov;107(11) 165 Citations |
| 1 | A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. (van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R) Oncotarget 2015 Oct 06;6(30):30408-19 63 Citations |
| 1 | Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis. (Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherril B, Ruiz-Soto R, Kaye JA, Hamadani M) J Oncol Pharm Pract 2016 Oct;22(5):666-78 5 Citations |
| 1 | Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. (Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R) J Clin Oncol 2015 Nov 10;33(32):3817-25 404 Citations |
| 1 | Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials. (Nagamani SC, Diaz GA, Rhead W, Berry SA, Le Mons C, Lichter-Konecki U, Bartley J, Feigenbaum A, Schulze A, Longo N, Berquist W, Gallagher R, Bartholomew D, Harding CO, Korson MS, McCandless SE, Smith W, Vockley J, Kronn D, Zori R, Cederbaum S, Merritt JL 2nd, Wong D, Coakley DF, Scharschmidt BF, Dickinson K, Marino M, Lee BH, Mokhtarani M) Mol Genet Metab 2015;116(1-2):29-34 19 Citations |
| 4 | Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis. (Hussain AS, Hari P, Brazauskas R, Arce-Lara C, Pasquini M, Hamadani M, D'Souza A) Am J Hematol 2015 Nov;90(11):E212-3 13 Citations |
| 4 | Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. (Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M) Biol Blood Marrow Transplant 2015 Dec;21(12):2091-2099 54 Citations |
| 1 | Genomic landscape of salivary gland tumors. (Kato S, Elkin SK, Schwaederle M, Tomson BN, Helsten T, Carter JL, Kurzrock R) Oncotarget 2015 Sep 22;6(28):25631-45 47 Citations |
| 2 | Impact of chemotherapy on survival in surgically resected retroperitoneal sarcoma. (Miura JT, Charlson J, Gamblin TC, Eastwood D, Banerjee A, Johnston FM, Turaga KK) Eur J Surg Oncol 2015 Oct;41(10):1386-92 81 Citations |
| 1 | Valproic acid suppresses the self-renewal and proliferation of head and neck cancer stem cells. (Lee SH, Nam HJ, Kang HJ, Samuels TL, Johnston N, Lim YC) Oncol Rep 2015 Oct;34(4):2065-71 21 Citations |
| 1 | Targeting c-MYC in Platinum-Resistant Ovarian Cancer. (Reyes-González JM, Armaiz-Peña GN, Mangala LS, Valiyeva F, Ivan C, Pradeep S, Echevarría-Vargas IM, Rivera-Reyes A, Sood AK, Vivas-Mejía PE) Mol Cancer Ther 2015 Oct;14(10):2260-9 115 Citations |
| 1 | Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. (Stephens DM, Ruppert AS, Weirda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam C, O'Brien S, Keating MJ, Muthusamy N, Abruzzo LV, Heerema NA, Byrd JC) Am J Hematol 2015 Nov;90(11):967-9 2 Citations |
| 1 | RIP1 Cleavage in the Kinase Domain Regulates TRAIL-Induced NF-κB Activation and Lymphoma Survival. (Zhang L, Blackwell K, Workman LM, Chen S, Pope MR, Janz S, Habelhah H) Mol Cell Biol 2015 Oct;35(19):3324-38 31 Citations |
| 1 | Green tea component epigallocatechin-3-gallate decreases expression of osteopontin via a decrease in mRNA half-life in cell lines of metastatic hepatocellular carcinoma. (Zapf MA, Kothari AN, Weber CE, Arffa ML, Wai PY, Driver J, Gupta GN, Kuo PC, Mi Z) Surgery 2015 Oct;158(4):1039-47; discussion 1047-8 16 Citations |
| 1 | Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. (Hong DS, Kurzrock R, Wheler JJ, Naing A, Falchook GS, Fu S, Kim KB, Davies MA, Nguyen LM, George GC, Xu L, Shumaker R, Ren M, Mink J, Bedell C, Andresen C, Sachdev P, O'Brien JP, Nemunaitis J) Clin Cancer Res 2015 Nov 01;21(21):4801-10 66 Citations |
| 5 | Safety and efficacy of transarterial chemoembolization in patients with transjugular intrahepatic portosystemic shunts. (Miura JT, Rilling WS, White SB, Hieb RA, Tutton SM, Patel PJ, Gamblin TC, Hohenwalter EJ) HPB (Oxford) 2015 Aug;17(8):707-12 15 Citations |
| 1 | Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. (Martin RC 2nd, Scoggins CR, Schreeder M, Rilling WS, Laing CJ, Tatum CM, Kelly LR, Garcia-Monaco RD, Sharma VR, Crocenzi TS, Strasberg SM) Cancer 2015 Oct 15;121(20):3649-58 133 Citations |
| 4 | Tyrosine dephosphorylation enhances the therapeutic target activity of epidermal growth factor receptor (EGFR) by disrupting its interaction with estrogen receptor (ER). (Ma S, Yin N, Qi X, Pfister SL, Zhang MJ, Ma R, Chen G) Oncotarget 2015 May 30;6(15):13320-33 16 Citations |
| 5 | p38γ MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion. (Qi X, Yin N, Ma S, Lepp A, Tang J, Jing W, Johnson B, Dwinell MB, Chitambar CR, Chen G) Stem Cells 2015 Sep;33(9):2738-47 32 Citations |
| 1 | Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. (Falchook GS, Venkatakrishnan K, Sarantopoulos J, Kurzrock R, Mita AC, Fu S, Mita MM, Zhou X, Jung JA, Ullmann CD, Milch C, Rosen LS) Int J Clin Pharmacol Ther 2015 Jul;53(7):563-72 9 Citations |
| 1 | Bromodomain and extraterminal inhibition blocks tumor progression and promotes differentiation in neuroblastoma. (Lee S, Rellinger EJ, Kim KW, Craig BT, Romain CV, Qiao J, Chung DH) Surgery 2015 Sep;158(3):819-26 27 Citations |
| 1 | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. (Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr) N Engl J Med 2015 Jun 25;372(26):2509-20 8339 Citations |
| 1 | Poly(lactide-co-glycolide) microspheres for MRI-monitored delivery of sorafenib in a rabbit VX2 model. (Chen J, White SB, Harris KR, Li W, Yap JW, Kim DH, Lewandowski RJ, Shea LD, Larson AC) Biomaterials 2015 Aug;61:299-306 50 Citations |
| 5 | Antiproliferative effects of mitochondria-targeted cationic antioxidants and analogs: Role of mitochondrial bioenergetics and energy-sensing mechanism. (Cheng G, Zielonka J, McAllister D, Hardy M, Ouari O, Joseph J, Dwinell MB, Kalyanaraman B) Cancer Lett 2015 Aug 28;365(1):96-106 70 Citations |
| 4 | The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees. (Neuner JM, Kamaraju S, Charlson JA, Wozniak EM, Smith EC, Biggers A, Smallwood AJ, Laud PW, Pezzin LE) J Natl Cancer Inst 2015 Aug;107(8) 44 Citations |
| 5 | Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. (Cornell RF, Zhong X, Arce-Lara C, Atallah E, Blust L, Drobyski WR, Fenske TS, Pasquini MC, Rizzo JD, Saber W, Hari PN) Bone Marrow Transplant 2015 Jul;50(7):914-7 27 Citations |
| 1 | Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. (Rodon J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R) Ann Oncol 2015 Aug;26(8):1791-8 68 Citations |
| 1 | Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report. (Mohammed A, Janku F, Qi M, Kurzrock R) J Med Case Rep 2015 Feb 28;9:45 5 Citations |
| 1 | XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. (Miyake T, Pradeep S, Wu SY, Rupaimoole R, Zand B, Wen Y, Gharpure KM, Nagaraja AS, Hu W, Cho MS, Dalton HJ, Previs RA, Taylor ML, Hisamatsu T, Kang Y, Liu T, Shacham S, McCauley D, Hawke DH, Wiktorowicz JE, Coleman RL, Sood AK) Clin Cancer Res 2015 Jul 15;21(14):3286-97 40 Citations |
| 1 | Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. (Hong DS, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R) Invest New Drugs 2015 Jun;33(3):621-31 61 Citations |
| 1 | A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients. (Cooper BW, Kindwall-Keller TL, Craig MD, Creger RJ, Hamadani M, Tse WW, Lazarus HM) Clin Lymphoma Myeloma Leuk 2015 Jul;15(7):428-432.e2 74 Citations |
| 3 | Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. (Miura JT, Johnston FM, Tsai S, George B, Thomas J, Eastwood D, Banerjee A, Christians KK, Turaga KK, Pawlik TM, Clark Gamblin T) Ann Surg Oncol 2015 Oct;22(11):3716-23 94 Citations |
| 1 | Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. (Phan AT) Clin Adv Hematol Oncol 2014 Dec;12(12 Suppl 19):3-5 2 Citations |
| 1 | Clinical characteristics and prognostic factors of adult hemophagocytic syndrome patients: a retrospective study of increasing awareness of a disease from a single-center in China. (Li F, Yang Y, Jin F, Dehoedt C, Rao J, Zhou Y, Li P, Yang G, Wang M, Zhang R, Yang Y) Orphanet J Rare Dis 2015 Feb 15;10:20 86 Citations |
| 1 | Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. (Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, Shimabukuro K, Parker BA, Fanta P, Kurzrock R) Cell Cycle 2015;14(8):1252-9 43 Citations |
| 1 | Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. (Gonzalez-Villasana V, Fuentes-Mattei E, Ivan C, Dalton HJ, Rodriguez-Aguayo C, Fernandez-de Thomas RJ, Aslan B, Del C Monroig P, Velazquez-Torres G, Previs RA, Pradeep S, Kahraman N, Wang H, Kanlikilicer P, Ozpolat B, Calin G, Sood AK, Lopez-Berestein G) Clin Cancer Res 2015 May 01;21(9):2127-37 71 Citations |
| 1 | Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. (Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E, Xu H, Huang J, Tao Y, Hao M, Franqui R, Levasseur D, Janz S, Tricot G, Zhan F) Cancer Res 2015 Feb 01;75(3):594-604 76 Citations |
| 1 | Photo activation of HPPH encapsulated in "Pocket" liposomes triggers multiple drug release and tumor cell killing in mouse breast cancer xenografts. (Sine J, Urban C, Thayer D, Charron H, Valim N, Tata DB, Schiff R, Blumenthal R, Joshi A, Puri A) Int J Nanomedicine 2015;10:125-45 32 Citations |
| 1 | Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. (Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Pan-Cancer Working Group) Discov Med 2014 Dec;18(101):331-9 16 Citations |
| 1 | Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. (Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Pan-Cancer Working Group) Discov Med 2014 Dec;18(101):323-30 10 Citations |
| 1 | Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. (Choi HJ, Armaiz Pena GN, Pradeep S, Cho MS, Coleman RL, Sood AK) Cancer Metastasis Rev 2015 Mar;34(1):19-40 85 Citations |
| 3 | Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation. (Eapen M, Logan BR, Horowitz MM, Zhong X, Perales MA, Lee SJ, Rocha V, Soiffer RJ, Champlin RE) J Clin Oncol 2015 Feb 01;33(4):364-9 48 Citations |
| 1 | Commentary on "Optimal schedule of bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: A meta-analysis of comparative studies." Zhu S, Tang Y, Li K, Shang Z, Jiang N, Nian X, Sun L, Niu Y, Department of Urology Tianjin Institute of Urology, 2nd Hospital of Tianjin Medical University, People's Republic of China.: BMC Cancer 2013; 13:332. doi:10.1186/1471-2407-13-332. (See WA) Urol Oncol 2014 Nov;32(8):1349-50 |
| 1 | miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. (Guinn D, Ruppert AS, Maddocks K, Jaglowski S, Gordon A, Lin TS, Larson R, Marcucci G, Hertlein E, Woyach J, Johnson AJ, Byrd JC) Leukemia 2015 May;29(5):1210-3 19 Citations |
| 2 | Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. (Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, Venkatanarayan A, Krohn M, Kristensen VN, Gagea M, Ram P, Liu W, Lopez-Berestein G, Lorenzi PL, Børresen-Dale AL, Chin K, Gray J, Dusetti NJ, McGuire SE, Flores ER, Sood AK, Mills GB) Cancer Cell 2014 Dec 08;26(6):863-879 49 Citations |
| 2 | Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. (Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG) Int J Radiat Oncol Biol Phys 2015 Jan 01;91(1):116-23 34 Citations |
| 1 | Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. (Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H, Silverman C, Raben A, Galloway TJ, Fortin A, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, Le QT) J Clin Oncol 2014 Dec 01;32(34):3858-66 418 Citations |
| 2 | Structural analysis of a novel small molecule ligand bound to the CXCL12 chemokine. (Smith EW, Liu Y, Getschman AE, Peterson FC, Ziarek JJ, Li R, Volkman BF, Chen Y) J Med Chem 2014 Nov 26;57(22):9693-9 23 Citations |
| 1 | Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation. (Shaw BE, Lee F, Krishnamurthy S, Byrne JL, Seedhouse C, Mayor NP, Maldonado-Torres H, Saudemont A, Marsh SG, Madrigal JA, Russell NH) Bone Marrow Transplant 2015 Feb;50(2):237-43 2 Citations |
| 1 | Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. (Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, Meric-Berstam F, Hong DS) Clin Cancer Res 2014 Dec 01;20(23):5956-63 10 Citations |
| 1 | BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. (Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R) Thyroid 2015 Jan;25(1):71-7 199 Citations |
| 1 | Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: a British Society of Blood and Marrow Transplantation study. (Nikolousis E, Nagra S, Pearce R, Perry J, Kirkland K, Byrne J, Dignan F, Tholouli E, Gilleece M, Russell N, Littlewood T, Cook M, Peniket A, Shaw BE, Cook G, Craddock C) Bone Marrow Transplant 2015 Jan;50(1):82-6 9 Citations |
| 1 | Heat shock protein-mediated protection against Cisplatin-induced hair cell death. (Baker TG, Roy S, Brandon CS, Kramarenko IK, Francis SP, Taleb M, Marshall KM, Schwendener R, Lee FS, Cunningham LL) J Assoc Res Otolaryngol 2015 Feb;16(1):67-80 36 Citations |
| 1 | Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. (Callander N, Markovina S, Eickhoff J, Hutson P, Campbell T, Hematti P, Go R, Hegeman R, Longo W, Williams E, Asimakopoulos F, Miyamoto S) Cancer Chemother Pharmacol 2014 Oct;74(4):875-82 34 Citations |
| 1 | Hematopoietic stem cell transplantation of an adolescent with neurological manifestations of homozygous missense PRF1 mutation. (Hussein AA, Hamadah T, Qandeel M, Sughayer M, Amarin R, Mansour A, Chiang SC, Al-Zaben A, Meeths M, Bryceson YT) Pediatr Blood Cancer 2014 Dec;61(12):2313-5 4 Citations |
| 1 | MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. (Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS) Clin Genitourin Cancer 2015 Feb;13(1):e19-26 17 Citations |
| 1 | A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. (Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM) BMC Cancer 2014 Aug 02;14:561 15 Citations |
| 1 | The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface. (Lee F, Luevano M, Veys P, Yong K, Madrigal A, Shaw BE, Saudemont A) PLoS One 2014;9(7):e103254 9 Citations |
| 1 | Lanreotide in metastatic enteropancreatic neuroendocrine tumors. (Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P, CLARINET Investigators) N Engl J Med 2014 Jul 17;371(3):224-33 1266 Citations |
| 1 | How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia. (Burke MJ) Future Oncol 2014 Dec;10(16):2615-27 48 Citations |
| 1 | Bortezomib for refractory autoimmunity in pediatrics. (Khandelwal P, Davies SM, Grimley MS, Jordan MB, Curtis BR, Jodele S, Marsh R, Filipovich AH) Biol Blood Marrow Transplant 2014 Oct;20(10):1654-9 44 Citations |
| 1 | Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. (Janku F, Kaseb AO, Tsimberidou AM, Wolff RA, Kurzrock R) Oncotarget 2014 May 30;5(10):3012-22 91 Citations |
| 1 | Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study. (Falchook G, Kurzrock R, Gouw L, Hong D, McGregor KA, Zhou X, Shi H, Fingert H, Sharma S) Invest New Drugs 2014 Dec;32(6):1181-7 34 Citations |
| 3 | Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation. (Cheng G, Zielonka J, McAllister D, Tsai S, Dwinell MB, Kalyanaraman B) Br J Cancer 2014 Jul 08;111(1):85-93 80 Citations |
| 1 | Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. (Rosean TR, Tompkins VS, Tricot G, Holman CJ, Olivier AK, Zhan F, Janz S) Immunol Res 2014 Aug;59(1-3):188-202 53 Citations |
| 1 | Understanding protein-nanoparticle interaction: a new gateway to disease therapeutics. (Giri K, Shameer K, Zimmermann MT, Saha S, Chakraborty PK, Sharma A, Arvizo RR, Madden BJ, Mccormick DJ, Kocher JP, Bhattacharya R, Mukherjee P) Bioconjug Chem 2014 Jun 18;25(6):1078-90 86 Citations |
| 1 | Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. (Bendell JC, Hong DS, Burris HA 3rd, Naing A, Jones SF, Falchook G, Bricmont P, Elekes A, Rock EP, Kurzrock R) Cancer Chemother Pharmacol 2014 Jul;74(1):125-30 103 Citations |
| 2 | Altered cerebral blood flow one month after systemic chemotherapy for breast cancer: a prospective study using pulsed arterial spin labeling MRI perfusion. (Nudelman KN, Wang Y, McDonald BC, Conroy SK, Smith DJ, West JD, O'Neill DP, Schneider BP, Saykin AJ) PLoS One 2014;9(5):e96713 52 Citations |
| 1 | Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. (Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R) Oncotarget 2014 May 15;5(9):2349-54 54 Citations |
| 1 | Old drug new use--amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity. (Kong R, Liu T, Zhu X, Ahmad S, Williams AL, Phan AT, Zhao H, Scott JE, Yeh LA, Wong ST) Clin Cancer Res 2014 Jul 01;20(13):3521-30 86 Citations |
| 1 | Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. (Hou MM, Liu X, Wheler J, Naing A, Hong D, Bodurka D, Schmeler K, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Hu CY, Lu K, Kurzrock R, Fu S) Anticancer Res 2014 May;34(5):2349-55 7 Citations |
| 1 | Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. (Gharpure KM, Chu KS, Bowerman CJ, Miyake T, Pradeep S, Mangala SL, Han HD, Rupaimoole R, Armaiz-Pena GN, Rahhal TB, Wu SY, Luft JC, Napier ME, Lopez-Berestein G, DeSimone JM, Sood AK) Mol Cancer Ther 2014 Jul;13(7):1750-7 29 Citations |
| 1 | MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. (Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R) Lancet Oncol 2014 May;15(6):656-66 187 Citations |
| 1 | AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake. (Rashmi R, DeSelm C, Helms C, Bowcock A, Rogers BE, Rader JL, Rader J, Grigsby PW, Schwarz JK) PLoS One 2014;9(4):e92948 80 Citations |
| 1 | Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. (Liu X, Lorusso P, Mita M, Piha-Paul S, Hong DS, Fu S, McQuinn L, Asatiani E, Doyle LA, Chen HX, Hess KR, Kurzrock R, Naing A) Oncologist 2014 Apr;19(4):426-8 11 Citations |
| 1 | HER2 aberrations in cancer: implications for therapy. (Yan M, Parker BA, Schwab R, Kurzrock R) Cancer Treat Rev 2014 Jul;40(6):770-80 202 Citations |
| 1 | HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer. (Rath KS, Naidu SK, Lata P, Bid HK, Rivera BK, McCann GA, Tierney BJ, Elnaggar AC, Bravo V, Leone G, Houghton P, Hideg K, Kuppusamy P, Cohn DE, Selvendiran K) Cancer Res 2014 Apr 15;74(8):2316-27 83 Citations |
| 1 | Polymeric micelles for apoptosis-targeted optical imaging of cancer and intraoperative surgical guidance. (Cho H, Cho CS, Indig GL, Lavasanifar A, Vakili MR, Kwon GS) PLoS One 2014;9(2):e89968 16 Citations |
| 1 | Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas. (Hamadani M, Abu Kar SM, Usmani SZ, Savani BN, Ayala E, Kharfan-Dabaja MA) Semin Hematol 2014 Jan;51(1):73-86 10 Citations |
| 1 | Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia. (Anzalone CL, Cohen PR, Kurzrock R, Cortes JE) Dermatol Online J 2014 Jan 15;20(1):21242 6 Citations |
| 1 | Patterns of radiation therapy practice for patients treated for intact cervical cancer in 2005 to 2007: a quality research in radiation oncology study. (Eifel PJ, Ho A, Khalid N, Erickson B, Owen J) Int J Radiat Oncol Biol Phys 2014 Jun 01;89(2):249-56 82 Citations |
| 1 | HE4 (WFDC2) gene overexpression promotes ovarian tumor growth. (Moore RG, Hill EK, Horan T, Yano N, Kim K, MacLaughlan S, Lambert-Messerlian G, Tseng YD, Padbury JF, Miller MC, Lange TS, Singh RK) Sci Rep 2014 Jan 06;4:3574 88 Citations |
| 1 | Adverse Drug Event-based Stratification of Tumor Mutations: A Case Study of Breast Cancer Patients Receiving Aromatase Inhibitors. (Wang C, Zimmermann MT, Prodduturi N, Chute CG, Jiang G) AMIA Annu Symp Proc 2014;2014:1160-9 2 Citations |
| 1 | Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases. (Morris-Stiff G, White AD, Gomez D, Cameron IC, Farid S, Toogood GJ, Lodge JP, Prasad KR) Eur J Surg Oncol 2014 Aug;40(8):1016-20 35 Citations |
| 1 | Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. (Fu S, Hou MM, Wheler J, Hong D, Naing A, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Falchook G, Kuo MT, Kurzrock R) Invest New Drugs 2014 Jun;32(3):465-72 35 Citations |
| 1 | Evidence-based nonpharmacologic interventions for pediatric pain: an editorial commentary. (Bingen K) J Pediatr Hematol Oncol 2014 Mar;36(2):150-1 1 Citation |
| 1 | A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. (Hong DS, Kurzrock R, Naing A, Wheler JJ, Falchook GS, Schiffman JS, Faulkner N, Pilat MJ, O'Brien J, LoRusso P) Invest New Drugs 2014 Jun;32(3):436-44 195 Citations |
| 1 | Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. (Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M) Cancer 2014 Mar 01;120(5):692-701 96 Citations |
| 1 | Optimization of carboxylate-terminated poly(amidoamine) dendrimer-mediated cisplatin formulation. (Kulhari H, Pooja D, Singh MK, Chauhan AS) Drug Dev Ind Pharm 2015 Feb;41(2):232-8 55 Citations |
| 1 | EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. (Fox CP, Burns D, Parker AN, Peggs KS, Harvey CM, Natarajan S, Marks DI, Jackson B, Chakupurakal G, Dennis M, Lim Z, Cook G, Carpenter B, Pettitt AR, Mathew S, Connelly-Smith L, Yin JA, Viskaduraki M, Chakraverty R, Orchard K, Shaw BE, Byrne JL, Brookes C, Craddock CF, Chaganti S) Bone Marrow Transplant 2014 Feb;49(2):280-6 80 Citations |
| 1 | Sensitizing cancer cells to TRAIL-induced death by micellar delivery of mitoxantrone. (Grandhi TS, Potta T, Taylor DJ, Tian Y, Johnson RH, Meldrum DR, Rege K) Nanomedicine (Lond) 2014;9(12):1775-88 6 Citations |
| 1 | Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs. (Jardim DL, Hess KR, Lorusso P, Kurzrock R, Hong DS) Clin Cancer Res 2014 Jan 15;20(2):281-8 48 Citations |
| 1 | Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. (Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O) Clin Cancer Res 2014 Jan 15;20(2):490-8 105 Citations |
| 1 | Targeting SRC and tubulin in mucinous ovarian carcinoma. (Liu T, Hu W, Dalton HJ, Choi HJ, Huang J, Kang Y, Pradeep S, Miyake T, Song JH, Wen Y, Lu C, Pecot CV, Bottsford-Miller J, Zand B, Jennings NB, Ivan C, Gallick GE, Baggerly KA, Hangauer DG, Coleman RL, Frumovitz M, Sood AK) Clin Cancer Res 2013 Dec 01;19(23):6532-43 37 Citations |
| 1 | Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases. (Garcia SS, Atkins JT, Falchook GS, Tsimberidou AM, Hong DS, Trivedi MV, Kurzrock R) Cancer Chemother Pharmacol 2013 Dec;72(6):1265-71 2 Citations |
| 1 | Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. (Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R) Mol Cancer Ther 2013 Dec;12(12):2857-63 42 Citations |
| 1 | Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. (Gadgeel SM, Lew DL, Synold TW, LoRusso P, Chung V, Christensen SD, Smith DC, Kingsbury L, Hoering A, Kurzrock R) Cancer Chemother Pharmacol 2013 Nov;72(5):1089-96 25 Citations |
| 1 | Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. (Practice Committee of American Society for Reproductive Medicine) Fertil Steril 2013 Nov;100(5):1214-23 260 Citations |
| 1 | Managing malignant melanoma. (Dzwierzynski WW) Plast Reconstr Surg 2013 Sep;132(3):446e-460e 62 Citations |
| 1 | Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. (Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheler JJ, Sood AK, Bustinza-Linares E, Parkhurst KL, Kurzrock R) Invest New Drugs 2013 Oct;31(5):1192-200 60 Citations |
| 2 | Mitochondria-targeted antioxidant and glycolysis inhibition: synergistic therapy in hepatocellular carcinoma. (Dilip A, Cheng G, Joseph J, Kunnimalaiyaan S, Kalyanaraman B, Kunnimalaiyaan M, Gamblin TC) Anticancer Drugs 2013 Oct;24(9):881-8 29 Citations |
| 1 | Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. (Hong D, Said R, Falchook G, Naing A, Moulder S, Tsimberidou AM, Galluppi G, Dakappagari N, Storgard C, Kurzrock R, Rosen LS) Clin Cancer Res 2013 Sep 01;19(17):4824-31 23 Citations |
| 1 | Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment. (Falchook GS, Lippman SM, Bastida CC, Kurzrock R) Head Neck 2014 Mar;36(3):E25-7 49 Citations |
| 1 | Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. (Wheler J, Falchook G, Tsimberidou AM, Hong D, Naing A, Piha-Paul S, Chen SS, Heymach J, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R) Oncotarget 2013 May;4(5):772-84 19 Citations |
| 1 | Commentary on "Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?" Mertens LS, Meijer RP, Kerst JM, Bergman AM, van Tinteren H, van Rhijn BW, Horenblas S, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands: J Urol 2012;188(4):1108-13 [Epub 2012 Aug 15]. (See WA) Urol Oncol 2013 Jul;31(5):716-7 2 Citations |
| 1 | Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. (Kornblit B, Maloney DG, Storb R, Storek J, Hari P, Vucinic V, Maziarz RT, Chauncey TR, Pulsipher MA, Bruno B, Petersen FB, Bethge WA, Hübel K, Bouvier ME, Fukuda T, Storer BE, Sandmaier BM) Biol Blood Marrow Transplant 2013 Sep;19(9):1340-7 24 Citations |
| 2 | Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. (Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M) J Clin Apher 2013 Oct;28(5):359-67 28 Citations |
| 1 | How do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey. (Burke MJ, Burns L, Linden MA, Lindgren B, Verneris MR, Weisdorf D, Ustun C) Am J Hematol 2013 Sep;88(9):826-7 2 Citations |
| 1 | Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. (Stessman HA, Mansoor A, Zhan F, Janz S, Linden MA, Baughn LB, Van Ness B) Leukemia 2013 Oct;27(10):2075-7 48 Citations |
| 1 | Tumor derived mutations of protein tyrosine phosphatase receptor type k affect its function and alter sensitivity to chemotherapeutics in glioma. (Agarwal S, Al-Keilani MS, Alqudah MA, Sibenaller ZA, Ryken TC, Assem M) PLoS One 2013;8(5):e62852 30 Citations |
| 1 | Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. (Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, Hong D, Sherman S) Ann Oncol 2013 Sep;24(9):2256-61 33 Citations |
| 1 | Artemisinin-derived dimer phosphate esters as potent anti-cytomegalovirus (anti-CMV) and anti-cancer agents: a structure-activity study. (Mott BT, He R, Chen X, Fox JM, Civin CI, Arav-Boger R, Posner GH) Bioorg Med Chem 2013 Jul 01;21(13):3702-7 36 Citations |
| 1 | A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. (Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F) Clin Cancer Res 2013 Jul 01;19(13):3659-70 195 Citations |
| 1 | A novel anti-tumor inhibitor identified by virtual screen with PLK1 structure and zebrafish assay. (Lu J, Xin S, Meng H, Veldman M, Schoenfeld D, Che C, Yan R, Zhong H, Li S, Lin S) PLoS One 2013;8(4):e53317 16 Citations |
| 1 | Waldenström macroglobulinaemia: the key questions. (D'Souza A, Ansell S, Reeder C, Gertz MA) Br J Haematol 2013 Aug;162(3):295-303 9 Citations |
| 1 | Structure of the human smoothened receptor bound to an antitumour agent. (Wang C, Wu H, Katritch V, Han GW, Huang XP, Liu W, Siu FY, Roth BL, Cherezov V, Stevens RC) Nature 2013 May 16;497(7449):338-43 423 Citations |
| 2 | Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research. (Foran JM, Pavletic SZ, Logan BR, Agovi-Johnson MA, Pérez WS, Bolwell BJ, Bornhäuser M, Bredeson CN, Cairo MS, Camitta BM, Copelan EA, Dehn J, Gale RP, George B, Gupta V, Hale GA, Lazarus HM, Litzow MR, Maharaj D, Marks DI, Martino R, Maziarz RT, Rowe JM, Rowlings PA, Savani BN, Savoie ML, Szer J, Waller EK, Wiernik PH, Weisdorf DJ) Biol Blood Marrow Transplant 2013 Jul;19(7):1102-8 16 Citations |
| 1 | RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. (Jain RK, Lee JJ, Hong D, Kurzrock R) J Natl Cancer Inst 2013 Jun 05;105(11):833 |
| 1 | Fool's gold, lost treasures, and the randomized clinical trial. (Stewart DJ, Kurzrock R) BMC Cancer 2013 Apr 16;13:193 49 Citations |
| 1 | Comparison of "sandwich chemo-radiotherapy" and six cycles of chemotherapy followed by adjuvant radiotherapy in patients with stage IIIC endometrial cancer: a single center experience. (Dogan NU, Yavas G, Yavas C, Ata O, Yılmaz SA, Celik C) Arch Gynecol Obstet 2013 Oct;288(4):845-50 8 Citations |
| 1 | Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib. (Falchook GS, Rady P, Hymes S, Nguyen HP, Tyring SK, Prieto VG, Hong DS, Kurzrock R) JAMA Dermatol 2013 Mar;149(3):322-6 29 Citations |
| 1 | Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration. (Giralt S, McCarthy PL, Anderson KC, Carter SL, Richardson PG, Rajkumar SV, Laport GG, Stadtmauer EA, Pasquini MC, Horowitz MM) Biol Blood Marrow Transplant 2013 Jun;19(6):858-9 2 Citations |
| 1 | Association between ipilimumab and celiac disease. (Gentile NM, D'Souza A, Fujii LL, Wu TT, Murray JA) Mayo Clin Proc 2013 Apr;88(4):414-7 60 Citations |
| 1 | Discovering new medicines targeting helicases: challenges and recent progress. (Shadrick WR, Ndjomou J, Kolli R, Mukherjee S, Hanson AM, Frick DN) J Biomol Screen 2013 Aug;18(7):761-81 113 Citations |
| 1 | Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo. (Starenki D, Park JI) J Clin Endocrinol Metab 2013 Apr;98(4):1529-40 44 Citations |
| 1 | Redox activation of Fe(III)-thiosemicarbazones and Fe(III)-bleomycin by thioredoxin reductase: specificity of enzymatic redox centers and analysis of reactive species formation by ESR spin trapping. (Myers JM, Cheng Q, Antholine WE, Kalyanaraman B, Filipovska A, Arnér ES, Myers CR) Free Radic Biol Med 2013 Jul;60:183-94 27 Citations |
| 1 | BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. (Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, Bastida CC, Blackman SC, Kurzrock R) Oncotarget 2013 Feb;4(2):310-5 153 Citations |
| 3 | Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome. (Hitzler JK, He W, Doyle J, Cairo M, Camitta BM, Chan KW, Diaz Perez MA, Fraser C, Gross TG, Horan JT, Kennedy-Nasser AA, Kitko C, Kurtzberg J, Lehmann L, O'Brien T, Pulsipher MA, Smith FO, Zhang MJ, Eapen M, Carpenter PA, CIBMTR Pediatric Cancer Working Committee) Biol Blood Marrow Transplant 2013 Jun;19(6):893-7 47 Citations |
| 1 | Reply to A. Levy et al. (Jain RK, Lee JJ, Hong D, Kurzrock R) J Clin Oncol 2013 Jan 20;31(3):396 1 Citation |
| 1 | Dodging a dogma: is treating beyond progression beneficial? (Naing A, Kurzrock R) Cancer Chemother Pharmacol 2013 May;71(5):1385-6 7 Citations |
| 1 | Statistical model for prediction of hearing loss in patients receiving cisplatin chemotherapy. (Johnson A, Tarima S, Wong S, Friedland DR, Runge CL) JAMA Otolaryngol Head Neck Surg 2013 Mar;139(3):256-64 15 Citations |
| 1 | Predictors of local recurrence in high-grade soft tissue sarcomas: hydrogen peroxide as a local adjuvant. (Wooldridge AN, Kolovich GP, Crist MK, Mayerson JL, Scharschmidt TJ) Orthopedics 2013 Feb;36(2):e207-15 7 Citations |
| 2 | Fragment-based optimization of small molecule CXCL12 inhibitors for antagonizing the CXCL12/CXCR4 interaction. (Ziarek JJ, Liu Y, Smith E, Zhang G, Peterson FC, Chen J, Yu Y, Chen Y, Volkman BF, Li R) Curr Top Med Chem 2012;12(24):2727-40 25 Citations |
| 1 | Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies. (Kindt N, Preillon J, Kaltner H, Gabius HJ, Chevalier D, Rodriguez A, Johnson BD, Megalizzi V, Decaestecker C, Laurent G, Saussez S) J Cancer Res Clin Oncol 2013 May;139(5):727-37 38 Citations |
| 1 | Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study. (Medd PG, Peniket AJ, Littlewood TJ, Pearce R, Perry J, Kirkland KE, Shaw BE, Potter MN, Craddock CF, Milligan DW, Fielding AK, Marks DI, Cook G, British Society of Blood and Marrow Transplantation) Bone Marrow Transplant 2013 Jul;48(7):982-7 10 Citations |
| 1 | Symptomatic radiation pneumonitis in elderly patients receiving thoracic irradiation. (Kharofa J, Gore E) Clin Lung Cancer 2013 May;14(3):283-7 22 Citations |
| 1 | Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302. (Bolaños-Meade J, Wu J, Logan BR, Levine JE, Ho VT, Alousi AM, Weisdorf DJ, Luznik L, Blood and Marrow Transplant Clinical Trials Network) Biol Blood Marrow Transplant 2013 Mar;19(3):481-5 5 Citations |
| 1 | PIK3CA mutations in advanced cancers: characteristics and outcomes. (Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R) Oncotarget 2012 Dec;3(12):1566-75 89 Citations |
| 1 | Piperlongumine inhibits proliferation and survival of Burkitt lymphoma in vitro. (Han SS, Son DJ, Yun H, Kamberos NL, Janz S) Leuk Res 2013 Feb;37(2):146-54 50 Citations |
| 1 | Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. (Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R) Cancer Treat Rev 2013 Jun;39(4):375-87 222 Citations |
| 1 | It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. (Westin JR, Kurzrock R) Mol Cancer Ther 2012 Dec;11(12):2549-55 53 Citations |
| 1 | RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. (Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, Schultz CJ, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Dicker AP, Bredel M, Mehta M) Int J Radiat Oncol Biol Phys 2013 Apr 01;85(5):1206-11 144 Citations |
| 1 | Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS. (Smith AR, Christiansen EC, Wagner JE, Cao Q, MacMillan ML, Stefanski HE, Trotz BA, Burke MJ, Verneris MR) Pediatr Blood Cancer 2013 Apr;60(4):705-10 28 Citations |
| 1 | Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. (Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Piha-Paul SA, Chen SS, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R) Ann Oncol 2013 Mar;24(3):838-42 21 Citations |
| 1 | PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. (Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R) Cancer Res 2013 Jan 01;73(1):276-84 262 Citations |
| 1 | Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. (Janku F, Berry DA, Gong J, Parsons HA, Stewart DJ, Kurzrock R) Clin Cancer Res 2012 Nov 15;18(22):6356-63 21 Citations |
| 1 | The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. (Serra S, Zheng L, Hassan M, Phan AT, Woodhouse LJ, Yao JC, Ezzat S, Asa SL) Cancer Res 2012 Nov 15;72(22):5683-91 45 Citations |
| 1 | Targeted therapy in rare cancers--adopting the orphans. (Munoz J, Kurzrock R) Nat Rev Clin Oncol 2012 Nov;9(11):631-42 36 Citations |
| 1 | Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. (Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R) Clin Cancer Res 2012 Nov 15;18(22):6373-83 471 Citations |
| 1 | Mechanistic basis for overcoming platinum resistance using copper chelating agents. (Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M, Zhang F, Chen HH, Hennessy BT, Mills GB, Savaraj N, Kuo MT) Mol Cancer Ther 2012 Nov;11(11):2483-94 73 Citations |
| 1 | Iron-targeting antitumor activity of gallium compounds and novel insights into triapine(®)-metal complexes. (Chitambar CR, Antholine WE) Antioxid Redox Signal 2013 Mar 10;18(8):956-72 64 Citations |
| 1 | Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. (Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA 3rd, Messersmith WA) Lancet Oncol 2012 Aug;13(8):773-81 514 Citations |
| 1 | Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. (Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA 3rd, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA) Lancet Oncol 2012 Aug;13(8):782-9 482 Citations |
| 1 | Gallium-containing anticancer compounds. (Chitambar CR) Future Med Chem 2012 Jun;4(10):1257-72 185 Citations |
| 1 | Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. (Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Lustig R, Ensley JF, Thorstad W, Schultz CJ, Yom SS, Ang KK) Int J Radiat Oncol Biol Phys 2012 Dec 01;84(5):1198-205 492 Citations |
| 1 | Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. (Naing A, Veasey-Rodrigues H, Hong DS, Fu S, Falchook GS, Wheler JJ, Tsimberidou AM, Wen S, Fessahaye SN, Golden EC, Aaron J, Ewer MS, Kurzrock R) Ann Oncol 2012 Nov;23(11):2960-2963 41 Citations |
| 1 | Ewing's sarcoma: overcoming the therapeutic plateau. (Subbiah V, Kurzrock R) Discov Med 2012 Jun;13(73):405-15 19 Citations |
| 1 | Capsaicin inhibits benzo(a)pyrene-induced lung carcinogenesis in an in vivo mouse model. (Anandakumar P, Kamaraj S, Jagan S, Ramakrishnan G, Asokkumar S, Naveenkumar C, Raghunandhakumar S, Devaki T) Inflamm Res 2012 Nov;61(11):1169-75 69 Citations |
| 1 | Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization. (Dogan U, Yavas G, Tekinalp M, Yavas C, Ata OY, Ozdemir K) Eur Rev Med Pharmacol Sci 2012 Apr;16(4):462-8 22 Citations |
| 1 | Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. (Jain RK, Lee JJ, Ng C, Hong D, Gong J, Naing A, Wheler J, Kurzrock R) J Clin Oncol 2012 Jul 20;30(21):2684-90 83 Citations |
| 1 | KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. (Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R) PLoS One 2012;7(5):e38033 50 Citations |
| 1 | A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. (Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Shapiro GI, Dezube BJ) Clin Cancer Res 2012 Jun 15;18(12):3396-406 220 Citations |
| 1 | Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. (D'Souza A, Lacy M, Gertz M, Kumar S, Buadi F, Hayman S, Dingli D, Zeldenrust S, Kyle R, Ansell S, Inwards D, Johnston P, Micallef I, Porrata L, Litzow M, Gastineau D, Hogan W, Dispenzieri A) Blood 2012 Jul 05;120(1):56-62 150 Citations |
| 1 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. (Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF) Lancet 2012 May 19;379(9829):1893-901 852 Citations |
| 2 | Lenalidomide after stem-cell transplantation for multiple myeloma. (McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C) N Engl J Med 2012 May 10;366(19):1770-81 |
| 2 | Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. (Tolar J, Deeg HJ, Arai S, Horwitz M, Antin JH, McCarty JM, Adams RH, Ewell M, Leifer ES, Gersten ID, Carter SL, Horowitz MM, Nakamura R, Pulsipher MA, Difronzo NL, Confer DL, Eapen M, Anderlini P) Biol Blood Marrow Transplant 2012 Jul;18(7):1007-11 49 Citations |
| 1 | Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model. (Moore RG, Lange TS, Robinson K, Kim KK, Uzun A, Horan TC, Kawar N, Yano N, Chu SR, Mao Q, Brard L, DePaepe ME, Padbury JF, Arnold LA, Brodsky A, Shen TL, Singh RK) PLoS One 2012;7(4):e34443 17 Citations |
| 1 | Outcomes after induction failure in childhood acute lymphoblastic leukemia. (Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A, Conter V, Otten J, Ohara A, Versluys AB, Escherich G, Heyman M, Silverman LB, Horibe K, Mann G, Camitta BM, Harbott J, Riehm H, Richards S, Devidas M, Zimmermann M) N Engl J Med 2012 Apr 12;366(15):1371-81 207 Citations |
| 1 | Overcoming platinum resistance through the use of a copper-lowering agent. (Fu S, Naing A, Fu C, Kuo MT, Kurzrock R) Mol Cancer Ther 2012 Jun;11(6):1221-5 75 Citations |
| 1 | Myeloproliferative neoplasms. (Kim J, Haddad RY, Atallah E) Dis Mon 2012 Apr;58(4):177-94 9 Citations |
| 1 | Medical therapy of endometrial cancer: current status and promising novel treatments. (Hill EK, Dizon DS) Drugs 2012 Mar 26;72(5):705-13 40 Citations |
| 1 | Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. (Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J) Pediatr Blood Cancer 2012 Jul 15;59(1):144-8 135 Citations |
| 1 | Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival. (Bachanova V, Burke MJ, Yohe S, Cao Q, Sandhu K, Singleton TP, Brunstein CG, Wagner JE, Verneris MR, Weisdorf DJ) Biol Blood Marrow Transplant 2012 Jun;18(6):963-8 43 Citations |
| 1 | Aerosolized 3-bromopyruvate inhibits lung tumorigenesis without causing liver toxicity. (Zhang Q, Pan J, North PE, Yang S, Lubet RA, Wang Y, You M) Cancer Prev Res (Phila) 2012 May;5(5):717-25 36 Citations |
| 1 | Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. (Wheler JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R) Ann Oncol 2012 Aug;23(8):1963-1967 16 Citations |
| 1 | A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. (de Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, Wong SJ, Kozloff MF, Nattam S, Lingen MW, Kunnavakkam R, Stenson KM, Blair EA, Bozeman J, Dancey JE, Vokes EE, Cohen EE) Clin Cancer Res 2012 Apr 15;18(8):2336-43 110 Citations |
| 3 | Immunophenotypic stability of Sézary cells by flow cytometry: usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy. (Vaughan J, Harrington AM, Hari PN, Kroft SH, Olteanu H) Am J Clin Pathol 2012 Mar;137(3):403-11 24 Citations |
| 1 | New strategies for advanced neuroendocrine tumors in the era of targeted therapy. (Dong M, Phan AT, Yao JC) Clin Cancer Res 2012 Apr 01;18(7):1830-6 50 Citations |
| 1 | Management of cancer in the older adult. (Kilari D, Mohile SG) Clin Geriatr Med 2012 Feb;28(1):33-49 14 Citations |
| 1 | Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study. (Chang BH, Willis SG, Stork L, Hunger SP, Carroll WL, Camitta BM, Winick NJ, Druker BJ, Schultz KR) Br J Haematol 2012 May;157(4):507-10 39 Citations |
| 1 | Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. (Clark RA, Watanabe R, Teague JE, Schlapbach C, Tawa MC, Adams N, Dorosario AA, Chaney KS, Cutler CS, Leboeuf NR, Carter JB, Fisher DC, Kupper TS) Sci Transl Med 2012 Jan 18;4(117):117ra7 323 Citations |
| 1 | Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. (Parsons HA, Tsimberidou AM, Pontikos M, Fu S, Hong D, Wen S, Baracos VE, Kurzrock R) Nutr Cancer 2012;64(2):206-17 29 Citations |
| 1 | Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. (Oliansky DM, Camitta B, Gaynon P, Nieder ML, Parsons SK, Pulsipher MA, Dillon H, Ratko TA, Wall D, McCarthy PL Jr, Hahn T, American Society for Blood and Marrow Transplantation) Biol Blood Marrow Transplant 2012 Apr;18(4):505-22 51 Citations |
| 1 | Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. (Subbiah V, Slopis J, Hong DS, Ketonen LM, Hamilton J, McCutcheon IE, Kurzrock R) J Clin Oncol 2012 Feb 10;30(5):e64-8 42 Citations |
| 1 | Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study. (Yavas C, Dogan U, Yavas G, Araz M, Ata OY) Support Care Cancer 2012 Oct;20(10):2343-7 36 Citations |
| 1 | Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy. (Munoz J, Hong D, Kurzrock R) Int J Hematol 2012 Jan;95(1):1-2 3 Citations |
| 1 | Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer. (Barlin JN, Yu C, Hill EK, Zivanovic O, Kolev V, Levine DA, Sonoda Y, Abu-Rustum NR, Huh J, Barakat RR, Kattan MW, Chi DS) Gynecol Oncol 2012 Apr;125(1):25-30 58 Citations |
| 1 | T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome. (Weisdorf D, Cooley S, Devine S, Fehniger TA, DiPersio J, Anasetti C, Waller EK, Porter D, Farag S, Drobyski W, Defor T, Haagenson M, Curtsinger J, Miller J) Biol Blood Marrow Transplant 2012 Jun;18(6):937-43 25 Citations |
| 1 | Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia. (LeGrand J, Park ES, Wang H, Gupta S, Owens JD Jr, Nelson PJ, DuBois W, Bair T, Janz S, Mushinski JF) Blood 2012 Jan 26;119(4):1018-28 6 Citations |
| 2 | Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy. (Mukhopadhyay P, Horváth B, Zsengellér Z, Zielonka J, Tanchian G, Holovac E, Kechrid M, Patel V, Stillman IE, Parikh SM, Joseph J, Kalyanaraman B, Pacher P) Free Radic Biol Med 2012 Jan 15;52(2):497-506 191 Citations |
| 1 | Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. (Miller TW, Rexer BN, Garrett JT, Arteaga CL) Breast Cancer Res 2011;13(6):224 394 Citations |
| 1 | Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity. (Rocque G, Onitilo A, Engel J, Pettke E, Boshoven A, Kim K, Rishi S, Waack B, Wisinski KB, Tevaarwerk A, Burkard ME) Breast Cancer Res Treat 2012 Jan;131(2):713-21 18 Citations |
| 1 | Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. (Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, Agura E, Maziarz RT, Langston A, Hari P, Pulsipher MA, Bethge W, Sahebi F, Bruno B, Maris MB, Yeager A, Petersen FB, Vindeløv L, McSweeney PA, Hübel K, Mielcarek M, Georges GE, Niederwieser D, Blume KG, Maloney DG, Storb R) JAMA 2011 Nov 02;306(17):1874-83 282 Citations |
| 1 | Prenatal and postnatal expression of glutathione transferase ζ 1 in human liver and the roles of haplotype and subject age in determining activity with dichloroacetate. (Li W, Gu Y, James MO, Hines RN, Simpson P, Langaee T, Stacpoole PW) Drug Metab Dispos 2012 Feb;40(2):232-9 33 Citations |
| 1 | Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver - Will it hit the moving target? (Subbiah V, Angelo LS, Kurzrock R) Expert Opin Investig Drugs 2011 Nov;20(11):1471-7 2 Citations |
| 1 | Building on the foundation of daring hypotheses: using the MKK4 metastasis suppressor to develop models of dormancy and metastatic colonization. (Knopeke MT, Ritschdorff ET, Clark R, Vander Griend DJ, Khan S, Thobe M, Shear JB, Rinker-Schaeffer CW) FEBS Lett 2011 Oct 20;585(20):3159-65 11 Citations |
| 1 | Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. (Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J, Bradley DP, Subakan O, Silva MD, Liu R, Pickard M, Li Z, Tayber O, Li P, Hales P, Carsillo M, Neppalli VT, Berger AJ, Kupperman E, Manfredi M, Bolen JB, Van Ness B, Janz S) Clin Cancer Res 2011 Dec 01;17(23):7313-23 95 Citations |
| 1 | An artemisinin-derived dimer has highly potent anti-cytomegalovirus (CMV) and anti-cancer activities. (He R, Mott BT, Rosenthal AS, Genna DT, Posner GH, Arav-Boger R) PLoS One 2011;6(8):e24334 60 Citations |
| 1 | Extended-field irradiation and intracavitary brachytherapy combined with cisplatin and amifostine for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of arm II of Radiation Therapy Oncology Group (RTOG) 0116. (Small W Jr, Winter K, Levenback C, Iyer R, Hymes SR, Jhingran A, Gaffney D, Erickson B, Greven K) Int J Gynecol Cancer 2011 Oct;21(7):1266-75 40 Citations |
| 1 | Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. (Kenkre VP, Long WL, Eickhoff JC, Blank JH, McFarland TA, Bottner W, Rezazedeh H, Werndli JE, Bailey HH, Kahl BS) Leuk Lymphoma 2011 Sep;52(9):1675-80 37 Citations |
| 1 | Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice. (Yu Y, Wang D, Liu C, Kaosaard K, Semple K, Anasetti C, Yu XZ) Blood 2011 Nov 03;118(18):5011-20 143 Citations |
| 1 | Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. (Ellingson BM, Cloughesy TF, Lai A, Mischel PS, Nghiemphu PL, Lalezari S, Schmainda KM, Pope WB) Neuro Oncol 2011 Oct;13(10):1151-61 73 Citations |
| 1 | Novel therapeutic targets in non-small cell lung cancer. (Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R) J Thorac Oncol 2011 Sep;6(9):1601-12 125 Citations |
| 1 | A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. (Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, André V, Kadam SK, Nasir A, Holzer TR, Meric-Bernstam F, Fishman M, Simon G) Clin Cancer Res 2011 Oct 15;17(20):6582-91 121 Citations |
| 1 | The inverted pyramid of biomarker-driven trials. (Garrido-Laguna I, Hidalgo M, Kurzrock R) Nat Rev Clin Oncol 2011 Aug 02;8(9):562-6 16 Citations |
| 1 | Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines. (Brard L, Lange TS, Robison K, Kim KK, Ara T, McCallum MM, Arnold LA, Moore RG, Singh RK) Gynecol Oncol 2011 Nov;123(2):370-8 14 Citations |
| 1 | Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. (Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG, International Myeloma Working Group) Leukemia 2012 Jan;26(1):149-57 667 Citations |
| 1 | Treatment of relapsed acute lymphoblastic leukemia: approaches used by pediatric oncologists and bone marrow transplant physicians. (Burke MJ, Lindgen B, Verneris MR) Pediatr Blood Cancer 2012 Jun;58(6):840-5 4 Citations |
| 1 | Abandonment of high-dose chemotherapy/hematopoietic cell transplants for breast cancer following negative trial results. (Howard DH, Kenline C, Lazarus HM, Lemaistre CF, Maziarz RT, McCarthy PL Jr, Parsons SK, Szwajcer D, Douglas Rizzo J, Majhail NS) Health Serv Res 2011 Dec;46(6pt1):1762-77 28 Citations |
| 1 | Cisplatin ototoxicity affecting cochlear implant benefit. (Harris MS, Gilbert JL, Lormore KA, Musunuru SA, Fritsch MH) Otol Neurotol 2011 Aug;32(6):969-72 12 Citations |
| 3 | Amelioration of oral mucositis pain by NASA near-infrared light-emitting diodes in bone marrow transplant patients. (Hodgson BD, Margolis DM, Salzman DE, Eastwood D, Tarima S, Williams LD, Sande JE, Vaughan WP, Whelan HT) Support Care Cancer 2012 Jul;20(7):1405-15 71 Citations |
| 2 | Disruption of a nuclear NFATc2 protein stabilization loop confers breast and pancreatic cancer growth suppression by zoledronic acid. (Singh SK, Baumgart S, Singh G, König AO, Reutlinger K, Hofbauer LC, Barth P, Gress TM, Lomberk G, Urrutia R, Fernandez-Zapico ME, Ellenrieder V) J Biol Chem 2011 Aug 19;286(33):28761-28771 24 Citations |
| 1 | Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. (Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R) J Clin Oncol 2011 Jul 01;29(19):2660-6 524 Citations |
| 1 | Autophagy as a target for anticancer therapy. (Janku F, McConkey DJ, Hong DS, Kurzrock R) Nat Rev Clin Oncol 2011 May 17;8(9):528-39 739 Citations |
| 1 | Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity. (Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R) Mol Cancer Ther 2011 Jul;10(7):1300-7 21 Citations |
| 1 | Improvement of survival and prospect of cure in patients with metastatic breast cancer. (Cheng YC, Ueno NT) Breast Cancer 2012 Jul;19(3):191-9 68 Citations |
| 1 | Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of ≤ 6 brain metastases: a multi-institutional phase II trial. (McHaffie DR, Chabot P, Dagnault A, Suh JH, Fortin MA, Chang E, Timmerman R, Souhami L, Grecula J, Nabid A, Schultz C, Werner-Wasik M, Gaspar LE, Brachman D, Mody T, Mehta MP) J Neurooncol 2011 Nov;105(2):301-8 19 Citations |
| 1 | Phase 1 clinical trials for sarcomas: the cutting edge. (Subbiah V, Kurzrock R) Curr Opin Oncol 2011 Jul;23(4):352-60 33 Citations |
| 1 | The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. (Vrooman LM, Neuberg DS, Stevenson KE, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Larsen EC, Laverdière C, Michon B, Schorin M, Schwartz CL, Cohen HJ, Lipshultz SE, Silverman LB, Sallan SE) Eur J Cancer 2011 Jun;47(9):1373-9 110 Citations |
| 1 | Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. (Subbiah V, Naing A, Brown RE, Chen H, Doyle L, LoRusso P, Benjamin R, Anderson P, Kurzrock R) PLoS One 2011 Apr 06;6(4):e18424 64 Citations |
| 1 | Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). (Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchison R, Lipshultz SE, Camitta BM) Blood 2011 Jul 28;118(4):874-83 160 Citations |
| 1 | Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): analysis of chemoradiation treatment approaches in the United States. (Wong SJ, Harari PM, Garden AS, Schwartz M, Bellm L, Chen A, Curran WJ, Murphy BA, Ang KK) Cancer 2011 Apr 15;117(8):1679-86 46 Citations |
| 1 | Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience. (Tsimberidou AM, Letourneau K, Wen S, Wheler J, Hong D, Naing A, Iskander NG, Uehara C, Kurzrock R) Clin Cancer Res 2011 Jun 15;17(12):4110-8 22 Citations |
| 1 | Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease. (Shaw BE, Apperley JF, Russell NH, Craddock C, Liakopoulou E, Potter MN, Wynn R, Gibson B, Pearce RM, Kirkland K, Lee J, Madrigal JA, Cook G, Byrne JL) Br J Haematol 2011 Apr;153(2):244-52 19 Citations |
| 1 | Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation. (Awan FT, Osman S, Kochuparambil ST, Gibson L, Remick SC, Abraham J, Craig M, Jillella A, Hamadani M) Bone Marrow Transplant 2012 Jan;47(1):146-8 5 Citations |
| 1 | Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. (Janku F, Tsimberidou AM, Wang X, Hong DS, Naing A, Gong J, Garrido-Laguna I, Parsons HA, Zinner RG, Kurzrock R) Oncologist 2011;16(3):327-35 8 Citations |
| 1 | Nilotinib cardiac toxicity: should we still be concerned? (Atallah E) Leuk Res 2011 May;35(5):577-8 11 Citations |
| 1 | Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas. (Iyer P, Molitch ME) Endocr Pract 2011;17(3):e55-8 20 Citations |
| 1 | Oral complications in the treatment of cancer patients. (Mosel DD, Bauer RL, Lynch DP, Hwang ST) Oral Dis 2011 Sep;17(6):550-9 106 Citations |
| 1 | An early computed tomography-guided antifungal treatment strategy is safe and efficacious in patients undergoing chemotherapy for high-risk acute leukemia. (Mohammed K, Dignan F, Ethell ME, Davies FE, Morgan GJ, Riley U, Evans S, Potter MN, Shaw BE) Leuk Lymphoma 2011 Feb;52(2):339-40 |
| 1 | Impact of neoadjuvant chemotherapy on breast reconstruction. (Hu YY, Weeks CM, In H, Dodgion CM, Golshan M, Chun YS, Hassett MJ, Corso KA, Gu X, Lipsitz SR, Greenberg CC) Cancer 2011 Jul 01;117(13):2833-41 47 Citations |
| 1 | Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial. (Tsimberidou AM, Takimoto CH, Moulder S, Uehara C, Mita M, Mita A, Urban P, Tan E, Wang Y, Vining D, Kurzrock R) Mol Cancer Ther 2011 Jan;10(1):209-17 5 Citations |
| 1 | ACR Appropriateness Criteria® on Advanced Cervical Cancer Expert Panel on Radiation Oncology-Gynecology. (Gaffney DK, Erickson-Wittmann BA, Jhingran A, Mayr NA, Puthawala AA, Moore D, Rao GG, Small W Jr, Varia MA, Wolfson AH, Yashar CM, Yuh W, Cardenes HR) Int J Radiat Oncol Biol Phys 2011 Nov 01;81(3):609-14 71 Citations |
| 1 | Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells. (Nithipatikom K, Isbell MA, Endsley MP, Woodliff JE, Campbell WB) Prostaglandins Other Lipid Mediat 2011 Feb;94(1-2):34-43 43 Citations |
| 1 | Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. (Tsimberidou AM, Akerley W, Schabel MC, Hong DS, Uehara C, Chhabra A, Warren T, Mather GG, Evans BA, Woodland DP, Swabb EA, Kurzrock R) Mol Cancer Ther 2010 Dec;9(12):3410-9 53 Citations |
| 1 | Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options. (Schultz KR, Prestidge T, Camitta B) Expert Rev Hematol 2010 Dec;3(6):731-42 17 Citations |
| 1 | Concomitant trastuzumab with thoracic radiotherapy: a morphological and functional study. (Yavas G, Yildiz F, Guler S, Sargon MF, Yildiz D, Yolcu T, Tuncer M, Akyol FH) Ann Oncol 2011 May;22(5):1120-1126 13 Citations |
| 1 | Farnesyltransferase inhibitors: where are we now? (Tsimberidou AM, Chandhasin C, Kurzrock R) Expert Opin Investig Drugs 2010 Dec;19(12):1569-80 38 Citations |
| 2 | Irradiation toxic effects during intra-arterial chemotherapy for retinoblastoma: should we be concerned? (Vijayakrishnan R, Shields CL, Ramasubramanian A, Emrich J, Rosenwasser R, Shields JA) Arch Ophthalmol 2010 Nov;128(11):1427-31 45 Citations |
| 1 | A first-in-human study of conatumumab in adult patients with advanced solid tumors. (Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, Juan G, Hwang YC, Wong S, Hill JS, Friberg G, LoRusso PM) Clin Cancer Res 2010 Dec 01;16(23):5883-91 126 Citations |
| 1 | Therapeutic targeting of C-terminal binding protein in human cancer. (Straza MW, Paliwal S, Kovi RC, Rajeshkumar B, Trenh P, Parker D, Whalen GF, Lyle S, Schiffer CA, Grossman SR) Cell Cycle 2010 Sep 15;9(18):3740-50 56 Citations |
| 3 | Unrelated donor bone marrow transplantation for myelodysplastic syndrome in children. (Woodard P, Carpenter PA, Davies SM, Gross TG, He W, Zhang MJ, Horn BN, Margolis DA, Perentesis JP, Sanders JE, Schultz KR, Seber A, Woods WG, Eapen M) Biol Blood Marrow Transplant 2011 May;17(5):723-8 25 Citations |
| 1 | A new pyrimidine-specific reporter gene: a mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine-based cytotoxic drugs. (Likar Y, Zurita J, Dobrenkov K, Shenker L, Cai S, Neschadim A, Medin JA, Sadelain M, Hricak H, Ponomarev V) J Nucl Med 2010 Sep;51(9):1395-403 59 Citations |
| 2 | The antioxidant transcription factor Nrf2 negatively regulates autophagy and growth arrest induced by the anticancer redox agent mitoquinone. (Rao VA, Klein SR, Bonar SJ, Zielonka J, Mizuno N, Dickey JS, Keller PW, Joseph J, Kalyanaraman B, Shacter E) J Biol Chem 2010 Nov 05;285(45):34447-59 131 Citations |
| 2 | Borderline resectable pancreatic cancer: definitions and the importance of multimodality therapy. (Evans DB, Erickson BA, Ritch P) Ann Surg Oncol 2010 Nov;17(11):2803-5 63 Citations |
| 1 | Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. (Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R) Cancer 2011 Jan 01;117(1):77-85 7 Citations |
| 1 | Response of histiocytoses to imatinib mesylate: fire to ashes. (Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock R) J Clin Oncol 2010 Nov 01;28(31):e633-6 77 Citations |
| 1 | Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors. (Cohen PR, Escudier SM, Kurzrock R) Am J Clin Dermatol 2011 Feb 01;12(1):63-7 38 Citations |
| 1 | A flexible multiwell format for immunofluorescence screening microscopy of small-molecule inhibitors. (Scholz AK, Klebl BM, Morkel M, Lehrach H, Dahl A, Lange BM) Assay Drug Dev Technol 2010 Oct;8(5):571-80 3 Citations |
| 1 | Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. (Bardsley MR, Horváth VJ, Asuzu DT, Lorincz A, Redelman D, Hayashi Y, Popko LN, Young DL, Lomberk GA, Urrutia RA, Farrugia G, Rubin BP, Ordog T) Gastroenterology 2010 Sep;139(3):942-52 102 Citations |
| 1 | Medical applications and toxicities of gallium compounds. (Chitambar CR) Int J Environ Res Public Health 2010 May;7(5):2337-61 349 Citations |
| 1 | The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. (Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC) Blood 2010 Nov 11;116(19):3705-14 109 Citations |
| 1 | Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. (Markovina S, Callander NS, O'Connor SL, Xu G, Shi Y, Leith CP, Kim K, Trivedi P, Kim J, Hematti P, Miyamoto S) Mol Cancer 2010 Jul 06;9:176 101 Citations |
| 1 | Development of curcumin as an epigenetic agent. (Fu S, Kurzrock R) Cancer 2010 Oct 15;116(20):4670-6 160 Citations |
| 1 | Patterns of fatigue in adolescents receiving chemotherapy. (Erickson JM, Beck SL, Christian B, Dudley WN, Hollen PJ, Albritton K, Sennett MM, Dillon R, Godder K) Oncol Nurs Forum 2010 Jul;37(4):444-55 38 Citations |
| 1 | Eating experiences of children and adolescents with chemotherapy-related nausea and mucositis. (Green R, Horn H, Erickson JM) J Pediatr Oncol Nurs 2010;27(4):209-16 48 Citations |
| 1 | Targeted therapy in non-small-cell lung cancer--is it becoming a reality? (Janku F, Stewart DJ, Kurzrock R) Nat Rev Clin Oncol 2010 Jul;7(7):401-14 255 Citations |
| 1 | Salirasib in the treatment of pancreatic cancer. (Bustinza-Linares E, Kurzrock R, Tsimberidou AM) Future Oncol 2010 Jun;6(6):885-91 46 Citations |
| 1 | Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. (Garrido-Laguna I, Janku F, Falchook GS, Fu S, Hong DS, Naing A, Aaron J, Wang X, Kies M, Kurzrock R) Clin Cancer Res 2010 Aug 01;16(15):4031-7 15 Citations |
| 1 | Mitochondrial targeting for photochemotherapy. Can selective tumor cell killing be predicted based on n-octanol/water distribution coefficients? (Belostotsky I, da Silva SM, Paez MG, Indig GL) Biotech Histochem 2011 Oct;86(5):302-14 17 Citations |
| 2 | Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure-based drug design. (Veldkamp CT, Ziarek JJ, Peterson FC, Chen Y, Volkman BF) J Am Chem Soc 2010 Jun 02;132(21):7242-3 63 Citations |
| 1 | Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. (Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS) J Clin Oncol 2010 Jun 10;28(17):2839-46 407 Citations |
| 3 | Efficacy and safety of long-term (>7 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia. (Olteanu H, Harrington AM, Ramirez S, Kroft SH, Hari P) Br J Haematol 2010 Aug;150(4):480-1 4 Citations |
| 1 | Growth suppression of mouse pituitary corticotroph tumor AtT20 cells by curcumin: a model for treating Cushing's disease. (Bangaru ML, Woodliff J, Raff H, Kansra S) PLoS One 2010 Apr 13;5(4):e9893 20 Citations |
| 1 | Chemotherapy resistance and retreatment: a dogma revisited. (Naing A, Kurzrock R) Clin Colorectal Cancer 2010 Apr;9(2):E1-4 |
| 1 | Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. (Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists' Group) BJU Int 2010 Apr;105(8):1074-81 98 Citations |
| 1 | Rituximab in chronic lymphocytic leukemia. (Jaglowski SM, Byrd JC) Semin Hematol 2010 Apr;47(2):156-69 33 Citations |
| 2 | Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. (Bautista MA, Stevens WT, Chen CS, Curtis BR, Aster RH, Hsueh CT) J Hematol Oncol 2010 Mar 26;3:12 63 Citations |
| 1 | Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. (Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, Coleman R, Lu K, Xiao L, Kurzrock R) Gynecol Oncol 2010 Jun;117(3):467-72 14 Citations |
| 1 | Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. (Bilgi N, Bell K, Ananthakrishnan AN, Atallah E) Ann Pharmacother 2010 May;44(5):926-8 111 Citations |
| 1 | Current management of primary central nervous system lymphoma. (Schultz CJ, Bovi J) Int J Radiat Oncol Biol Phys 2010 Mar 01;76(3):666-78 36 Citations |
| 1 | A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. (Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, Bray G, Mendelson D) Clin Cancer Res 2010 Feb 15;16(4):1256-63 155 Citations |
| 1 | Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. (Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, Wheler J, Kurzrock R) Clin Cancer Res 2010 Feb 15;16(4):1289-97 120 Citations |
| 2 | Expression of natural killer receptors in T- and NK-cells: comparison of healthy individuals, patients with prior stem cell transplant, and patients undergoing chemotherapy. (Olteanu H, Schur BC, Bredeson C, Atallah E, Kroft SH) Leuk Lymphoma 2010 Mar;51(3):481-7 5 Citations |
| 1 | Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? (Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM) Oncologist 2010;15(2):130-41 107 Citations |
| 1 | Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience. (Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Feng L, Kurzrock R) Clin Breast Cancer 2010 Feb;10(1):46-51 |
| 1 | Nanoparticulate cellular patches for cell-mediated tumoritropic delivery. (Cheng H, Kastrup CJ, Ramanathan R, Siegwart DJ, Ma M, Bogatyrev SR, Xu Q, Whitehead KA, Langer R, Anderson DG) ACS Nano 2010 Feb 23;4(2):625-31 140 Citations |
| 1 | Juice plus or toxicity plus. (Naing A, Aaron J, Kurzrock R) Am J Med 2010 Jan;123(1):e1-2 3 Citations |
| 1 | Prevalence of dysplasia in juvenile-onset recurrent respiratory papillomatosis. (Sajan JA, Kerschner JE, Merati AL, Osipov V, Szabo S, Blumin JH) Arch Otolaryngol Head Neck Surg 2010 Jan;136(1):7-11 25 Citations |
| 1 | Identification and characterization of the first small molecule inhibitor of MDMX. (Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, Zhu F, Mills N, Smithson DC, Regni CA, Bashford D, Cicero SA, Schulman BA, Jochemsen AG, Guy RK, Dyer MA) J Biol Chem 2010 Apr 02;285(14):10786-96 182 Citations |
| 1 | Inhibition of aldehyde dehydrogenase expands hematopoietic stem cells with radioprotective capacity. (Muramoto GG, Russell JL, Safi R, Salter AB, Himburg HA, Daher P, Meadows SK, Doan P, Storms RW, Chao NJ, McDonnell DP, Chute JP) Stem Cells 2010 Mar 31;28(3):523-34 64 Citations |
| 1 | Target validation using Phase 0 clinical trials: Promises and pitfalls. (Angelo LS, Kurzrock R) Cancer Biol Ther 2009 Nov;8(21):2010-2 1 Citation |
| 1 | Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. (Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Laverdière C, Michon B, Schorin M, Schwartz CL, O'Brien JE, Cohen HJ, Sallan SE) Blood 2010 Feb 18;115(7):1351-3 92 Citations |
| 1 | Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies. (Traynor AM, Thomas JP, Ramanathan RK, Mody TD, Alberti D, Wilding G, Bailey HH) Invest New Drugs 2011 Apr;29(2):316-22 6 Citations |
| 1 | Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. (Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, Sanchez V, Dugger TC, de Matos Granja N, Narasanna A, Cook RS, Kennedy JP, Lindsley CW, Arteaga CL) Clin Cancer Res 2009 Dec 01;15(23):7266-76 115 Citations |
| 2 | Role of radiation therapy in cutaneous melanoma. (Shuff JH, Siker ML, Daly MD, Schultz CJ) Clin Plast Surg 2010 Jan;37(1):147-60 8 Citations |
| 1 | Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R, European LeukemiaNet) J Clin Oncol 2009 Dec 10;27(35):6041-51 1163 Citations |
| 1 | Ocular surface squamous neoplasia after corneal graft. (Ramasubramanian A, Shields CL, Sinha N, Shields JA) Am J Ophthalmol 2010 Jan;149(1):62-5 22 Citations |
| 1 | Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial. (Tsimberidou AM, Braiteh F, Stewart DJ, Kurzrock R) J Clin Oncol 2009 Dec 20;27(36):6243-50 77 Citations |
| 1 | Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect? (James E, Podoltsev N, Salehi E, Curtis BR, Saif MW) Clin Colorectal Cancer 2009 Oct;8(4):220-4 28 Citations |
| 1 | Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). (Burke MJ, Cao Q, Trotz B, Weigel B, Kumar A, Smith A, Verneris MR) Pediatr Blood Cancer 2009 Dec 15;53(7):1289-94 24 Citations |
| 1 | Dual LOX/COX inhibitors: potential novel anti-cancer drugs. (Vijayakrishnan R) Ir J Med Sci 2009 Dec;178(4):517 2 Citations |
| 1 | Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. (Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge Y, Newman RA, Cohen L, Liu L, Thornton B, Chang DZ, Liao Z, Kurzrock R) Cancer 2009 Nov 15;115(22):5309-18 265 Citations |
| 2 | The role of NF-kappaB and Smad3 in TGF-beta-mediated Foxp3 expression. (Jana S, Jailwala P, Haribhai D, Waukau J, Glisic S, Grossman W, Mishra M, Wen R, Wang D, Williams CB, Ghosh S) Eur J Immunol 2009 Sep;39(9):2571-83 45 Citations |
| 1 | Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription. (Féau C, Arnold LA, Kosinski A, Zhu F, Connelly M, Guy RK) ACS Chem Biol 2009 Oct 16;4(10):834-43 24 Citations |
| 1 | Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder. (Oravecz-Wilson KI, Philips ST, Yilmaz OH, Ames HM, Li L, Crawford BD, Gauvin AM, Lucas PC, Sitwala K, Downing JR, Morrison SJ, Ross TS) Cancer Cell 2009 Aug 04;16(2):137-48 63 Citations |
| 1 | Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia. (Hamadani M, Awan FT) Hematol Oncol 2010 Mar;28(1):3-12 10 Citations |
| 1 | Practical considerations for the management of patients in the tyrosine kinase inhibitor era. (O'Dwyer M, Atallah E) Semin Hematol 2009 Apr;46(2 Suppl 3):S16-21 12 Citations |
| 1 | Focus on molecules: maspin. (Narayan M, Twining S) Exp Eye Res 2010 Jan;90(1):2-3 12 Citations |
| 1 | Antiangiogenic action of redox-modulating Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin, MnTE-2-PyP(5+), via suppression of oxidative stress in a mouse model of breast tumor. (Rabbani ZN, Spasojevic I, Zhang X, Moeller BJ, Haberle S, Vasquez-Vivar J, Dewhirst MW, Vujaskovic Z, Batinic-Haberle I) Free Radic Biol Med 2009 Oct 01;47(7):992-1004 89 Citations |
| 1 | Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. (Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, Sanchez V, Nolting DD, Buck JR, Zhao P, Ansari MS, Baldwin RM, Gore JC, Schiff R, Arteaga CL, Manning HC) Clin Cancer Res 2009 Jul 15;15(14):4712-21 78 Citations |
| 1 | Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model. (Mach CM, Mathew L, Mosley SA, Kurzrock R, Smith JA) Anticancer Res 2009 Jun;29(6):1895-9 58 Citations |
| 1 | Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. (Ling HT, Field JJ, Blinder MA) Am J Hematol 2009 Jul;84(7):418-21 56 Citations |
| 1 | A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. (Moulder S, Dhillon N, Ng C, Hong D, Wheler J, Naing A, Tse S, La Paglia A, Dorr R, Hersh E, Boytim M, Kurzrock R) Invest New Drugs 2010 Oct;28(5):634-40 33 Citations |
| 1 | Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. (Tsimberidou AM, Rudek MA, Hong D, Ng CS, Blair J, Goldsweig H, Kurzrock R) Cancer Chemother Pharmacol 2010 Jan;65(2):235-41 35 Citations |
| 1 | Medullary thyroid cancer: management guidelines of the American Thyroid Association. (American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr) Thyroid 2009 Jun;19(6):565-612 1187 Citations |
| 2 | Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. (Alousi AM, Weisdorf DJ, Logan BR, Bolaños-Meade J, Carter S, Difronzo N, Pasquini M, Goldstein SC, Ho VT, Hayes-Lattin B, Wingard JR, Horowitz MM, Levine JE, Blood and Marrow Transplant Clinical Trials Network) Blood 2009 Jul 16;114(3):511-7 203 Citations |
| 1 | Cancer's craving for sugar: an opportunity for clinical exploitation. (Yeluri S, Madhok B, Prasad KR, Quirke P, Jayne DG) J Cancer Res Clin Oncol 2009 Jul;135(7):867-77 52 Citations |
| 1 | Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. (Ratanatharathorn V, Logan B, Wang D, Horowitz M, Uberti JP, Ringden O, Gale RP, Khoury H, Arora M, Spellman S, Cutler C, Antin J, Bornhaüser M, Hale G, Verdonck L, Cairo M, Gupta V, Pavletic S, Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA) Br J Haematol 2009 Jun;145(6):816-24 65 Citations |
| 1 | Longitudinal oncology registry of head and neck carcinoma (LORHAN): initial supportive care findings. (Murphy BA, Chen A, Curran WJ Jr, Garden AS, Harari PM, Wong SJ, Ang KK) Support Care Cancer 2009 Nov;17(11):1393-401 11 Citations |
| 1 | Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. (Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR) Bone Marrow Transplant 2009 Aug;44(3):169-74 12 Citations |
| 1 | Neuroendocrine tumors: novel approaches in the age of targeted therapy. (Phan AT, Yao JC) Oncology (Williston Park) 2008 Dec;22(14):1617-23; discussion 1623-4, 1629 12 Citations |
| 1 | The impact of extramedullary disease at presentation on the outcome of myeloma. (Wu P, Davies FE, Boyd K, Thomas K, Dines S, Saso RM, Potter MN, Ethell ME, Shaw BE, Morgan GJ) Leuk Lymphoma 2009 Feb;50(2):230-5 105 Citations |
| 1 | Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. (Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB) Ann Surg Oncol 2009 Apr;16(4):836-47 444 Citations |
| 1 | Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. (Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, Harari PM) Clin Cancer Res 2009 Mar 01;15(5):1585-92 86 Citations |
| 1 | Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. (Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, Feng L, Kurzrock R) Cancer 2009 Mar 01;115(5):1091-9 75 Citations |
| 1 | Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells. (Symes JC, Siatskas C, Fowler DH, Medin JA) Cancer Gene Ther 2009 May;16(5):439-52 8 Citations |
| 2 | Treatment options for metastatic neuroendocrine tumors. (Phan AT, Yao JC, Evans DB) Surgery 2008 Dec;144(6):895-8 5 Citations |
| 1 | Rehabilitation of dysphagia following head and neck cancer. (Pauloski BR) Phys Med Rehabil Clin N Am 2008 Nov;19(4):889-928, x 166 Citations |
| 1 | Neoadjuvant chemoradiation for rectal cancer reduces lymph node harvest in proctectomy specimens. (de la Fuente SG, Manson RJ, Ludwig KA, Mantyh CR) J Gastrointest Surg 2009 Feb;13(2):269-74 56 Citations |
| 1 | Dendrimers for enhanced drug solubilization. (Svenson S, Chauhan AS) Nanomedicine (Lond) 2008 Oct;3(5):679-702 139 Citations |
| 1 | Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. (Rodon J, DeSantos V, Ferry RJ Jr, Kurzrock R) Mol Cancer Ther 2008 Sep;7(9):2575-88 148 Citations |
| 1 | Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel. (Symes JC, Kurin M, Fleshner NE, Medin JA) Mol Cancer Ther 2008 Sep;7(9):3018-28 22 Citations |
| 2 | Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. (Bunin NJ, Davies SM, Aplenc R, Camitta BM, DeSantes KB, Goyal RK, Kapoor N, Kernan NA, Rosenthal J, Smith FO, Eapen M) J Clin Oncol 2008 Sep 10;26(26):4326-32 49 Citations |
| 1 | Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. (Burke MJ, Trotz B, Luo X, Baker KS, Weisdorf DJ, Wagner JE, Verneris MR) Bone Marrow Transplant 2009 Jan;43(2):107-13 47 Citations |
| 1 | High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. (Hamadani M, Benson DM Jr, Lin TS, Porcu P, Blum KA, Devine SM) Eur J Haematol 2008 Dec;81(6):425-31 28 Citations |
| 1 | Effects of cancer treatment on ovarian function. (Stroud JS, Mutch D, Rader J, Powell M, Thaker PH, Grigsby PW) Fertil Steril 2009 Aug;92(2):417-27 94 Citations |
| 1 | Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. (Hitchcock YJ, Tward JD, Szabo A, Bentz BG, Shrieve DC) Int J Radiat Oncol Biol Phys 2009 Mar 01;73(3):779-88 104 Citations |
| 2 | Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. (Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks DI, McCarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten HC, Zander AR, Horowitz MM, Maziarz RT) Blood 2008 Oct 15;112(8):3500-7 120 Citations |
| 1 | Novel dual-reporter preclinical screen for antiastrocytoma agents identifies cytostatic and cytotoxic compounds. (Hawes JJ, Nerva JD, Reilly KM) J Biomol Screen 2008 Sep;13(8):795-803 11 Citations |
| 1 | Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. (Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA) J Clin Oncol 2008 Jul 20;26(21):3496-502 685 Citations |
| 1 | Phase II trial of curcumin in patients with advanced pancreatic cancer. (Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R) Clin Cancer Res 2008 Jul 15;14(14):4491-9 1269 Citations |
| 1 | Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress. (Wolff RA, Varadhachary GR, Evans DB) Ann Surg Oncol 2008 Oct;15(10):2773-86 53 Citations |
| 1 | Role of oxidative stress in the induction of metallothionein-2A and heme oxygenase-1 gene expression by the antineoplastic agent gallium nitrate in human lymphoma cells. (Yang M, Chitambar CR) Free Radic Biol Med 2008 Sep 15;45(6):763-72 71 Citations |
| 1 | Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. (Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, Diwan AH, Evans HL, Kurzrock R) Arch Dermatol 2008 Jun;144(6):779-82 48 Citations |
| 1 | Review: isolated skeletal involvement in hairy cell leukemia. (Hamadani M, Kraut EH) Clin Adv Hematol Oncol 2008 Apr;6(4):294-6 2 Citations |
| 1 | Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia. (Tholouli E, Liakopoulou E, Greenfield HM, Shaw BE, Tauro S, Byrne JL, Dennis M, Burthem J, Lucas GS, Craddock C, Russell NH, Liu Yin JA) Br J Haematol 2008 Jun;142(2):318-20 7 Citations |
| 1 | Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. (Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, Varadhachary GR, Hwang RF) J Am Coll Surg 2008 May;206(5):833-46; discussion 846-8 761 Citations |
| 1 | Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. (Hong D, Ye L, Gagel R, Chintala L, El Naggar AK, Wright J, Kurzrock R) Mol Cancer Ther 2008 May;7(5):1001-6 54 Citations |
| 1 | Antiangiogenic effect of inhibitors of cytochrome P450 on rats with glioblastoma multiforme. (Zagorac D, Jakovcevic D, Gebremedhin D, Harder DR) J Cereb Blood Flow Metab 2008 Aug;28(8):1431-9 35 Citations |
| 1 | Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. (Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM) Oncogene 2008 Jun 26;27(28):3944-56 488 Citations |
| 1 | CD36-TSP-HRGP interactions in the regulation of angiogenesis. (Silverstein RL, Febbraio M) Curr Pharm Des 2007;13(35):3559-67 37 Citations |
| 1 | Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer. (Nguyen TT, Wright JD, Powell MA, Gibb RK, Rader JS, Allsworth JE, Mutch DG) Int J Gynecol Cancer 2008;18(6):1194-9 14 Citations |
| 2 | Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. (Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN, Burns LJ, Cairo MS, Freytes CO, Goldstein SC, Hale GA, Inwards DJ, Lemaistre CF, Maharaj D, Marks DI, Schouten HC, Slavin S, Vose JM, Lazarus HM, van Besien K) Biol Blood Marrow Transplant 2008 Feb;14(2):236-45 151 Citations |
| 1 | Cryopreservation of sperm after chemotherapy. (Brannigan RE, Sandlow JI) J Androl 2008;29(3):e1-2 6 Citations |
| 2 | Allogeneic hematopoietic cell transplantation for metastatic breast cancer. (Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ, Bregni M, Carella A, Blaise D, Bashey A, Bitran JD, Bolwell BJ, Elfenbein GJ, Fields KK, Freytes CO, Gale RP, Lazarus HM, Champlin RE, Stiff PJ, Niederwieser D) Bone Marrow Transplant 2008 Mar;41(6):537-45 44 Citations |
| 1 | The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines. (Lyu MA, Kurzrock R, Rosenblum MG) Biochem Pharmacol 2008 Feb 15;75(4):836-46 19 Citations |
| 3 | Outcomes after HLA-matched sibling transplantation or chemotherapy in children with acute lymphoblastic leukemia in a second remission after an isolated central nervous system relapse: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. (Eapen M, Zhang MJ, Devidas M, Raetz E, Barredo JC, Ritchey AK, Godder K, Grupp S, Lewis VA, Malloy K, Carroll WL, Davies SM, Camitta BM, Children's Oncology Group, Center for International Blood and Marrow Transplant Research) Leukemia 2008 Feb;22(2):281-6 49 Citations |
| 1 | Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. (Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE) Blood 2008 Jan 01;111(1):25-41 147 Citations |
| 1 | Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. (Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE, American Society of Clinical Oncology, American Society of Hematology) J Clin Oncol 2008 Jan 01;26(1):132-49 268 Citations |
| 1 | Interleukin-6 and its receptor in cancer: implications for translational therapeutics. (Hong DS, Angelo LS, Kurzrock R) Cancer 2007 Nov 01;110(9):1911-28 361 Citations |
| 1 | Studies in target-based treatment. (Kurzrock R) Mol Cancer Ther 2007 Sep;6(9):2385 4 Citations |
| 1 | Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. (Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields AL, Mayer RJ) J Clin Oncol 2007 Aug 10;25(23):3456-61 418 Citations |
| 1 | Future chemoradiation strategies in pancreatic cancer. (Crane CH, Varadhachary G, Pisters PW, Evans DB, Wolff RA) Semin Oncol 2007 Aug;34(4):335-46 29 Citations |
| 1 | Dramatic response to single-agent rituximab in a patient with intravascular lymphoma. (Vrindavanam N, Hamadani M, Steele B, Awan F, Suster S, Benson DM Jr) Am J Hematol 2007 Dec;82(12):1120-1 2 Citations |
| 1 | Development of gallium compounds for treatment of lymphoma: gallium maltolate, a novel hydroxypyrone gallium compound, induces apoptosis and circumvents lymphoma cell resistance to gallium nitrate. (Chitambar CR, Purpi DP, Woodliff J, Yang M, Wereley JP) J Pharmacol Exp Ther 2007 Sep;322(3):1228-36 110 Citations |
| 2 | Utility of single versus tandem autotransplants for advanced testes/germ cell cancer: a center for international blood and marrow transplant research (CIBMTR) analysis. (Lazarus HM, Stiff PJ, Carreras J, Logan BR, Akard L, Bolwell BJ, Childs RW, Gale RP, Klein JP, Lill MC, Pérez WS, Stadtmauer EA, Rizzo JD) Biol Blood Marrow Transplant 2007 Jul;13(7):778-89 10 Citations |
| 1 | I have good news! You have leukemia. (Kurzrock R) Clin Dermatol 2007;25(3):350-2 1 Citation |
| 1 | Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. (Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS) J Clin Oncol 2007 Jun 10;25(17):2369-76 180 Citations |
| 1 | Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group. (Salzer WL, Devidas M, Shuster JJ, Wang C, Chauvenet A, Asselin BL, Camitta BM, Kurtzberg J, Children's Oncology Group) J Pediatr Hematol Oncol 2007 Jun;29(6):369-75 17 Citations |
| 1 | Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. (Reyes-Gibby CC, Chan W, Abbruzzese JL, Xiong HQ, Ho L, Evans DB, Varadhachary G, Bhat S, Wolff RA, Crane C) J Pain Symptom Manage 2007 Sep;34(3):244-52 44 Citations |
| 1 | Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. (Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL, Sobocinski KA, Horowitz MM, Chronic Leukemia Working Committee, Center for International Blood and Marrow Transplant Research) Br J Haematol 2007 Jun;137(5):461-7 71 Citations |
| 1 | Congestive heart failure is a rare event in patients receiving imatinib therapy. (Atallah E, Durand JB, Kantarjian H, Cortes J) Blood 2007 Aug 15;110(4):1233-7 220 Citations |
| 1 | Nanotechnology applications in cancer. (Nie S, Xing Y, Kim GJ, Simons JW) Annu Rev Biomed Eng 2007;9:257-88 1082 Citations |
| 1 | Uncommon tumors and exceptional therapies: paradox or paradigm? (Braiteh F, Kurzrock R) Mol Cancer Ther 2007 Apr;6(4):1175-9 52 Citations |
| 1 | Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. (Li L, Ahmed B, Mehta K, Kurzrock R) Mol Cancer Ther 2007 Apr;6(4):1276-82 337 Citations |
| 1 | Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death. (Uwagawa T, Li Z, Chang Z, Xia Q, Peng B, Sclabas GM, Ishiyama S, Hung MC, Evans DB, Abbruzzese JL, Chiao PJ) Cancer 2007 May 15;109(10):2142-53 43 Citations |
| 1 | Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116. (Small W Jr, Winter K, Levenback C, Iyer R, Gaffney D, Asbell S, Erickson B, Jhingran A, Greven K) Int J Radiat Oncol Biol Phys 2007 Jul 15;68(4):1081-7 129 Citations |
| 1 | Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? (Aloia TA, Lee JE, Vauthey JN, Abdalla EK, Wolff RA, Varadhachary GR, Abbruzzese JL, Crane CH, Evans DB, Pisters PW) J Am Coll Surg 2007 Mar;204(3):347-55 116 Citations |
| 2 | Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate. (Yang M, Kroft SH, Chitambar CR) Mol Cancer Ther 2007 Feb;6(2):633-43 36 Citations |
| 1 | A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. (Fenaux P, Raza A, Mufti GJ, Aul C, Germing U, Kantarjian H, Cripe L, Kerstens R, De Porre P, Kurzrock R) Blood 2007 May 15;109(10):4158-63 104 Citations |
| 1 | Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). (Gonzalez RJ, Buzdar AU, Fraser Symmans W, Yen TW, Broglio KR, Lucci A, Esteva FJ, Yin G, Kuerer HM) Breast J 2007;13(1):72-5 24 Citations |
| 1 | In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. (Atallah E, Kantarjian H, Cortes J) Nat Med 2007 Jan;13(1):14; author reply 15-6 39 Citations |
| 1 | Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. (Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB 3rd, Strumberg D, Yanagihara R, Yao JC, Phan AT, Ajani JA) Cancer 2007 Jan 01;109(1):33-40 55 Citations |
| 1 | Gallium-induced cell death in lymphoma: role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition. (Chitambar CR, Wereley JP, Matsuyama S) Mol Cancer Ther 2006 Nov;5(11):2834-43 57 Citations |
| 1 | Outcomes in 24 selected patients with stage IVB cervical cancer and excellent performance status treated with radiotherapy and chemotherapy. (Zighelboim I, Taylor NP, Powell MA, Gibb RK, Rader JS, Mutch DG, Grigsby PW) Radiat Med 2006 Nov;24(9):625-30 38 Citations |
| 1 | Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome. (Montero AJ, Estrov Z, Freireich EJ, Khouri IF, Koller CA, Kurzrock R) Leuk Lymphoma 2006 Oct;47(10):2049-54 23 Citations |
| 1 | Adjuvant therapy for renal cell carcinoma. (Jacobsohn KM, Wood CG) Semin Oncol 2006 Oct;33(5):576-82 40 Citations |
| 1 | Role of intra-arterial steroid administration in the management of steroid-refractory acute gastrointestinal graft-versus-host disease. (Tfayli A, Selby G, Maqbool F, Bierbaum W, Hamadani M) Am J Hematol 2006 Dec;81(12):959-62 12 Citations |
| 1 | Emerging use of nanoparticles in diagnosis and treatment of breast cancer. (Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, O'Regan RM) Lancet Oncol 2006 Aug;7(8):657-67 506 Citations |
| 1 | Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710. (Colman H, Berkey BA, Maor MH, Groves MD, Schultz CJ, Vermeulen S, Nelson DF, Mehta MP, Yung WK, Radiation Therapy Oncology Group) Int J Radiat Oncol Biol Phys 2006 Nov 01;66(3):818-24 51 Citations |
| 1 | Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. (Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N) Clin Lymphoma Myeloma 2006 Jul;7(1):51-8 153 Citations |
| 1 | Primary pancreatic lymphoma: diagnostic and therapeutic dilemma. (Battula N, Srinivasan P, Prachalias A, Rela M, Heaton N) Pancreas 2006 Aug;33(2):192-4 65 Citations |
| 1 | Relationship between swallow motility disorders on videofluorography and oral intake in patients treated for head and neck cancer with radiotherapy with or without chemotherapy. (Pauloski BR, Rademaker AW, Logemann JA, Newman L, MacCracken E, Gaziano J, Stachowiak L) Head Neck 2006 Dec;28(12):1069-76 80 Citations |
| 1 | POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group. (Kung FH, Schwartz CL, Ferree CR, London WB, Ternberg JL, Behm FG, Wharam MD, Falletta JM, de Alarcon P, Chauvenet AR, Children's Oncology Group) J Pediatr Hematol Oncol 2006 Jun;28(6):362-8 81 Citations |
| 1 | Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. (Herzog TJ, Powell MA, Rader JS, Gibb R, Mutch DG) Gynecol Oncol 2006 Nov;103(2):637-41 11 Citations |
| 1 | Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? (Wong SJ, Machtay M, Li Y) J Clin Oncol 2006 Jun 10;24(17):2653-8 119 Citations |
| 1 | Are bone scans necessary in men with low prostate specific antigen levels following localized therapy? (Warren KS, Chodak GW, See WA, Iverson P, McLeod D, Wirth M, Morris C, Armstrong J) J Urol 2006 Jul;176(1):70-3; discussion 73-4 12 Citations |
| 1 | Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R, European LeukemiaNet) Blood 2006 Sep 15;108(6):1809-20 1147 Citations |
| 1 | Measuring response in a post-RECIST world: from black and white to shades of grey. (Michaelis LC, Ratain MJ) Nat Rev Cancer 2006 May;6(5):409-14 171 Citations |
| 2 | Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. (Curtis BR, Kaliszewski J, Marques MB, Saif MW, Nabelle L, Blank J, McFarland JG, Aster RH) Am J Hematol 2006 Mar;81(3):193-8 103 Citations |
| 1 | Re: Modified intrapleural cisplatin treatment for lung cancer with positive pleural lavage cytology or malignant effusion, by Muraoka M, Oka T, Akamine S, et al. (Johnstone DW) J Surg Oncol 2006 Mar 15;93(4):255-6 |
| 4 | Chemoembolization in patients at high risk: results and complications. (Kiely JM, Rilling WS, Touzios JG, Hieb RA, Franco J, Saeian K, Quebbeman EJ, Pitt HA) J Vasc Interv Radiol 2006 Jan;17(1):47-53 50 Citations |
| 1 | Preoperative chemoradiation for pancreatic cancer. (Evans DB) Semin Oncol 2005 Dec;32(6 Suppl 9):S25-9 15 Citations |
| 1 | Resistance to the antineoplastic agent gallium nitrate results in marked alterations in intracellular iron and gallium trafficking: identification of novel intermediates. (Davies NP, Suryo Rahmanto Y, Chitambar CR, Richardson DR) J Pharmacol Exp Ther 2006 Apr;317(1):153-62 40 Citations |
| 1 | Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. (Routes JM, Ryan S, Morris K, Takaki R, Cerwenka A, Lanier LL) J Exp Med 2005 Dec 05;202(11):1477-82 68 Citations |
| 1 | Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. (McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, Friedl A, Kolesar J, Marnocha R, Volkman J, Zhang J, Hammershaimb L, Zwiebel JA, Wilding G) Clin Cancer Res 2005 Nov 01;11(21):7851-60 145 Citations |
| 1 | The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. (Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P, Larson RA, Parsons S, Seidenfeld J, Weisdorf D, McCarthy PL Jr) Biol Blood Marrow Transplant 2005 Nov;11(11):823-61 67 Citations |
| 1 | Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. (Strock CJ, Park JI, Rosen DM, Ruggeri B, Denmeade SR, Ball DW, Nelkin BD) J Clin Endocrinol Metab 2006 Jan;91(1):79-84 44 Citations |
| 1 | APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial. (Wimmer RS, Chauvenet AR, London WB, Villaluna D, de Alarcon PA, Schwartz CL) Pediatr Blood Cancer 2006 Mar;46(3):320-4 8 Citations |
| 2 | NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. (Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR) Blood 2006 Jan 15;107(2):827-34 110 Citations |
| 1 | Farnesyltransferase inhibitors. (Kurzrock R) Clin Adv Hematol Oncol 2005 Mar;3(3):161-2 7 Citations |
| 1 | Toxic epidermal necrolysis in two rhesus macaques (Macaca mulatta) after administration of rituximab. (Allen KP, Funk AJ, Mandrell TD) Comp Med 2005 Aug;55(4):377-81 14 Citations |
| 1 | Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. (Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P, Armstrong J, Morris C, 'Casodex' Early Prostate Cancer Trialists Group) Radiother Oncol 2005 Jul;76(1):4-10 62 Citations |
| 1 | Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice. (Johnson BD, Gershan JA, Natalia N, Zujewski H, Weber JJ, Yan X, Orentas RJ) J Immunother 2005;28(5):449-60 32 Citations |
| 1 | Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. (Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R) Cancer 2005 Aug 15;104(4):879-90 237 Citations |
| 1 | A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells. (Nithipatikom K, Endsley MP, Isbell MA, Wheelock CE, Hammock BD, Campbell WB) Biochem Biophys Res Commun 2005 Jul 15;332(4):1028-33 50 Citations |
| 1 | Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. (Kröger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, Nagler A, Binder T, Eiermann T, Madrigal A, Schwerdtfeger R, Kiehl M, Sayer HG, Beyer J, Bornhäuser M, Ayuk F, Zander AR, Marks DI, Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group) Br J Haematol 2005 Jun;129(5):631-43 105 Citations |
| 1 | Treatment of metastatic malignant melanoma. (Atallah E, Flaherty L) Curr Treat Options Oncol 2005 May;6(3):185-93 166 Citations |
| 1 | A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. (Dy GK, Thomas JP, Wilding G, Bruzek L, Mandrekar S, Erlichman C, Alberti D, Binger K, Pitot HC, Alberts SR, Hanson LJ, Marnocha R, Tutsch K, Kaufmann SH, Adjei AA) Clin Cancer Res 2005 May 01;11(9):3410-6 66 Citations |
| 1 | Results of multimodal treatment for desmoplastic small round cell tumors. (Lal DR, Su WT, Wolden SL, Loh KC, Modak S, La Quaglia MP) J Pediatr Surg 2005 Jan;40(1):251-5 265 Citations |
| 1 | Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. (Tibes R, Trent J, Kurzrock R) Annu Rev Pharmacol Toxicol 2005;45:357-84 107 Citations |
| 1 | Evidence-based medicine: can it be applied to stimulation of erythropoiesis for patients with malignancy? (Rizzo JD) Best Pract Res Clin Haematol 2005;18(3):439-48 2 Citations |
| 1 | Risks and benefits of phase 1 oncology trials, revisited. (Kurzrock R, Benjamin RS) N Engl J Med 2005 Mar 03;352(9):930-2 80 Citations |
| 1 | Acute bilateral serous macular detachment associated with gallium nitrate in a patient with non-Hodgkin lymphoma. (Moon SJ, Han DP) Retina 2005;25(2):212-4 3 Citations |
| 1 | Lack of benefit of concurrent chemotherapy in patients with cervical cancer and negative lymph nodes by FDG-PET. (Grigsby PW, Mutch DG, Rader J, Herzog TJ, Zoberi I, Siegel BA, Dehdashti F) Int J Radiat Oncol Biol Phys 2005 Feb 01;61(2):444-9 31 Citations |
| 1 | Apoptotic mechanisms of gallium nitrate: basic and clinical investigations. (Chitambar CR) Oncology (Williston Park) 2004 Nov;18(13 Suppl 10):39-44 31 Citations |
| 1 | Gallium compounds as antineoplastic agents. (Chitambar CR) Curr Opin Oncol 2004 Nov;16(6):547-52 58 Citations |
| 1 | Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. (Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K, Casodex Early Prostate Cancer Trialists' Group) J Urol 2004 Nov;172(5 Pt 1):1865-70 201 Citations |
| 1 | Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: a patterns of care study. (Eifel PJ, Moughan J, Erickson B, Iarocci T, Grant D, Owen J) Int J Radiat Oncol Biol Phys 2004 Nov 15;60(4):1144-53 122 Citations |
| 1 | Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. (Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R) Cancer 2004 Nov 15;101(10):2351-62 294 Citations |
| 3 | Alpha phenyl-tert-butyl nitrone (PBN) protects syngeneic marrow transplant recipients from the lethal cytokine syndrome occurring after agonistic CD40 antibody administration. (Gendelman M, Halligan N, Komorowski R, Logan B, Murphy WJ, Blazar BR, Pritchard KA Jr, Drobyski WR) Blood 2005 Jan 01;105(1):428-31 10 Citations |
| 1 | Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program. (Iversen P, Wirth MP, See WA, McLeod DG, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Lundmo P, Tammela TL, Johansson JE, Morris T, Carroll K, Casodex Early Prostate Cancer Trialists' Group) Urology 2004 May;63(5):928-33 16 Citations |
| 2 | Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. (Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK, Radiation Therapy Oncology Group 9501/Intergroup) N Engl J Med 2004 May 06;350(19):1937-44 2935 Citations |
| 1 | The P2Y agonist UTP activates cutaneous afferent fibers. (Stucky CL, Medler KA, Molliver DC) Pain 2004 May;109(1-2):36-44 64 Citations |
| 1 | Evaluation of photodynamic therapy near functional brain tissue in patients with recurrent brain tumors. (Schmidt MH, Meyer GA, Reichert KW, Cheng J, Krouwer HG, Ozker K, Whelan HT) J Neurooncol 2004;67(1-2):201-7 68 Citations |
| 1 | Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. (Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M) Blood 2004 Aug 01;104(3):655-8 122 Citations |
| 1 | Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. (Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G, Thomas DA, Giles FJ, Ryback ME, Thibault A, De Porre P, Kantarjian HM) J Clin Oncol 2004 Apr 01;22(7):1287-92 149 Citations |
| 1 | Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia. (Rosenblum MD, LaBelle JL, Chang CC, Margolis DA, Schauer DW, Vesole DH) Blood 2004 Mar 01;103(5):1969-71 46 Citations |
| 1 | In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. (Ramakers-van Woerden NL, Beverloo HB, Veerman AJ, Camitta BM, Loonen AH, van Wering ER, Slater RM, Harbott J, den Boer ML, Ludwig WD, Haas OA, Janka-Schaub GE, Pieters R) Leukemia 2004 Mar;18(3):521-9 75 Citations |
| 1 | Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. (Hwang RF, Yokoi K, Bucana CD, Tsan R, Killion JJ, Evans DB, Fidler IJ) Clin Cancer Res 2003 Dec 15;9(17):6534-44 154 Citations |
| 1 | Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review. (Mittal BB, Pauloski BR, Haraf DJ, Pelzer HJ, Argiris A, Vokes EE, Rademaker A, Logemann JA) Int J Radiat Oncol Biol Phys 2003 Dec 01;57(5):1219-30 190 Citations |
| 1 | The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. (Shaw BE, Peggs K, Bird JM, Cavenagh J, Hunter A, Alejandro Madrigal J, Russell NH, Sirohi B, Towlson K, Williams CD, Marks DI, Clinical Trials Committee of the British Society of Blood and Marrow Transplantation) Br J Haematol 2003 Dec;123(5):886-95 24 Citations |
| 1 | A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. (Rader JS, Clarke-Pearson D, Moore M, Carson L, Holloway R, Kao MS, Wiznitzer I, Douglass EC) Gynecol Oncol 2003 Nov;91(2):318-25 14 Citations |
| 1 | Apoptotic pathways of epothilone BMS 310705. (Uyar D, Takigawa N, Mekhail T, Grabowski D, Markman M, Lee F, Canetta R, Peck R, Bukowski R, Ganapathi R) Gynecol Oncol 2003 Oct;91(1):173-8 21 Citations |
| 1 | Phase II study of alemtuzumab in chronic lymphoproliferative disorders. (Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP, Keating MJ) Cancer 2003 Aug 15;98(4):773-8 126 Citations |
| 1 | Non-small and small cell lung carcinoma cell lines exhibit cell type-specific sensitivity to edelfosine-induced cell death and different cell line-specific responses to edelfosine treatment. (Shafer SH, Williams CL) Int J Oncol 2003 Aug;23(2):389-400 20 Citations |
| 1 | Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. (Efferth T, Sauerbrey A, Steinbach D, Gebhart E, Drexler HG, Miyachi H, Chitambar CR, Becker CM, Zintl F, Humeny A) Int J Oncol 2003 Aug;23(2):509-17 48 Citations |
| 1 | E1A oncogene-induced sensitization of human tumor cells to innate immune defenses and chemotherapy-induced apoptosis in vitro and in vivo. (Cook JL, Miura TA, Iklé DN, Lewis AM Jr, Routes JM) Cancer Res 2003 Jun 15;63(12):3435-43 16 Citations |
| 1 | Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. (Meadows SM, Mulkerin D, Berlin J, Bailey H, Kolesar J, Warren D, Thomas JP) Int J Gastrointest Cancer 2002;32(2-3):125-8 67 Citations |
| 1 | Gallium nitrate revisited. (Chitambar CR) Semin Oncol 2003 Apr;30(2 Suppl 5):1-4 19 Citations |
| 1 | Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. (Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M) Ann Intern Med 2003 May 20;138(10):819-30 285 Citations |
| 1 | The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs. (Veldman RJ, Mita A, Cuvillier O, Garcia V, Klappe K, Medin JA, Campbell JD, Carpentier S, Kok JW, Levade T) FASEB J 2003 Jun;17(9):1144-6 40 Citations |
| 1 | The management of Hodgkin disease in the young child. (Schwartz CL) Curr Opin Pediatr 2003 Feb;15(1):10-6 31 Citations |
| 1 | Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. (DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ, Radiation Therapy Oncology Group Study 93-10) J Clin Oncol 2002 Dec 15;20(24):4643-8 669 Citations |
| 1 | Genomic imbalances in drug-resistant T-cell acute lymphoblastic CEM leukemia cell lines. (Efferth T, Verdorfer I, Miyachi H, Sauerbrey A, Drexler HG, Chitambar CR, Haber M, Gebhart E) Blood Cells Mol Dis 2002;29(1):1-13 25 Citations |
| 1 | Anti-tumor effect of Merocyanine 540-mediated photochemotherapy combined with Edelfosine: potential implications for the ex vivo purging of hematopoietic stem cell grafts from breast cancer patients. (Anderson GS, Miyagi K, Sampson RW, Sieber F) J Photochem Photobiol B 2002 Nov;68(2-3):101-8 24 Citations |
| 1 | Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. (Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D, Simon K, Feierabend C, Binger K, Marnocha R, Dresen A, Wilding G) Cancer Chemother Pharmacol 2002 Dec;50(6):465-72 121 Citations |
| 1 | Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. (Kurzrock R, Cortes J, Kantarjian H) Semin Hematol 2002 Oct;39(4 Suppl 3):20-4 33 Citations |
| 1 | Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. (Blanco JG, Edick MJ, Hancock ML, Winick NJ, Dervieux T, Amylon MD, Bash RO, Behm FG, Camitta BM, Pui CH, Raimondi SC, Relling MV) Pharmacogenetics 2002 Nov;12(8):605-11 98 Citations |
| 1 | Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. (Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, Rackoff W, Koller C, O'Brien S, Garcia-Manero G, Talpaz M, Kantarjian H) Blood 2003 Mar 01;101(5):1692-7 215 Citations |
| 1 | Role of ceramide in TNF-alpha-induced impairment of endothelium-dependent vasorelaxation in coronary arteries. (Zhang DX, Yi FX, Zou AP, Li PL) Am J Physiol Heart Circ Physiol 2002 Nov;283(5):H1785-94 67 Citations |
| 1 | Fast facts and concepts #14 palliative chemotherapy. (Weissman DE) J Palliat Med 2002 Aug;5(4):559-60 |
| 1 | The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. (Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T, Tsao MS, Evans DB, Abbruzzese JL, McDonnell TJ, Chiao PJ) Oncogene 2002 Sep 19;21(42):6510-9 161 Citations |
| 1 | Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies. (Cortes JE, Kurzrock R, Kantarjian HM) Semin Hematol 2002 Jul;39(3 Suppl 2):26-30 20 Citations |
| 1 | Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies. (Kantarjian HM, Cortes JE, Rowe JM, Kurzrock R) Semin Hematol 2002 Jul;39(3 Suppl 2):36-8 5 Citations |
| 1 | Myelodysplastic syndrome overview. (Kurzrock R) Semin Hematol 2002 Jul;39(3 Suppl 2):18-25 26 Citations |
| 1 | Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. (Mehta MP, Shapiro WR, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA, Schultz CJ, Roa WH, Leibenhaut M, Ford J, Curran W, Phan S, Smith JA, Miller RA, Renschler MF) J Clin Oncol 2002 Aug 15;20(16):3445-53 137 Citations |
| 1 | Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. (See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Vaage S, Tammela TL, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJ, Casodex Early Prostate Cancer Trialist Group) J Urol 2002 Aug;168(2):429-35 214 Citations |
| 1 | Mechanism of action of non-cisplatin type DNA-targeted platinum anticancer agents: DNA interactions of novel acridinylthioureas and their platinum conjugates. (Baruah H, Rector CL, Monnier SM, Bierbach U) Biochem Pharmacol 2002 Jul 15;64(2):191-200 88 Citations |
| 1 | Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. (Atallah E, Talpaz M, O'brien S, Rios MB, Guo JQ, Arlinghaus R, Fernandes-Reese S, Kantarjian H) Cancer 2002 Jun 01;94(11):2996-9 19 Citations |
| 1 | Office-based treatment of laryngeal papillomatosis with percutaneous injection of cidofovir. (Chhetri DK, Blumin JH, Shapiro NL, Berke GS) Otolaryngol Head Neck Surg 2002 Jun;126(6):642-8 40 Citations |
| 1 | Infantile hemangioma: clinical resolution with 5% imiquimod cream. (Martinez MI, Sanchez-Carpintero I, North PE, Mihm MC Jr) Arch Dermatol 2002 Jul;138(7):881-4; discussion 884 108 Citations |
| 1 | Chronic myelogenous leukemia in chronic phase. (Kurzrock R, Kantarjian H, Talpaz M) Curr Treat Options Oncol 2001 Jun;2(3):245-52 7 Citations |
| 1 | Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. (Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W, Silverman LB, Biondi A, Harms DO, Vilmer E, Schrappe M, Camitta B) Lancet 2002 Jun 01;359(9321):1909-15 335 Citations |
| 2 | Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. (Kotamraju S, Chitambar CR, Kalivendi SV, Joseph J, Kalyanaraman B) J Biol Chem 2002 May 10;277(19):17179-87 222 Citations |
| 1 | A survey of diagnosis, management, and grading of chronic GVHD. (Lee SJ, Vogelsang G, Gilman A, Weisdorf DJ, Pavletic S, Antin JH, Horowitz MM, Akpek G, Flowers ME, Couriel D, Martin PJ) Biol Blood Marrow Transplant 2002;8(1):32-9 91 Citations |
| 1 | Comparison of manual and automated leukocyte counts for determination of the absolute neutrophil count: application to a pediatric oncology clinic. (Parham DM, Ready R, Stine K, Quiggins C, Becton D, North P) Med Pediatr Oncol 2002 Mar;38(3):183-6 7 Citations |
| 1 | Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. (Plaxe SC, Blessing JA, Husseinzadeh N, Webster KD, Rader JS, Dunton CJ) Gynecol Oncol 2002 Feb;84(2):241-4 20 Citations |
| 1 | Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs. (Broome HE, Yu AL, Diccianni M, Camitta BM, Monia BP, Dean NM) Leuk Res 2002 Mar;26(3):311-6 30 Citations |
| 2 | Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase. (Green DA, Antholine WE, Wong SJ, Richardson DR, Chitambar CR) Clin Cancer Res 2001 Nov;7(11):3574-9 98 Citations |
| 1 | Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication. (Shao L, Diccianni MB, Tanaka T, Gribi R, Yu AL, Pullen JD, Camitta BM, Yu J) Cancer Res 2001 Oct 01;61(19):7333-8 63 Citations |
| 1 | Intravesical valrubicin in the treatment of carcinoma in situ of the bladder. (Kuznetsov DD, Alsikafi NF, O'Connor RC, Steinberg GD) Expert Opin Pharmacother 2001 Jun;2(6):1009-13 25 Citations |
| 1 | Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium. (Kalivendi SV, Kotamraju S, Zhao H, Joseph J, Kalyanaraman B) J Biol Chem 2001 Dec 14;276(50):47266-76 217 Citations |
| 1 | Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. (Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH) Cancer 2001 Jul 15;92(2):406-13 260 Citations |
| 1 | High-dose intra-arterial cisplatin boost with hyperfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. (Regine WF, Valentino J, Arnold SM, Haydon RC, Sloan D, Kenady D, Strottmann J, Pulmano C, Mohiuddin M) J Clin Oncol 2001 Jul 15;19(14):3333-9 31 Citations |
| 1 | Effects of xerostomia on perception and performance of swallow function. (Logemann JA, Smith CH, Pauloski BR, Rademaker AW, Lazarus CL, Colangelo LA, Mittal B, MacCracken E, Gaziano J, Stachowiak L, Newman LA) Head Neck 2001 Apr;23(4):317-21 114 Citations |
| 1 | Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants. (Carbone PP, Pirsch JD, Thomas JP, Douglas JA, Verma AK, Larson PO, Snow S, Tutsch KD, Pauk D) Cancer Epidemiol Biomarkers Prev 2001 Jun;10(6):657-61 30 Citations |
| 1 | BCR rearrangement-negative chronic myelogenous leukemia revisited. (Kurzrock R, Bueso-Ramos CE, Kantarjian H, Freireich E, Tucker SL, Siciliano M, Pilat S, Talpaz M) J Clin Oncol 2001 Jun 01;19(11):2915-26 97 Citations |
| 1 | Preoperative chemoradiation for resectable and locally advanced adenocarcinoma of the pancreas. (Evans DB) J Gastrointest Surg 2001;5(1):2-5 19 Citations |
| 1 | Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon alpha: involvement of tumor necrosis factor as ligand for the CD95 receptor. (Gisslinger H, Kurzrock R, Gisslinger B, Jiang S, Li S, Virgolini I, Woloszczuk W, Andreeff M, Talpaz M) Blood 2001 May 01;97(9):2791-7 17 Citations |
| 1 | Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. (Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans DB) Ann Surg Oncol 2001 Mar;8(2):123-32 332 Citations |
| 1 | The anti-malarial artesunate is also active against cancer. (Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR) Int J Oncol 2001 Apr;18(4):767-73 582 Citations |
| 1 | Regulated production of interferon-inducible T-cell chemoattractants by human intestinal epithelial cells. (Dwinell MB, Lügering N, Eckmann L, Kagnoff MF) Gastroenterology 2001 Jan;120(1):49-59 190 Citations |
| 1 | Antitumor interaction of short-course endostatin and ionizing radiation. (Hanna NN, Seetharam S, Mauceri HJ, Beckett MA, Jaskowiak NT, Salloum RM, Hari D, Dhanabal M, Ramchandran R, Kalluri R, Sukhatme VP, Kufe DW, Weichselbaum RR) Cancer J 2000;6(5):287-93 60 Citations |
| 1 | rhIL-11 for the prevention of dose-limiting chemotherapy-induced thrombocytopenia. (Kurzrock R) Oncology (Williston Park) 2000 Sep;14(9 Suppl 8):9-11 9 Citations |
| 2 | Donor leukocyte infusions in acute lymphocytic leukemia. (Collins RH Jr, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W, Barrett J, Johnson M, Kirk A, Horowitz M, Parker P) Bone Marrow Transplant 2000 Sep;26(5):511-6 220 Citations |
| 1 | High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. (Stiff PJ, Veum-Stone J, Lazarus HM, Ayash L, Edwards JR, Keating A, Klein JP, Oblon DJ, Shea TC, Thomé S, Horowitz MM) Ann Intern Med 2000 Oct 03;133(7):504-15 49 Citations |
| 1 | The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. (Nag S, Erickson B, Thomadsen B, Orton C, Demanes JD, Petereit D) Int J Radiat Oncol Biol Phys 2000 Aug 01;48(1):201-11 445 Citations |
| 1 | Continuous antegrade infusion of adriamycin as adjuvant therapy for upper tract urothelial malignancies. (See WA) Urology 2000 Aug 01;56(2):216-22 14 Citations |
| 1 | Current approaches and future strategies for pancreatic carcinoma. (Wolff RA, Chiao P, Lenzi R, Pisters PW, Lee JE, Janjan NA, Crane CH, Evans DB, Abbruzzese JL) Invest New Drugs 2000 Feb;18(1):43-56 36 Citations |
| 1 | Small cell lung carcinoma exhibits greater phospholipase C-beta1 expression and edelfosine resistance compared with non-small cell lung carcinoma. (Strassheim D, Shafer SH, Phelps SH, Williams CL) Cancer Res 2000 May 15;60(10):2730-6 49 Citations |
| 1 | All-trans-retinoic acid decreases vein graft intimal hyperplasia and matrix metalloproteinase activity in vivo. (Leville CD, Dassow MS, Seabrook GR, Jean-Claude JM, Towne JB, Cambria RA) J Surg Res 2000 May 15;90(2):183-90 26 Citations |
| 1 | Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. (Aricò M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, Gaynon P, Silverman L, Janka-Schaub G, Kamps W, Pui CH, Masera G) N Engl J Med 2000 Apr 06;342(14):998-1006 522 Citations |
| 1 | Unusual bone marrow manifestations of parvovirus B19 infection in immunocompromised patients. (Crook TW, Rogers BB, McFarland RD, Kroft SH, Muretto P, Hernandez JA, Latimer MJ, McKenna RW) Hum Pathol 2000 Feb;31(2):161-8 50 Citations |
| 1 | Reversal of drug resistance in sarcoma-45 by the new calmodulin antagonist--trihydrochloride of [1,2,5-trimethyl-4-phenyl-4-beta-[N-(beta-ethylamino)-N-4'-methoxybe nzy l]-ethylamino] piperidine (AR-2). (Alexanian AR, Arutyunian NS) Invest New Drugs 1999;17(2):105-10 3 Citations |
| 1 | Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. (Zhou M, Gu L, Abshire TC, Homans A, Billett AL, Yeager AM, Findley HW) Leukemia 2000 Jan;14(1):61-7 81 Citations |
| 1 | A phase I study of recombinant interferon-beta in patients with advanced malignant disease. (Ravandi F, Estrov Z, Kurzrock R, Breitmeyer JB, Maschek BJ, Talpaz M) Clin Cancer Res 1999 Dec;5(12):3990-8 16 Citations |
| 1 | Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. (Uckun FM, Messinger Y, Chen CL, O'Neill K, Myers DE, Goldman F, Hurvitz C, Casper JT, Levine A) Clin Cancer Res 1999 Dec;5(12):3906-13 71 Citations |
| 1 | Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies. (Chen CL, Levine A, Rao A, O'Neill K, Messinger Y, Myers DE, Goldman F, Hurvitz C, Casper JT, Uckun FM) J Clin Pharmacol 1999 Dec;39(12):1248-55 25 Citations |
| 1 | Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in chronic myelogenous leukemia in chronic phase. (Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR) Leuk Res 1999 Sep;23(9):817-26 8 Citations |
| 1 | Rab11BP/Rabphilin-11, a downstream target of rab11 small G protein implicated in vesicle recycling. (Mammoto A, Ohtsuka T, Hotta I, Sasaki T, Takai Y) J Biol Chem 1999 Sep 03;274(36):25517-24 84 Citations |
| 1 | Preclinical evaluation of benzoporphyrin derivative combined with a light-emitting diode array for photodynamic therapy of brain tumors. (Schmidt MH, Reichert KW 2nd, Ozker K, Meyer GA, Donohoe DL, Bajic DM, Whelan NT, Whelan HT) Pediatr Neurosurg 1999 May;30(5):225-31 27 Citations |
| 1 | Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute myelogenous leukemia in 1st remission. (Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR) Leuk Res 1999 Aug;23(8):709-18 13 Citations |
| 1 | RAS and leukemia: from basic mechanisms to gene-directed therapy. (Beaupre DM, Kurzrock R) J Clin Oncol 1999 Mar;17(3):1071-9 169 Citations |
| 1 | Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture. (Kantarjian HM, Talpaz M, O'Brien S, Kurzrock R, Gutterman J, Keating MJ, McCredie KB, Freireich EJ) Clin Cancer Res 1997 Dec;3(12 Pt 2):2723-33 16 Citations |
| 1 | Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. (Ramchandran R, Dhanabal M, Volk R, Waterman MJ, Segal M, Lu H, Knebelmann B, Sukhatme VP) Biochem Biophys Res Commun 1999 Feb 24;255(3):735-9 261 Citations |
| 2 | Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine. (Wong SJ, Myette MS, Wereley JP, Chitambar CR) Clin Cancer Res 1999 Feb;5(2):439-43 20 Citations |
| 1 | 2-chlorodeoxyadenosine-associated transient acantholytic dermatosis in hairy cell leukemia patients. (Cohen PR, Kurzrock R) Am J Dermatopathol 1999 Feb;21(1):106-8 12 Citations |
| 1 | Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. (Dhanabal M, Ramchandran R, Volk R, Stillman IE, Lombardo M, Iruela-Arispe ML, Simons M, Sukhatme VP) Cancer Res 1999 Jan 01;59(1):189-97 261 Citations |
| 1 | Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute lymphoblastic leukemia in first remission. (Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR) Leuk Res 1998 Nov;22(11):973-81 14 Citations |
| 1 | Report of the first case of invasive fungal sinusitis caused by Scopulariopsis acremonium: review of scopulariopsis infections. (Ellison MD, Hung RT, Harris K, Campbell BH) Arch Otolaryngol Head Neck Surg 1998 Sep;124(9):1014-6 27 Citations |
| 1 | Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: effects on the proliferation of human leukemic cells. (Myette MS, Elford HL, Chitambar CR) Cancer Lett 1998 Jul 17;129(2):199-204 25 Citations |
| 1 | Gallium-pyridoxal isonicotinoyl hydrazone (Ga-PIH), a novel cytotoxic gallium complex. A comparative study with gallium nitrate. (Knorr GM, Chitambar CR) Anticancer Res 1998;18(3A):1733-7 19 Citations |
| 1 | Neuropathies associated with malignancy. (Amato AA, Collins MP) Semin Neurol 1998;18(1):125-44 |
| 1 | Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. (Miller AR, Robinson EK, Lee JE, Pisters PW, Chiao PJ, Lenzi RL, Abbruzzese JL, Evans DB) Surg Oncol Clin N Am 1998 Jan;7(1):183-97 20 Citations |
| 1 | Establishment of primary cultures from human colonic tissue during tumor progression: vitamin-D responses and vitamin-D-receptor expression. (Tong WM, Bises G, Sheinin Y, Ellinger A, Genser D, Pötzi R, Wrba F, Wenzl E, Roka R, Neuhold N, Peterlik M, Cross HS) Int J Cancer 1998 Jan 30;75(3):467-72 30 Citations |
| 1 | Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. (Lee SJ, Kuntz KM, Horowitz MM, McGlave PB, Goldman JM, Sobocinski KA, Hegland J, Kollman C, Parsons SK, Weinstein MC, Weeks JC, Antin JH) Ann Intern Med 1997 Dec 15;127(12):1080-8 64 Citations |
| 1 | Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. (Sarkar M, Mulliken JB, Kozakewich HP, Robertson RL, Burrows PE) Plast Reconstr Surg 1997 Nov;100(6):1377-86 423 Citations |
| 1 | Elevated ferritin production, iron containment, and oxidant resistance in hemin-treated leukemia cells. (Lin F, Girotti AW) Arch Biochem Biophys 1997 Oct 01;346(1):131-41 42 Citations |
| 1 | Topotecan in platinum- and paclitaxel-resistant ovarian cancer. (Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ) Gynecol Oncol 1997 Sep;66(3):480-6 147 Citations |
| 1 | Future therapies for the treatment of bladder neoplasms. (See WA, Berman CJ) Semin Surg Oncol 1997;13(5):376-88 1 Citation |
| 1 | The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia. (Talpaz M, Kantarjian HM, O'Brien S, Kurzrock R) Baillieres Clin Haematol 1997 Jun;10(2):291-305 13 Citations |
| 1 | Resistance to the antitumor agent gallium nitrate in human leukemic cells is associated with decreased gallium/iron uptake, increased activity of iron regulatory protein-1, and decreased ferritin production. (Chitambar CR, Wereley JP) J Biol Chem 1997 May 02;272(18):12151-7 51 Citations |
| 1 | Second cancer risk in hairy cell leukemia: analysis of 350 patients. (Kurzrock R, Strom SS, Estey E, O'Brien S, Keating MJ, Jiang H, Adams T, Talpaz M) J Clin Oncol 1997 May;15(5):1803-10 110 Citations |
| 1 | Carboplatin as a radiation sensitizer in locally advanced cervical cancer: a pilot study. (Muderspach LI, Curtin JP, Roman LD, Gebhardt JA, Klement V, Qian D, Morrow CP, Felix JC, Formenti SC, Muggia FM) Gynecol Oncol 1997 May;65(2):336-42 45 Citations |
| 1 | High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. (Antman KH, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK, Freytes CO, Gale RP, Hillner BE, Holland HK, Kennedy MJ, Klein JP, Lazarus HM, McCarthy PL Jr, Saez R, Spitzer G, Stadtmauer EA, Williams SF, Wolff S, Sobocinski KA, Armitage JO, Horowitz MM) J Clin Oncol 1997 May;15(5):1870-9 310 Citations |
| 1 | Effects of spermine and its cytotoxic analogs on nucleosome formation on topologically stressed DNA in vitro. (Basu HS, Smirnov IV, Peng HF, Tiffany K, Jackson V) Eur J Biochem 1997 Jan 15;243(1-2):247-58 37 Citations |
| 1 | The alkyl-lysophospholipid, ET-18-OCH3 synergistically enhances the Merocyanine 540-mediated photoinactivation of leukemia cells: implications for the extracorporeal purging of autologous hematopoietic stem cells. (Yamazaki T, Sieber F) Bone Marrow Transplant 1997 Jan;19(2):113-9 22 Citations |
| 1 | A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer. (Dreicer R, Kemp JD, Stegink LD, Cardillo T, Davis CS, Forest PK, See WA) Cancer Invest 1997;15(4):311-7 22 Citations |
| 1 | Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA). (Kroft SH, Tallman MS, Shaw JM, Thangavelu M, Peterson LC) Leukemia 1997 Jan;11(1):170 23 Citations |
| 1 | Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. (Seymour JF, Talpaz M, Kurzrock R) Leukemia 1997 Jan;11(1):42-7 68 Citations |
| 1 | Effect of gallium nitrate therapy on Ga-67 scintigraphic detection of lymphoma: case report. (Akansel G, Liu Y, Chitambar CR, Kitapci MT, Akansel S, Krasnow AZ, Isitman AT, Collier BD) Clin Nucl Med 1997 Jan;22(1):21-4 3 Citations |
| 1 | Recombinant human interferon-beta (rHuIFN-beta) and radiation therapy for inoperable non-small cell lung cancer. (Byhardt RW, Vaickus L, Witt PL, Chang AY, McAuliffe T, Wilson JF, Lawton CA, Breitmeyer J, Alger ME, Borden EC) J Interferon Cytokine Res 1996 Nov;16(11):891-902 13 Citations |
| 1 | Combined modality therapy for cutaneous T-cell lymphoma. (Duvic M, Lemak NA, Redman JR, Eifel PJ, Tucker SL, Cabanillas FF, Kurzrock R) J Am Acad Dermatol 1996 Jun;34(6):1022-9 81 Citations |
| 1 | Evaluation of transferrin and gallium-pyridoxal isonicotinoyl hydrazone as potential therapeutic agents to overcome lymphoid leukemic cell resistance to gallium nitrate. (Chitambar CR, Boon P, Wereley JP) Clin Cancer Res 1996 Jun;2(6):1009-15 28 Citations |
| 1 | Brachytherapy and continuous infusion 5-fluorouracil for treatment of locally advanced, lymph node negative, prostate cancer: a phase I trial. (See WA, Dreicer R, Wheeler JA, Forest PK, Loening S) Cancer 1996 Mar 01;77(5):924-7 5 Citations |
| 1 | Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation. (Evans DB, Abbruzzese JL, Cleary KR, Buchholz DJ, Fenoglio CJ, Collier C, Rich TA) Int J Radiat Oncol Biol Phys 1995 Nov 01;33(4):913-8 32 Citations |
| 1 | Interferon-alpha therapy for chronic myelogenous leukemia. (Wetzler M, Kantarjian H, Kurzrock R, Talpaz M) Am J Med 1995 Oct;99(4):402-11 55 Citations |
| 1 | Effect of hydroxyurea on cellular iron metabolism in human leukemic CCRF-CEM cells: changes in iron uptake and the regulation of transferrin receptor and ferritin gene expression following inhibition of DNA synthesis. (Chitambar CR, Wereley JP) Cancer Res 1995 Oct 01;55(19):4361-6 23 Citations |
| 2 | Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee. (Zhang MJ, Hoelzer D, Horowitz MM, Gale RP, Messerer D, Klein JP, Löffler H, Sobocinski KA, Thiel E, Weisdorf DJ) Ann Intern Med 1995 Sep 15;123(6):428-31 92 Citations |
| 1 | Phase IA/IB evaluation of mammalian cell-derived glycosylated recombinant human interleukin (SIGOSIX) before and after cytotoxic chemotherapy. (Ritch PS, Keever C, Schiller J, Rivkin S, Witt PL, Grossberg SE, Truitt RL, Burris H, von Hoff DD, Vaickus L) Ann N Y Acad Sci 1995 Jul 21;762:359-60 |
| 1 | Circumvention of confluence-dependent resistance in a human multi-drug-resistant colon-cancer cell line. (Garrido C, Chauffert B, Pinard D, Tibaut F, Genne P, Assem M, Dimanche-Boitrel MT) Int J Cancer 1995 Jun 09;61(6):873-9 24 Citations |
| 1 | Interleukin-1 and its inhibitors: implications for disease biology and therapy. (Estrov Z, Kurzrock R, Talpaz M) Cancer Treat Res 1995;80:51-82 10 Citations |
| 1 | Pinch-off syndrome: a rare etiology for central venous catheter occlusion. (Andris DA, Krzywda EA, Schulte W, Ausman R, Quebbeman EJ) JPEN J Parenter Enteral Nutr 1994;18(6):531-3 87 Citations |
| 1 | Efficacy of fluorescence in situ hybridization for detecting PML/RARA gene fusion in treated and untreated acute promyelocytic leukemia. (Schad CR, Hanson CA, Paietta E, Casper J, Jalal SM, Dewald GW) Mayo Clin Proc 1994 Nov;69(11):1047-53 |
| 2 | Pancreatitis associated with brain tumor therapy. (Margolis DA, Werlin SL, Murray KJ, Strother DR) Am J Pediatr Hematol Oncol 1994 Nov;16(4):301-4 2 Citations |
| 1 | Urinary bladder cancer: mechanisms of development and progression. (Kroft SH, Oyasu R) Lab Invest 1994 Aug;71(2):158-74 104 Citations |
| 1 | Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. (Friedman HS, Dolan ME, Kaufmann SH, Colvin OM, Griffith OW, Moschel RC, Schold SC, Bigner DD, Ali-Osman F) Cancer Res 1994 Jul 01;54(13):3487-93 54 Citations |
| 3 | Gallium nitrate delays the progression of microscopic disease in a human medulloblastoma murine model. (Whelan HT, Williams MB, Bajic DM, Flores RE, Schmidt MH, McAuliffe TL, Chitambar CR) Pediatr Neurol 1994 Jul;11(1):44-6 6 Citations |
| 4 | Prevention of gallium toxicity by hyperhydration in treatment of medulloblastoma. (Whelan HT, Williams MB, Bajic DM, Segura AD, McAuliffe TL, Chitambar CR) Pediatr Neurol 1994 May;10(3):217-20 6 Citations |
| 1 | NG-methyl-L-arginine, an inhibitor of nitric oxide formation, reverses IL-2-mediated hypotension in dogs. (Kilbourn RG, Owen-Schaub LB, Cromeens DM, Gross SS, Flaherty MJ, Santee SM, Alak AM, Griffith OW) J Appl Physiol (1985) 1994 Mar;76(3):1130-7 44 Citations |
| 1 | Adjuvant radiotherapy and chemotherapy for biliary and pancreatic cancer. (Rich TA, Evans DB, Curley SA, Ajani JA) Ann Oncol 1994;5 Suppl 3:75-80 25 Citations |
| 1 | The style of early clinical research reporting: what are we saying and how do we say it? (Weissman DE, Gedney C) J Cancer Educ 1993;8(4):291-5 1 Citation |
| 1 | Pyrethroid insecticide-induced alterations in mammalian synaptic membrane potential. (Eells JT, Bandettini PA, Holman PA, Propp JM) J Pharmacol Exp Ther 1992 Sep;262(3):1173-81 56 Citations |
| 3 | Antineoplastic effects of gallium nitrate on human medulloblastoma in vivo. (Whelan HT, Schmidt MH, Anderson GS, Chan BK, Hunter K, Kubacki D, Segura AD, Chitambar CR) Pediatr Neurol 1992;8(5):323-7 8 Citations |
| 1 | Nicotine-induced depolarization of cerebral cortical synaptosomes is dependent upon sodium. (Hillard CJ) Neuropharmacology 1992 Sep;31(9):909-14 4 Citations |
| 1 | Regulatory effects of gallium on transferrin-independent iron uptake by human leukemic HL60 cells. (Chitambar CR, Sax D) Blood 1992 Jul 15;80(2):505-11 50 Citations |
| 1 | Structure-activity relationships in the antiviral and antileukemic photoproperties of merocyanine dyes. (Günther WH, Searle R, Sieber F) Semin Hematol 1992 Apr;29(2):88-94 26 Citations |
| 1 | Effects of glutathione or polyamine depletion on in vivo thermosensitization. (Laskowitz DT, Elion GB, Dewhirst MW, Griffith OW, Casero RA Jr, Scott PA, Bullock N, Bigner DD, Friedman HS) Int J Hyperthermia 1992;8(2):199-208 1 Citation |
| 1 | Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). (Estey EH, Kurzrock R, Kantarjian HM, O'Brien SM, McCredie KB, Beran M, Koller C, Keating MJ, Hirsch-Ginsberg C, Huh YO) Blood 1992 Feb 15;79(4):882-7 184 Citations |
| 1 | Magnetic resonance imaging of penile rhabdomyosarcoma. (Ganesan GS, Cory D, Mitchell ME, Jones JA) Br J Radiol 1992 Feb;65(770):175-8 4 Citations |
| 1 | Therapy decisions in leukemia. (Atkinson KA, Horowitz MM, Sobocinski KA, Rimm AA, Bortin MM, Gale RP) Bone Marrow Transplant 1992 Jan;9(1):5-10 8 Citations |
| 1 | Cancer after bone marrow transplantation. IBMTR and EBMT/EULEP Study Group on Late Effects. (Kolb HJ, Guenther W, Duell T, Socie G, Schaeffer E, Holler E, Schumm M, Horowitz MM, Gale RP, Fliedner TM) Bone Marrow Transplant 1992;10 Suppl 1:135-8 24 Citations |
| 2 | Alteration of DNA synthesis in human brain tumor cells by gallium nitrate in vitro. (Whelan HT, Przybylski C, Chitambar CR) Pediatr Neurol 1991;7(5):352-4 7 Citations |
| 1 | Does more intensive therapy increase cures in acute leukemia? (Gale RP, Butturini A, Horowitz MM) Semin Hematol 1991 Jul;28(3 Suppl 4):93-4 2 Citations |
| 2 | Differential effects of gallium nitrate on proliferation of brain tumor cells in vitro. (Whelan HT, Przybylski C, Chitambar CR) Pediatr Neurol 1991;7(1):23-7 8 Citations |
| 2 | Interaction of gallium nitrate with fludarabine and iron chelators: effects on the proliferation of human leukemic HL60 cells. (Lundberg JH, Chitambar CR) Cancer Res 1990 Oct 15;50(20):6466-70 42 Citations |
| 1 | Development of drug resistance to gallium nitrate through modulation of cellular iron uptake. (Chitambar CR, Zivkovic-Gilgenbach Z, Narasimhan J, Antholine WE) Cancer Res 1990 Aug 01;50(15):4468-72 26 Citations |
| 1 | Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. (Kantarjian HM, Kurzrock R, Talpaz M) Hematol Oncol Clin North Am 1990 Apr;4(2):389-404 46 Citations |
| 1 | Adjunctive therapy (whole body hyperthermia versus lonidamine) to total body irradiation for the treatment of favorable B-cell neoplasms: a report of two pilot clinical trials and laboratory investigations. (Robins HI, Longo WL, Steeves RA, Cohen JD, Schmitt CL, Neville AJ, O'Keefe S, Lagoni R, Riggs C) Int J Radiat Oncol Biol Phys 1990 Apr;18(4):909-20 30 Citations |
| 2 | Glucose administration augments in vivo uptake and phototoxicity of the tumor-localizing fraction of hematoporphyrin derivative. (Thomas JP, Girotti AW) Photochem Photobiol 1989 Mar;49(3):241-7 70 Citations |
| 1 | Endocrine late effects among survivors of cancer. (Hobbie WL, Schwartz CL) Semin Oncol Nurs 1989 Feb;5(1):14-21 4 Citations |
| 1 | Continuous venous access in children with urological diseases. (Springer JC, Azizkhan RG, Mesrobian HG) J Urol 1989 Feb;141(2):364-6 4 Citations |
| 1 | Phase I trial of lonidamine with whole body hyperthermia in advanced cancer. (Robins HI, Longo WL, Lagoni RK, Neville AJ, Hugander A, Schmitt CL, Riggs C) Cancer Res 1988 Nov 15;48(22):6587-92 29 Citations |
| 1 | Reaction between ortho-semiquinones and oxygen: pulse radiolysis, electron spin resonance, and oxygen uptake studies. (Kalyanaraman B, Korytowski W, Pilas B, Sarna T, Land EJ, Truscott TG) Arch Biochem Biophys 1988 Oct;266(1):277-84 35 Citations |
| 1 | Therapy of chronic myelogenous leukemia: chemotherapy and interferons. (Talpaz M, Kantarjian HM, Kurzrock R, Gutterman J) Semin Hematol 1988 Jan;25(1):62-73 68 Citations |
| 1 | Molecular aspects, physiological function, and clinical significance of metallothioneins. (Nath R, Kambadur R, Gulati S, Paliwal VK, Sharma M) Crit Rev Food Sci Nutr 1988;27(1):41-85 86 Citations |
| 1 | Elimination of clonogenic malignant human T cells using monoclonal antibodies in combination with 2'-deoxycoformycin. (Schwartz CL, Minniti CP, Harwood P, Na S, Banquerigo ML, Strauss LC, Kurtzberg J, Smith SD, Civin CI) J Clin Oncol 1987 Dec;5(12):1900-11 5 Citations |
| 1 | Etiology and treatment of chemotherapeutic agent extravasation injuries: a review. (Rudolph R, Larson DL) J Clin Oncol 1987 Jul;5(7):1116-26 116 Citations |
| 1 | ESR of copper and iron complexes with antitumor and cytotoxic properties. (Antholine WE, Kalyanaraman B, Petering DH) Environ Health Perspect 1985 Dec;64:19-35 47 Citations |
| 1 | Mechanism of DNA strand breaks by mitonafide, an imide derivative of 3-nitro-1,8-naphthalic acid. (Sinha BK, Strong J, Gibson NW, Kalyanaraman B) Biochem Pharmacol 1985 Nov 01;34(21):3845-52 16 Citations |
| 1 | Effects of selected repeated intravitreal chemotherapeutic agents. (Vernot J, Peyman GA, Gailitis R, Fiscella R, Woodhouse M, Weinberg D) Int Ophthalmol 1985 Nov;8(4):193-8 8 Citations |
| 1 | Neuromuscular syndromes associated with cancer. (Whelan HT) Compr Ther 1985 Sep;11(9):50-7 3 Citations |
| 1 | What is the appropriate management of tissue extravasation by antitumor agents? (Larson DL) Plast Reconstr Surg 1985 Mar;75(3):397-405 167 Citations |
| 1 | Nephrotoxicities of antineoplastic and immunosuppressive agents. (Raymond JR) Curr Probl Cancer 1984 Oct;8(16):1-32 3 Citations |
| 1 | QT interval prolongation and cardiac dysrhythmia in a patient receiving amsacrine. (Schwartz CL, Bender KS, Burke PJ, Kan JS, Civin CI) Cancer Treat Rep 1984;68(7-8):1043-4 5 Citations |
| 1 | Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. (Weinstein HJ, Mayer RJ, Rosenthal DS, Coral FS, Camitta BM, Gelber RD) Blood 1983 Aug;62(2):315-9 217 Citations |
| 1 | The treatment of acute myelogenous leukemia in children and adults: VAPA update. (Weinstein HJ, Mayer RJ, Rosenthal DS, Coral FS, Camitta BM, Gelber RD, Nathan DG, Frei E 3rd) Haematol Blood Transfus 1983;28:41-5 |
| 1 | Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy. (Von Hoff DD, Casper J, Bradley E, Sandbach J, Jones D, Makuch R) Am J Med 1981 May;70(5):1027-41 328 Citations |
| 1 | Thyroid carcinoma following treatment for acute lymphoblastic leukemia. (Tang TT, Holcenberg JS, Duck SC, Hodach AE, Oechler HW, Camitta BM) Cancer 1980 Oct 01;46(7):1572-6 21 Citations |
| 2 | Failure of early intensive chemotherapy to improve prognosis in childhood acute lymphocytic leukemia. (Camitta BM, Pinkel D, Thatcher LG, Casper J, Kun LE, Lauer S) Med Pediatr Oncol 1980;8(4):383-9 10 Citations |
| 1 | Shifts in expression of cell membrane phenotypes in childhood lymphoid malignancies at relapse. (Borella L, Casper JT, Lauer SJ) Blood 1979 Jul;54(1):64-71 49 Citations |
| 1 | Effects of methionine sulfoximine analogs on the synthesis of glutamine and glutathione: possible chemotherapeutic implications. (Meister A, Griffith OW) Cancer Treat Rep 1979 Jun;63(6):1115-21 72 Citations |
| 1 | Hepatopathy following irradiation and adriamycin. (Kun LE, Camitta BM) Cancer 1978 Jul;42(1):81-4 48 Citations |
| 1 | Development of an effective treatment program for childhood acute lymphocytic leukemia: a preliminary report. (Furman L, Camitta BM, Jaffe N, Sallan SE, Cassady JR, Traggis D, Leavitt P, Nathan DG, Frei E 3rd) Med Pediatr Oncol 1976;2(2):157-66 21 Citations |
| 1 | Interpretation of the methylene blue reduction test of human plasma and the possible cancer protecting effect of selenium. (Schrauzer GN, Rhead WJ) Experientia 1971 Sep 15;27(9):1069-71 36 Citations |
